var title_f23_8_23680="Ear tube PI";
var content_f23_8_23680=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F67163&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F67163&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 537px\">",
"   <div class=\"ttl\">",
"    Surgery to treat fluid in the ear (tympanostomy tube)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 517px; height: 331px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This surgery might be done when fluid in the middle ear does not go away. This treatment can also be used to prevent more ear infections in children who get them a lot. The figure on the left shows an eardrum before the tube is inserted. The figure on the right shows fluid draining from the middle ear after the tube has been placed in the eardrum.",
"    <div class=\"footnotes\">",
"     <p class=\"MsoNormal\" style=\"margin:0in 0in 0pt;background:white\">",
"      &nbsp;",
"     </p>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_8_23680=[""].join("\n");
var outline_f23_8_23680=null;
var title_f23_8_23681="Corneal abrasion II";
var content_f23_8_23681=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F87225&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F87225&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Corneal abrasion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 405px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Corneal abrasion unmasked with use of fluorescein dye. Blue light will further enhance visualization of abraded region where exposed basement membrane picks up the dye. The dye has diffused under the edge of intact epithelium, making the boundary appear less distinct than it actually is.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Image created by Christopher J Rapuano, MD. Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_8_23681=[""].join("\n");
var outline_f23_8_23681=null;
var title_f23_8_23682="Basic case 3 with answer";
var content_f23_8_23682=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F66491&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F66491&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 551px\">",
"   <div class=\"ttl\">",
"    Atrial fibrillation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 531px; height: 90px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lead V1 showing coarse atrial fibrillation with moderate ventricular response. The two characteristic findings in AF are present: the very rapid atrial fibrillatory waves (f waves) which are variable in appearance; and the irregularly irregular ventricular response as the R-R interval between beats is unpredictable. Coarse atrial fibrillation may appear similar to atrial flutter. However, the variable height and duration of the f waves differentiate them from atrial flutter (F) waves which are identical in appearance and occur at a constant rate of about 250 to 350 beats/min.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ary Goldberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_8_23682=[""].join("\n");
var outline_f23_8_23682=null;
var title_f23_8_23683="Superficial retinal hemorrhages";
var content_f23_8_23683=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F68695&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F68695&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Superficial retinal hemorrhages",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 408px; height: 407px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Superficial retinal hemorrhages are small, linear, flame-shaped, red streaks in the fundi. They are shaped by the superficial bundles of nerve fibers that radiate from the optic disc in the pattern illustrated. Sometimes the hemorrhages occur in clusters and then simulate a larger hemorrhage, but the linear streaking at the edges shows their true nature. An occasional superficial hemorrhage has a white center consisting of fibrin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bickley, LS and Szilagyi, P. Bates' Guide to Physical Examination and History Taking, 8th Ed. Philadelphia: Lippincott Williams &amp; Wilkins 2003. Copyright &copy;2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_8_23683=[""].join("\n");
var outline_f23_8_23683=null;
var title_f23_8_23684="Sevelamer: Pediatric drug information";
var content_f23_8_23684=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sevelamer: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?39/44/40645?source=see_link\">",
"    see \"Sevelamer: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?22/1/22548?source=see_link\">",
"    see \"Sevelamer: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F220777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Renagel&reg;;",
"     </li>",
"     <li>",
"      Renvela&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F220778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Renagel&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1062073\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Phosphate Binder",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1062067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?39/44/40645?source=see_link\">",
"      see \"Sevelamer: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: In a small pilot study of 17 pediatric patients aged 11.8 &plusmn; 3.7 years on hemodialysis (n=3) or peritoneal dialysis (n=14), initial doses of 121 &plusmn; 50 mg/kg/day (4.5 &plusmn; 5 g/day) were used. Doses were adjusted based on the serum phosphorus with final doses of 163 &plusmn; 46 mg/kg (6.7 &plusmn; 2.4 g/day) without any adverse effects (Mahdavi, 2003). In a study of 18 patients aged 0.9-18 years with chronic kidney disease, a mean dose of 140 &plusmn; 86 mg/kg/day (5.38 &plusmn; 3.24 g/day) resulted in good phosphorus control with minimal adverse effects. Initial doses were based on prior phosphate-binder dose and were adjusted based on the serum phosphorus (Pieper, 2006).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults (not taking another phosphate binder, eg, calcium acetate): 800-1600 mg with each meal; the initial dose may be based on the serum phosphorus: See table:",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <col align=\"center\" width=\"230\">",
"     </col>",
"     <col align=\"center\" width=\"230\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Serum Phosphorus",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mg/dL)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Initial Sevelamer Dose",
"         <sup>",
"          1",
"         </sup>",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mg)",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tfoot valign=\"middle\">",
"      <tr>",
"       <td align=\"left\" colspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          1",
"         </sup>",
"         Administered 3 times/day.",
"        </p>",
"       </td>",
"      </tr>",
"     </tfoot>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &gt;5.5 and &lt;7.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         800",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &ge;7.5 and &lt;9",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1200-1600",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &ge;9",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1600",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adjust the daily dosage by 400-800 mg per meal at 2-week intervals depending upon the serum phosphorus.  The manufacturer recommends the following titration schedule:",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <col align=\"center\" width=\"230\">",
"     </col>",
"     <col align=\"center\" width=\"230\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Serum Phosphorus",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mg/dL)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Sevelamer Dosage Adjustment",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &gt;5.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Increase by 400-800 mg per meal at 2-week intervals",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3.5-5.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Maintain current dose",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &lt;3.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Decrease by 400-800 mg per meal",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">",
"     Patients changing from calcium acetate to sevelamer may use the following conversions:",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <col align=\"center\" width=\"230\">",
"     </col>",
"     <col align=\"center\" width=\"230\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium Acetate Dosage",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mg)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Initial Sevelamer Dose",
"         <sup>",
"          1",
"         </sup>",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mg)",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tfoot valign=\"middle\">",
"      <tr>",
"       <td align=\"left\" colspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          1",
"         </sup>",
"         Administer 3 times/day.",
"        </p>",
"       </td>",
"      </tr>",
"     </tfoot>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         667 (1 tablet)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         800",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1334 (2 tablets)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1200-1600",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2001 (3 tablets)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2000-2400",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F220760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for suspension, oral, as carbonate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renvela&reg;: 0.8 g/packet (90s); 2.4 g/packet (90s) [contains propylene glycol; citrus-cream flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as carbonate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renvela&reg;: 800 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renagel&reg;: 400 mg, 800 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F220745\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1062076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral:  Administer with meals, at least 1 hour before or 3 hours after other medications.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablets: Because the contents will expand with water, swallow tablets whole; do not chew or crush.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Packets for oral suspension: Mix powder with water prior to administration. The 0.8 g packet should be mixed with 30 mL of water and the 2.4 g packet should be mixed with 60 mL of water (multiple packets may be mixed together using the appropriate amount of water). Stir vigorously to suspend mixture just prior to drinking; powder does not dissolve. Drink within 30 minutes of preparing or resuspend just prior to drinking.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1062070\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at controlled room temperature; protect from moisture",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1062075\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reduction of serum phosphorus in patients with chronic kidney disease on hemodialysis (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F220802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Renagel&reg; may be confused with Reglan&reg;, Regonol&reg;, Renvela&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Renvela&reg; may be confused with Reglan&reg;, Regonol&reg;, Renagel&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Sevelamer may be confused with Savella&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Renagel [U.S., Canada, and multiple international markets] may be confused with Remegel brand name for aluminium hydroxide and magnesium carbonate [Netherlands] and for calcium carbonate [Hungary, Great Britain and Ireland] and with Remegel Wind Relief brand name for calcium carbonate and simethicone [Great Britain]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F220800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypercalcemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, constipation, diarrhea, dyspepsia, flatulence, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Peritonitis (peritoneal dialysis)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Fecal impaction, ileus (rare), intestinal obstruction (rare), intestinal perforation (rare), pruritus, rash",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1062079\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to sevelamer or any component; hypophosphatemia, bowel obstruction",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1062066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with GI disorders including dysphagia, swallowing disorders, severe GI motility disorders, or major GI surgery; bowel obstruction and perforation have been reported",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1062065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In preclinical animal studies, sevelamer (at doses of 6-100 times the recommended human dose) reduced the levels of vitamin D, E, K, and folic acid; no evidence of decreased vitamin levels has been shown in human trials, however, most patients were receiving vitamin supplements",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F220754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcitriol: Sevelamer may decrease the serum concentration of Calcitriol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Levothyroxine: Sevelamer may decrease the serum concentration of Levothyroxine.  Management: Consider separating administration of sevelamer and levothyroxine by at least several hours whenever possible in order to decrease the risk of a significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Sevelamer may decrease the serum concentration of Mycophenolate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Sevelamer may decrease the absorption of Quinolone Antibiotics.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F220756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F220768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have shown reduced or irregular ossification of fetal bones. Because sevelamer may cause a reduction in the absorption of some vitamins, it should be used with caution in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1062072\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum electrolytes",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1062064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sevelamer is a cationic polymeric compound that binds phosphate in the intestinal lumen, limiting absorption and decreasing serum phosphate concentrations without altering calcium, aluminum, or bicarbonate concentrations. It may also lower low-density lipoprotein (LDL) and total serum cholesterol levels.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1062078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Not systemically absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Feces 100%",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Mahdavi H, Kuizon BD, Gales B, et al, &ldquo;Sevelamer Hydrochloride: An Effective Phosphate Binder in Dialyzed Children,&rdquo;",
"      <i>",
"       Pediatr Nephrol",
"      </i>",
"      , 2003, 18(12):1260-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/8/23684/abstract-text/14586677/pubmed\" id=\"14586677\" target=\"_blank\">",
"        14586677",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pieper AK, Haffner D, Hoppe B, et al, \"A Randomized Crossover Trial Comparing Sevelamer With Calcium Acetate in Children With CKD,\"",
"      <i>",
"       Am J Kidney Dis",
"      </i>",
"      , 2006, 47(4):625-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/8/23684/abstract-text/16564940/pubmed\" id=\"16564940\" target=\"_blank\">",
"        16564940",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12975 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-9F69235DB9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_8_23684=[""].join("\n");
var outline_f23_8_23684=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220777\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220778\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062073\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062067\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220760\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220745\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062076\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062070\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062075\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220802\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220800\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062079\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062066\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062065\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300038\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220754\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220756\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220768\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062072\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062064\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062078\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12975\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12975|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?39/44/40645?source=related_link\">",
"      Sevelamer: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?22/1/22548?source=related_link\">",
"      Sevelamer: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_8_23685="Relation between total and ionized serum calcium concentration";
var content_f23_8_23685=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Relation between total and ionized serum calcium concentration",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/8/23685/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/8/23685/contributors\">",
"     Zalman S Agus, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/8/23685/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/8/23685/contributors\">",
"     Stanley Goldfarb, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/8/23685/contributors\">",
"     Mitchell Geffner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/8/23685/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/8/23685/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/8/23685/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The plasma (or serum) calcium concentration measured in the laboratory is usually reported in units of",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    in the United States, in",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    in many other countries, and in",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in some laboratories. The relationship between these units is defined by the following equations:",
"   </p>",
"   <p>",
"    &nbsp;",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    &nbsp;= &nbsp;",
"    <span class=\"nowrap\">",
"     [mg/dL",
"    </span>",
"    &nbsp;x &nbsp;10] &nbsp;&divide; &nbsp;mol wt",
"   </p>",
"   <p>",
"    &nbsp;",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    &nbsp;= &nbsp;",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    &nbsp;x &nbsp;valence",
"   </p>",
"   <p>",
"    Since the molecular weight of calcium is 40 and the valence is +2, 1",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    is equivalent to 0.25",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    and to 0.5",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    Thus, the normal range of total serum calcium concentration of 8.8 to 10.3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    is equivalent to 2.2 to 2.6",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    and 4.4 to 5.2",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DETERMINANTS OF THE SERUM CALCIUM CONCENTRATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The total serum calcium concentration consists of three fractions [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23685/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately 15 percent is bound to multiple organic and inorganic anions such as sulfate, phosphate, lactate, and citrate.",
"     </li>",
"     <li>",
"      Approximately 40 percent is bound to albumin in a ratio of 0.8",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0.2",
"      <span class=\"nowrap\">",
"       mmol/L",
"      </span>",
"      or 0.4",
"      <span class=\"nowrap\">",
"       meq/L)",
"      </span>",
"      of calcium per 1.0",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      (10",
"      <span class=\"nowrap\">",
"       g/L)",
"      </span>",
"      of albumin.",
"     </li>",
"     <li>",
"      The remaining 45 percent circulates as physiologically active ionized (or free) calcium. The ionized serum calcium concentration is tightly regulated by parathyroid hormone and vitamin D, and can be modified by a variety of factors. (See",
"      <a class=\"local\" href=\"#H404424\">",
"       'Change in ionized fraction but not total calcium'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The wide range in the normal",
"    <strong>",
"     total",
"    </strong>",
"    serum calcium concentration is probably due to variations in the serum concentration of albumin among normal healthy individuals and occasionally to variations in the state of hydration that can alter the serum albumin concentration.",
"   </p>",
"   <p>",
"    Thus, measurement of the total serum calcium concentration alone is sometimes misleading, since this parameter can change",
"    <strong>",
"     without",
"    </strong>",
"    affecting the concentration of ionized calcium [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23685/abstract/3\">",
"     3",
"    </a>",
"    ]. In addition, the ionized fraction can change without an alteration in the total serum calcium concentration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H404378\">",
"    <span class=\"h2\">",
"     Change in total but not ionized calcium",
"    </span>",
"    &nbsp;&mdash;&nbsp;An abnormal total serum calcium concentration in the absence of an abnormal ionized calcium concentration can occur in patients with hypoalbuminemia, hyperalbuminemia, and multiple myeloma. If the total serum calcium is low but the ionized calcium is normal, it is called",
"    <strong>",
"     pseudohypocalcemia",
"    </strong>",
"    . If the total serum calcium is high in the setting of a normal ionized calcium, it is called",
"    <strong>",
"     pseudohypercalcemia",
"    </strong>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h3\">",
"     Hypoalbuminemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The total serum calcium concentration will change in parallel to the albumin concentration. Thus, hypoalbuminemia due to hepatic or renal disease is associated with hypocalcemia. In comparison, globulins only minimally bind calcium and changes in the globulin level are usually not associated with changes in the calcium concentration with the occasional exception of marked hyperglobulinemia in multiple myeloma.",
"   </p>",
"   <p>",
"    In general, the serum calcium concentration falls by 0.8",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.2",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    for every 1.0",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    (10",
"    <span class=\"nowrap\">",
"     g/L)",
"    </span>",
"    fall in the serum albumin concentration. Thus, the measured serum calcium concentration can be corrected for the presence of hypoalbuminemia from the following equation:",
"   </p>",
"   <p>",
"    &nbsp;Corrected [Ca] &nbsp; = &nbsp; Measured total [Ca] &nbsp;+ &nbsp;(0.8 &nbsp;x &nbsp;(4.5 &nbsp;- &nbsp;[alb]))",
"   </p>",
"   <p>",
"    where the serum calcium and albumin concentrations are measured in units of",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    respectively. A calculator is available to correct the calcium concentration for hypoalbuminemia using",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?17/35/17969?source=see_link\">",
"     calculator 1",
"    </a>",
"    ), and",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?14/51/15153?source=see_link\">",
"     calculator 2",
"    </a>",
"    ). As an example, if the measured values for total serum calcium and albumin are 7.6",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    and 2.5",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    respectively, then:",
"   </p>",
"   <p>",
"    &nbsp;Corrected [Ca] &nbsp; = &nbsp; 7.6 &nbsp;+ &nbsp;(0.8 &nbsp;x &nbsp;2) &nbsp; = &nbsp; 9.2",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H177755193\">",
"    <span class=\"h3\">",
"     Hyperalbuminemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;An elevation in serum albumin, leading to a rise in serum calcium, can be induced by extracellular volume depletion or by fluid movement out of the vascular space due, for example, to a tight tourniquet [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23685/abstract/4\">",
"     4",
"    </a>",
"    ]. Hyperalbuminemia has also been reported in athletes who consume very high protein diets (more than 2 g of protein per kg of body weight per day) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23685/abstract/5\">",
"     5",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Multiple myeloma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myeloma can induce pseudohypercalcemia by a mechanism other than hyperalbuminemia. Rarely, a monoclonal myeloma protein binds calcium with high affinity, potentially leading to a marked elevation in the total serum calcium concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23685/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. The absence of hypercalcemic symptoms is the major clue suggesting that the ionized fraction is normal in this setting and that therapy aimed at correcting the hypercalcemia is",
"    <strong>",
"     not",
"    </strong>",
"    indicated.",
"   </p>",
"   <p>",
"    The hyperproteinemia in myeloma can also cause a spurious elevation in the serum phosphate concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23685/abstract/9\">",
"     9",
"    </a>",
"    ]. The mechanism is uncertain but may involve interference with the normal assay used to measure to serum phosphate concentration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H404424\">",
"    <span class=\"h2\">",
"     Change in ionized fraction but not total calcium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physiologically important changes in the ionized calcium concentration may occur without an alteration in the total serum calcium concentration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30614447\">",
"    <span class=\"h3\">",
"     Acid-base disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acid-base disorders can lead to changes in the ionized calcium concentration. An elevation in extracellular pH (alkalemia) increases the binding of calcium to albumin, thereby lowering the serum ionized calcium concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23685/abstract/10\">",
"     10",
"    </a>",
"    ]. The fall in ionized calcium with",
"    <strong>",
"     acute",
"    </strong>",
"    respiratory alkalosis is approximately 0.16",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.04",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    or 0.08",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    for each 0.1 unit increase in pH [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23685/abstract/10\">",
"     10",
"    </a>",
"    ]. Thus, acute respiratory alkalosis, as in the hyperventilation syndrome, can induce symptoms of hypocalcemia, including cramps, paresthesias, tetany, and seizures although the alkalosis is likely to be of primary importance. The same relationship is true in vitro when the pH is changed in specimens of whole blood or serum [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23685/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is also a significant fall in the ionized calcium concentration in",
"    <strong>",
"     chronic",
"    </strong>",
"    respiratory alkalosis. However, the fall in ionized calcium in this setting is not due to increased calcium binding, since the renal adaptation lowers the serum bicarbonate concentration and minimizes the rise in extracellular pH. The hypocalcemia in this setting is due both to relative hypoparathyroidism and to renal resistance to PTH, with resultant hypercalciuria [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23685/abstract/12\">",
"     12",
"    </a>",
"    ]. Why these changes occur is not well understood. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27288?source=see_link\">",
"     \"Simple and mixed acid-base disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In chronic metabolic acidosis, the increase in ionized calcium due to less albumin binding may not be recognized by measurement of total calcium concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23685/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. In one study, for example, the total serum calcium underestimated the diagnosis of hypercalcemia in incident renal transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23685/abstract/14\">",
"     14",
"    </a>",
"    ]. This was explained primarily by the high prevalence of metabolic acidosis in these patients.",
"   </p>",
"   <p>",
"    The binding of calcium to albumin that is induced by an elevation in extracellular pH may be important in patients with severe chronic kidney disease who often have both hypocalcemia and metabolic acidosis, which will tend to raise the ionized calcium concentration. Treatment of the metabolic acidosis with bicarbonate therapy or dialysis can lower the ionized calcium concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23685/abstract/15,16\">",
"     15,16",
"    </a>",
"    ], which may exacerbate preexisting hypocalcemia and precipitate symptoms such as tetany [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23685/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Parathyroid hormone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parathyroid hormone (PTH) may decrease the binding of calcium to albumin and therefore increase ionized calcium at the expense of the protein-bound fraction, resulting in an increased ratio of ionized to total calcium in patients with elevated levels of PTH [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23685/abstract/17\">",
"     17",
"    </a>",
"    ]. On the other hand, the sensitivities of ionized and total calcium concentrations in the diagnosis of primary hyperparathyroidism were identical in a large cohort of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23685/abstract/18\">",
"     18",
"    </a>",
"    ], suggesting that this effect of PTH on protein binding of calcium does not have diagnostic implications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5545?source=see_link&amp;anchor=H11#H11\">",
"     \"Diagnosis and differential diagnosis of primary hyperparathyroidism\", section on 'Normocalcemic primary hyperparathyroidism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Hyperphosphatemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute hyperphosphatemia (as with phosphate release from cells due to a marked increase in cell breakdown) can reduce the ionized serum calcium concentration by binding to circulating calcium. The total serum calcium concentration will also fall in a short period of time as the calcium-phosphate precipitates and is deposited in soft tissues. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/25/24984?source=see_link\">",
"     \"Etiology of hypocalcemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H701808710\">",
"    <span class=\"h1\">",
"     MEASURING THE SERUM CALCIUM IN PATIENTS WITH CKD",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with a reduced glomerular filtration rate (GFR less than 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73m2), the total serum calcium concentration does",
"    <strong>",
"     not",
"    </strong>",
"    reliably predict the ionized calcium concentration, even if the total serum calcium is corrected for a low serum albumin [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23685/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. This was best shown in 691 consecutive patients with CKD who had simultaneous measurement of total serum calcium, ionized calcium, and serum albumin [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23685/abstract/13\">",
"     13",
"    </a>",
"    ]. The total serum calcium failed to identify 44 of the 109 (40 percent) patients who had low ionized calcium levels, and also failed to identify 6 of the 28 (21 percent) patients who had a high ionized calcium. In addition, 11 percent of patients with normal ionized calcium concentrations were mistakenly identified as having either hypocalcemia or hypercalcemia by using the total serum calcium. Correcting the total calcium for the serum albumin did not substantially improve the reliability of the total serum calcium.",
"   </p>",
"   <p>",
"    Two major factors contributed to the unreliability of the total serum calcium [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23685/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with CKD often have metabolic acidosis, which can lead to an underestimate of the ionized calcium concentration when only the total serum calcium is measured. (See",
"      <a class=\"local\" href=\"#H30614447\">",
"       'Acid-base disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The standard equations used to correct for a low serum albumin frequently overestimated the ionized calcium.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, in patients with reduced GFR who have a low serum bicarbonate",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a low serum albumin, measuring the ionized calcium is preferable to measuring the total calcium in order to diagnose hypocalcemia or hypercalcemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The total serum calcium concentration consists of three fractions: (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Determinants of the serum calcium concentration'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      15 percent is bound to organic and inorganic anions.",
"     </li>",
"     <li>",
"      40 percent is bound to albumin.",
"     </li>",
"     <li>",
"      45 percent is physiologically active ionized (or free) calcium.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Measurement of the total serum calcium concentration alone is sometimes misleading, since this parameter can change",
"      <strong>",
"       without",
"      </strong>",
"      affecting the concentration of ionized calcium, such as with:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Hypoalbuminemia, because a large fraction of calcium circulates bound to albumin. The total serum calcium can be adjusted for the concentration of albumin using the following equation: (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Hypoalbuminemia'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Corrected [Ca] &nbsp; = &nbsp; Measured total [Ca] &nbsp;+ &nbsp;(0.8 &nbsp;x &nbsp;(4.5 &nbsp;- &nbsp;[alb])) (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?17/35/17969?source=see_link\">",
"       calculator 1",
"      </a>",
"      and",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?14/51/15153?source=see_link\">",
"       calculator 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Hyperalbuminemia, as may occur with extracellular volume depletion or by fluid movement out of the vascular space due to a tight tourniquet, and can also result from a very high protein diet.",
"     </li>",
"     <li>",
"      Some cases of multiple myeloma, in which calcium binds to the monoclonal immunoglobulin. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Multiple myeloma'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The ionized fraction can change without an alteration in the total serum calcium concentration, as with:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Acid-base disorders, in which an increase in blood pH may enhance binding of calcium to albumin, thereby decreasing the ionized fraction. (See",
"      <a class=\"local\" href=\"#H30614447\">",
"       'Acid-base disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hyperparathyroidism, which increases the ionized calcium at the expense of that bound to albumin. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Parathyroid hormone'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hyperphosphatemia, which increases the fraction bound to inorganic anions, decreasing ionized calcium. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Hyperphosphatemia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients who have CKD and a low serum bicarbonate, a low serum albumin, or both, measuring the ionized calcium is preferable to measuring the total calcium in order to diagnose hypocalcemia or hypercalcemia. (See",
"      <a class=\"local\" href=\"#H701808710\">",
"       'Measuring the serum calcium in patients with CKD'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23685/abstract/1\">",
"      Moore EW. Ionized calcium in normal serum, ultrafiltrates, and whole blood determined by ion-exchange electrodes. J Clin Invest 1970; 49:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23685/abstract/2\">",
"      Bushinsky DA, Monk RD. Electrolyte quintet: Calcium. Lancet 1998; 352:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23685/abstract/3\">",
"      Ladenson JH, Lewis JW, Boyd JC. Failure of total calcium corrected for protein, albumin, and pH to correctly assess free calcium status. J Clin Endocrinol Metab 1978; 46:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23685/abstract/4\">",
"      DENT CE. Some problems of hyperparathyroidism. Br Med J 1962; 2:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23685/abstract/5\">",
"      Mutlu EA, Keshavarzian A, Mutlu GM. Hyperalbuminemia and elevated transaminases associated with high-protein diet. Scand J Gastroenterol 2006; 41:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23685/abstract/6\">",
"      Lindg&auml;rde F, Zettervall O. Hypercalcemia and normal ionized serum calcium in a case of myelomatosis. Ann Intern Med 1973; 78:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23685/abstract/7\">",
"      Merlini G, Fitzpatrick LA, Siris ES, et al. A human myeloma immunoglobulin G binding four moles of calcium associated with asymptomatic hypercalcemia. J Clin Immunol 1984; 4:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23685/abstract/8\">",
"      Pearce CJ, Hine TJ, Peek K. Hypercalcaemia due to calcium binding by a polymeric IgA kappa-paraprotein. Ann Clin Biochem 1991; 28 ( Pt 3):229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23685/abstract/9\">",
"      McCloskey EV, Galloway J, Morgan MA, Kanis JA. Pseudohyperphosphataemia in multiple myeloma. BMJ 1989; 299:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23685/abstract/10\">",
"      Oberleithner H, Greger R, Lang F. The effect of respiratory and metabolic acid-base changes on ionized calcium concentration: in vivo and in vitro experiments in man and rat. Eur J Clin Invest 1982; 12:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23685/abstract/11\">",
"      Wang S, McDonnell EH, Sedor FA, Toffaletti JG. pH effects on measurements of ionized calcium and ionized magnesium in blood. Arch Pathol Lab Med 2002; 126:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23685/abstract/12\">",
"      Krapf R, Jaeger P, Hulter HN. Chronic respiratory alkalosis induces renal PTH-resistance, hyperphosphatemia and hypocalcemia in humans. Kidney Int 1992; 42:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23685/abstract/13\">",
"      Gauci C, Moranne O, Fouqueray B, et al. Pitfalls of measuring total blood calcium in patients with CKD. J Am Soc Nephrol 2008; 19:1592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23685/abstract/14\">",
"      Evenepoel P, Bammens B, Claes K, et al. Measuring total blood calcium displays a low sensitivity for the diagnosis of hypercalcemia in incident renal transplant recipients. Clin J Am Soc Nephrol 2010; 5:2085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23685/abstract/15\">",
"      Movilli E, Zani R, Carli O, et al. Direct effect of the correction of acidosis on plasma parathyroid hormone concentrations, calcium and phosphate in hemodialysis patients: a prospective study. Nephron 2001; 87:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23685/abstract/16\">",
"      Kaye M, Somerville PJ, Lowe G, et al. Hypocalcemic tetany and metabolic alkalosis in a dialysis patient: an unusual event. Am J Kidney Dis 1997; 30:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23685/abstract/17\">",
"      Ladenson JH, Lewis JW, McDonald JM, et al. Relationship of free and total calcium in hypercalcemic conditions. J Clin Endocrinol Metab 1979; 48:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23685/abstract/18\">",
"      Nordenstr&ouml;m E, Katzman P, Bergenfelz A. Biochemical diagnosis of primary hyperparathyroidism: Analysis of the sensitivity of total and ionized calcium in combination with PTH. Clin Biochem 2011; 44:849.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 845 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-3A8E13EC2C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_8_23685=[""].join("\n");
var outline_f23_8_23685=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DETERMINANTS OF THE SERUM CALCIUM CONCENTRATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H404378\">",
"      Change in total but not ionized calcium",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      - Hypoalbuminemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H177755193\">",
"      - Hyperalbuminemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H404424\">",
"      Change in ionized fraction but not total calcium",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30614447\">",
"      - Acid-base disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Parathyroid hormone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Hyperphosphatemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H701808710\">",
"      MEASURING THE SERUM CALCIUM IN PATIENTS WITH CKD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?17/35/17969?source=related_link\" title=\"calculator 1\">",
"      Calculator: Calcium correction in hypoalbuminemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?14/51/15153?source=related_link\" title=\"calculator 2\">",
"      Calculator: Calcium correction in hypoalbuminemia (SI units)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5545?source=related_link\">",
"      Diagnosis and differential diagnosis of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/25/24984?source=related_link\">",
"      Etiology of hypocalcemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27288?source=related_link\">",
"      Simple and mixed acid-base disorders",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_8_23686="Teniposide: Pediatric drug information";
var content_f23_8_23686=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Teniposide: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?4/55/4983?source=see_link\">",
"    see \"Teniposide: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?35/17/36116?source=see_link\">",
"    see \"Teniposide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F225346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Vumon&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F225347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Vumon&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1037877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antineoplastic Agent, Podophyllotoxin Derivative",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1037908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/55/4983?source=see_link\">",
"      see \"Teniposide: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Patients with Down syndrome may be more sensitive to the myelosuppressive effects; administer the first course at half the usual dose and adjust dose in subsequent cycles upward based on degree of toxicities (myelosuppression and mucositis) in the previous course(s).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants &ge;6 months, Children, and Adolescents:",
"     <b>",
"      Acute lymphoblastic leukemia (ALL; combination therapy):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Manufacturer&rsquo;s labeling: Regimens may vary: I.V.: 165 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     twice weekly for 8-9 doses or 250 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     weekly for 4-8 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alternate dosing: I.V.: 165 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose days 1 and 2 of weeks 3, 13, and 23 (Lauer, 2001)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal or hepatic impairment:",
"     </b>",
"     No specific recommendation (insufficient data). Dose adjustments may be necessary in patient with significant renal or hepatic impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F225326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vumon&reg;: 10 mg/mL (5 mL) [contains benzyl alcohol, dehydrated ethanol 42.7%, polyoxyethylated castor oil]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F225311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1037915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: I.V. infusion: Further dilute with either D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS to a final concentration of 0.1, 0.2, 0.4, or 1 mg/mL. Precipitation may occur at any concentration; inspect closely for particulates and administer as soon as possible after preparation. Administer slowly by I.V. infusion over at least 30-60 minutes to minimize the risk of hypotensive reactions; do not administer by rapid I.V. Administer through non-DEHP-containing administration sets; flush infusion line with D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS before and after infusion; incompatible with heparin. Observe patient continuously for at least the first 60 minutes of infusion, observe frequently thereafter. Stop infusion and treat accordingly for signs of anaphylaxis or clinically significant hypotension; if infusion is restarted after being withheld for hypotension, reinitiate at a slower infusion rate.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F1037899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR, NS",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, allopurinol, amifostine, amikacin, aminophylline, amphotericin B, ampicillin, ampicillin/sulbactam, aztreonam, bleomycin, bumetanide, buprenorphine, butorphanol, calcium gluconate, carboplatin, carmustine, cefazolin, cefoperazone, cefotaxime, cefotetan, cefoxitin, ceftazidime, ceftizoxime, ceftriaxone, cefuroxime, chlorpromazine, cimetidine, ciprofloxacin, cisplatin, cladribine, clindamycin, co-trimoxazole, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, daunorubicin, dexamethasone sodium phosphate, diphenhydramine, doxorubicin, doxycycline, droperidol, enalaprilat, etoposide, etoposide phosphate, famotidine, floxuridine, fluconazole, fludarabine, fluorouracil, furosemide, ganciclovir, gemcitabine, gentamicin, granisetron, haloperidol, hydrocortisone sodium phosphate, hydrocortisone sodium succinate, hydromorphone, hydroxyzine, ifosfamide, imipenem/cilastatin, leucovorin, lorazepam, mannitol, mechlorethamine, melphalan, meperidine, mesna, methotrexate, methylprednisolone sodium succinate, metoclopramide, metronidazole, minocycline, mitomycin, mitoxantrone, morphine, nalbuphine, netilmicin, ondansetron, piperacillin, plicamycin, potassium chloride, prochlorperazine edisylate, promethazine, ranitidine, sargramostim, sodium bicarbonate, streptozocin, thiotepa, ticarcillin, ticarcillin/clavulanate, tobramycin, vancomycin, vinblastine, vincristine, vinorelbine, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Idarubicin, heparin",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1037895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store ampuls at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Protect from light. Solutions diluted in D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS for infusion to a concentration of 0.1-0.4 mg/mL are stable at room temperature for up to 24 hours after preparation; solutions diluted to 1 mg/mL should be used within 4 hours of preparation. Refrigeration of diluted solutions is not recommended. Because precipitation may occur at any concentration, the manufacturer recommends administrating as soon as possible after preparation. In order to prevent extraction of the plasticizer DEHP,",
"     <b>",
"      solutions should be prepared in non-DEHP-containing containers, such as glass or polyolefin containers",
"     </b>",
"     . The use of polyvinyl chloride containers is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1037878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of childhood acute lymphoblastic leukemia (ALL) refractory to induction with other therapy (FDA approved in pediatric patients ages &ge;6 months)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F2138085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Teniposide may be confused with etoposide",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F225389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Hypotension (associated with rapid [&lt;30 minutes] infusions)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Fever",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia (usually reversible), rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, mucositis, nausea/vomiting (mild to moderate)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, leukopenia, myelosuppression, neutropenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Bleeding",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Hypersensitivity reactions (includes bronchospasm, chills, dyspnea, fever, flushing, hyper-/hypotension, tachycardia, or urticaria); infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Arrhythmia, CNS depression, confusion, headache, hepatic dysfunction, intractable hypotension, metabolic abnormality, metabolic acidosis, neuropathy (severe), neurotoxicity, renal dysfunction, thrombophlebitis, tissue necrosis (upon extravasation), weakness",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1037881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to teniposide, polyoxyethylated castor oil (Cremophor&reg; EL), or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F4431945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with renal or hepatic impairment; may require dosage reduction in patients with significant impairment. Use with caution in patients with hypoalbuminemia; teniposide is highly bound to albumin plasma protein. Should be administered under the supervision of an experienced cancer chemotherapy physician",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1037882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     . Severe, dose-related myelosuppression with resulting infection or bleeding may occur",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; monitor for infection and bleeding. Patients with Down syndrome and leukemia may be more sensitive to the myelosuppressive effects; reduced initial doses are recommended.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hypersensitivity reactions, including anaphylaxis-like reactions, have been reported",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; hypersensitivity reactions may include bronchospasm, dyspnea, hypertension, hypotension, tachycardia, flushing, chills, fever, or urticaria. Monitor closely during infusion; observe continuously for first 60 minutes, frequently thereafter. Stop infusion for signs of anaphylaxis; immediate treatment for anaphylactic reaction should be available during administration; may require treatment with epinephrine, corticosteroids, antihistamines, pressors, or volume expanders. Patients experiencing prior hypersensitivity are at risk for recurrence; retreat only if the potential benefit outweighs the risk of hypersensitivity; premedication (with corticosteroids and antihistamines) is recommended for retreatment.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hypotension may occur with rapid infusion; infuse slowly over at least 30-60 minutes; discontinue for clinically significant hypotension. If infusion is restarted after being withheld for hypotension, reinitiate at a slower infusion rate. Acute CNS depression, hypotension, and metabolic acidosis have been reported; these events occurred in patients who received high-dose teniposide (investigational protocol) and were premedicated with antiemetics, which along with the alcohol content of teniposide, may have contributed to the depression. Neurotoxicity and severe neuropathy have been reported when teniposide is used in combination with vincristine.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Teniposide injection contains benzyl alcohol which may cause allergic reactions in susceptible individuals; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (\"gasping syndrome&rdquo;) in neonates; use teniposide injection with caution in neonates. The injection contains polyoxyl 35 castor oil (Cremophor&reg; EL) which may be associated with hypotension and hypersensitivity reactions. Teniposide formulation contains ~43% alcohol and may contribute to adverse effects such as CNS depression, somnolence, lethargy, hypotension, and metabolic acidosis.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Teniposide may cause local tissue necrosis or thrombophlebitis if extravasation occurs. Teniposide is a potential carcinogen; may cause fetal harm when administered to pregnant women; may induce a secondary leukemia.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F225381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C9 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F225320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May decrease the serum concentration of Teniposide. Management: Consider alternatives to combined treatment with barbiturates and teniposide due to the potential for decreased teniposide concentrations.  If the combination cannot be avoided, monitor teniposide response closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of Teniposide. Management: Consider alternatives to combined treatment with phenytoin and teniposide due to the potential for decreased teniposide concentrations.  If the combination cannot be avoided, monitor teniposide response closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of Teniposide. Management: Consider alternatives to combined treatment with phenytoin and teniposide due to the potential for decreased teniposide concentrations.  If the combination cannot be avoided, monitor teniposide response closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine: Teniposide may enhance the neurotoxic effect of VinCRIStine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): Teniposide may enhance the neurotoxic effect of VinCRIStine (Liposomal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F225322\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9645716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects were observed in animal reproduction studies. May cause fetal harm if administered during pregnancy. Women of childbearing potential should avoid becoming pregnant during teniposide treatment.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F4431946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC, platelet count, renal and hepatic function tests; blood pressure; monitor for hypersensitivity reaction (observe continuously for first 60 minutes of infusion, frequently thereafter)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1037900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Type II topoisomerase inhibitor that induces single-stranded DNA breaks, double-stranded DNA breaks, and DNA-protein cross-links; induces late S phase or early G2-phase arrest resulting in inhibition of DNA synthesis",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1037902\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Mainly into liver, kidneys, small intestine, and adrenals; limited distribution into CSF &lt;1%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: V",
"     <sub>",
"      d",
"     </sub>",
"     : 3-11 L/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: V",
"     <sub>",
"      d",
"     </sub>",
"     : 8-44 L/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &gt;99%; primarily albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic, extensive",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Children: 5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine (44%, 4% to 12% as unchanged drug); feces (&le;10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: Renal: 10% of total body clearance",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1037922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?35/17/36116?source=see_link\">",
"      see \"Teniposide: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Notify physician if fever, sore throat, painful/burning urination, bleeding problems, tiredness or weakness, skin rash, pain or numbness in extremities, or shortness of breath occur. Advise women of childbearing potential to avoid becoming pregnant while receiving teniposide.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Clark PI and Slevin ML, &ldquo;The Clinical Pharmacology of Etoposide and Teniposide,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1987, 12(4):223-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/8/23686/abstract-text/3297462/pubmed\" id=\"3297462\" target=\"_blank\">",
"        3297462",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lauer SJ, Shuster JJ, Mahoney DH Jr, et al, \"A Comparison of Early Intensive Methotrexate/Mercaptopurine With Early Intensive Alternating Combination Chemotherapy for High-Risk B-Precursor Acute Lymphoblastic Leukemia: A Pediatric Oncology Group Phase III Randomized Trial,\"",
"      <i>",
"       Leukemia",
"      </i>",
"      , 2001, 15(7):1038-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/8/23686/abstract-text/11455971/pubmed\" id=\"11455971\" target=\"_blank\">",
"        11455971",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sinkule JA, Stewart CF, Crom WR, et al, &ldquo;Teniposide (VM26) Disposition in Children With Leukemia,&rdquo;",
"      <i>",
"       Cancer Res",
"      </i>",
"      , 1984, 44(3):1235-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/8/23686/abstract-text/6581866/pubmed\" id=\"6581866\" target=\"_blank\">",
"        6581866",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13052 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-684EC2BD62-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_8_23686=[""].join("\n");
var outline_f23_8_23686=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709983\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225346\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225347\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1037877\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1037908\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225326\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225311\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1037915\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1037899\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1037895\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1037878\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2138085\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225389\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1037881\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4431945\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1037882\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225381\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225320\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225322\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9645716\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4431946\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1037900\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1037902\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1037922\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13052\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13052|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/55/4983?source=related_link\">",
"      Teniposide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?35/17/36116?source=related_link\">",
"      Teniposide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_8_23687="TMJ dislocation";
var content_f23_8_23687=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F79109%7EEM%2F59637&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F79109%7EEM%2F59637&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    TMJ dislocation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 326px; height: 286px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The temporomandibular joint (TMJ) is the articulation of the temporal and mandibular bones. TMJ dislocation occurs when the condyle travels anteriorly along the articular eminence and becomes locked in the anterior superior aspect of the eminence, preventing closure of the mouth.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    TMJ dislocation reduction technique",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 592px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAJQAgMDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKjW4haZoVljMq8lAw3D8KkoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiuf1nxdpWkaq2m3I1Ka9WFLho7LS7q72RuzqpYwxsFyY3ABOflNAHQUVyv/CeaR/z5+JP/AAnNR/8AjFbWg6xZa9piahpjyvbO8kf72F4XDxu0bqyOAykMrAggdKANCiiq2p3iafp1zeShmSCNpCq9WwM4HuegoAyPEXiE2F7BpOlW32/XblDJFbb9qRR5wZZnwdiA8dCWPCgnOIYPCpvB5vii+l1eZuTbnMVmv+yIAcMP+uhc+/arfhbR3022mub4pJrF+/n30ynIL4wEU/3EGFUegyeSSdugDBuvB3hm6thb3Ph7SJIRjCNZx4XHTHHGO2OlZLaHpujPJ/ZXiC/0TyzloZrrzYD6YSfcAv8A1zK89+tdpVe6ufs8lspXKyyeWWzjZ8pIP4kAfiKAOXbXda022+2XqaVq+kRZNzfafK0TwqPvN5LbwQoyTiTOBwp6V2FZl3oVhdarFqMkcqXca7C0UzxiVcggSKpAkAxwGyBk+pyWedOvFsXObaQE2pJ+7gcxfgOV9sj+HJANOiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuGvNUttD8c+MNVv32Wtl4f0+4lP+yst+T+PFdzXD+ItD1ibxPqd3a6PoOs6XqOnWtnNbanePCN0Mtw5yoglVlPnr1xyvSgDx74DeN/ER+IFvF4s1DU57XxbaS3tpHeRzJFbzLI7COAyAKUMRBzH8vKjsK9v+Gn/ACLl5/2GtW/9ONxWdLZeIpm09pvBfg2RtPwbMtq0h+zYAA8v/Qvk4AHGOgrb8C6XfaR4fNvqq2y3st7eXkiW0rSxp591LMFDMqlsCQDO0cg8UAdBWJ4wjMukQoCADf2Wc9CPtURI/EZH41t1g+NwF8OSztjy7Se3vXzn7kM6St09kNAG9RRVbUL630+AS3chRWYIoClmdj0VVAJJ9gKALNZWoTvPq9np0HO0i6uT/cjGdg+rOBj2R+embEN811p7XFnAzv0SORgmT7kZwPXqfbPFR6LYzWqXE960b311J5kzR52qMYVFzztVQB2ydzYG4igDRrO14bdNkuR9+0IuVPf5OSAe2V3L9GNaNYWu6hFcaJq8MSXAlEEkY821dVZ2BVQu9Qr5YgADOc0AbtFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFQ3t3b2FpLdXs8VvbQqXkllcIiKOpJPAFYMXiW4v8AnRND1G6iP3bm5UWkJ/7+fvCPcIRQB0lFZmnjWZJxJqJsLeEZ/wBHt98pPv5rbePbZ+NadABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABVfULOHUNPubK6Xfb3MTQyL6qwII/I1YooAw/BV/NqHhqya9cNqEK/Zrz1E8fySf8AjwJHsQe9Zvj6WOB9MNw/7mZ3t9u7acsuS2f4f3aypu42+ZkkAEjLmmj1fxVdar4XvoIv7OSI3jxKzreZZ1dHCsAxREO04zkjBwMHrdO0ayiaW6kC3t3cptlupgGaRDj5RxgJjHyjA78kkkAyvCUtvbXs1isbW91LELiW3WJUjicHaVAGDwpjUHADKoIJ+bHVVhw6JdQT28cOqSjTIZRKtuyZcAA4jEmQdmcHBBPGM44rcoAbKGaNgjbGIwGxnH4VzVx4cuyNYmGpz3N1cxoLTz2wsDp8ynauF++AchQa6euf8Q3F3p93FPa3dtELp4Lbbc7nAJl2/JGCuSfM5O7jaODQBr6ddi+sorhY3iLAho3HzIwOGU9sggjjjjirNVtPtFsrUQq7yfO8jO2MszMWY8e7GrNABRRRQAUUUUAFFFFABRRRQAVS1LVLPTngS6lImnJWKGNGkkkx12ooJIGRk4wO+KfqN01pbho4/NndhHFHuxuY+/OABkk4OACcHFYk0lr4clN1fGe/1S9ZsuqjcEBzsQEgJGuRxnknJyxJIBdF7qt45W004WUYOPPvmViR2KxoxJH+8yEehrnNS1G4nnkinv4lSBmjcqSgYg85UMMewJPAFaUniqRx/o2n/jNMFx+QNVZr+5vH3vDaQOf40jDyD6M3+FAGfb2OQs9ndNICOMSFQfo6YI+vNX7bVbyzfa1yUQdY75SVH+7KP65P0p1nCkCbIwcEliSSSSTkkk8k5rRi7UwI18Q3EpUxnSAh7/bS3/sgrF1TxNcXOsjT49c07SbOK1kubm9UJIw2tGuFZzsTHmDllbJIwODXTLDG5y8aMfUqDWG+nw6746iS5UPYaFAk6Q4BRrqUttYj1jRAR7yg9QMIDOtIPtNzDcaZpWt69cI4ZL/W7pre1BHRxEe46hkgweoPQ12EemXU4DanqM8rd47XNvGD7bTv/NyPataigBFAVQBnAGOTk0tFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXP+M9QubfT00/SHA1rUibe0J58rj55j/sxr83udq9WFb5IUEkgAckmud8MomqX1z4kb5lukEFiT2tVOQw9PMYl8918vP3aAHzabNoz211okBmjgto7OSyDBTJEhOwoTwHXc3BIDbsEjAIZYTwPLINAvEEo+d9NutybeeoUjfF+RX/AGec10dU9U0uy1WARahbJMqnchPDRt/eRhyrejAgigBthqcF5NJBh4LyIZktpQBIo7N6FT/eBI6jOQRV6uR1ixktbdE1KW5ms4Pmt9VhP+lWR9X4+ZeMFsHI4dSNzFLTxcljY3cevPG2oWkaSIbVfkv43O2J4Bk5LsQmzJIc4yQVZgDr65mTRtPt/EGnQWlrFA7LLeSTomZpGjZAA0h+Yg+YScnJxjoSKjvH8UNapdTT6fYQdZ4Le3a5mhTByVkLBWI4yPL9cbuAdXStMSGYX0t/c6jO8WxJ5mTAjJBwoRVUAkAk4ycDJOBgA1aKKKACiiigAooooAKKKKACiikkdY0Z3OFUZJ9BQBnalIP7S0uIMAwkkmbI/gWNlJ9uXXn/ABrn/GOoxSXUNotvA7LGJluHOSFbI+TGPTrnHsataRFNrWnHW7ryftF9aMllA3McMEgDKrddzNhC/BHAAyBlrmhaXPa+HobS6h063vIRIEeyhCxKxYkSKhHyschiORknk9aAOCTTYoovOaymdGP+slO0Of8AZDEbv+Ag1r6dEIo8eTHFnnCHP58Cq5sdZa5dWtJXnBKmZw8hbB7M20Y445/CtSx0TVFyfJXc33muJwPyCBgKYixF2q7F2qMaPqePlks4z77n/wAKmi8OmWTdqd7LcIOkEQ8mI/UAlj9C2PagYyXVbC0k8u4vII5P7hcbvy61neHdThTxxqtozYTUYIru1dkZfNKDy5UGRyVHlN9JPY1taOkFnrGp6fBFFEqLDcokYChUcFAMDp80Tn8frVjW9E07XIIodUtVnWKQSxtkq0bjjcrKQVOCRweQSOhNIDRornYPBukW8rPAdTiLHJCardKp/wCAiTGPbFaemaRYaYXaytY45HADycs7AdAWOSfxNAF+iiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiimyyJFG8krBI0BZmY4AA6k0Ac14pUa5eR+GY5SkU0YuNRKHn7NuwI89vNIZc/3Vkxg4rpkVUVVRQqqMAAYAFc14Dja50+4124Rludak+1gN1SDGIEx2xGFJH95n9a6agAooooAiFxCbk24lj+0bd/l7hu29M464964r4ieH9Pm0YSWD2enaxYrcXlhIwCqG2HzQR/dYH5iOhw3VRXY39lBfQ+XcKTg7kdSVZG/vKw5B9xXJ+LoDPo0ln4h8xY4HE9tqsfyojDO0zBeU4LK5xsKk8ru2gA7ONt8avtZdwBwwwR7GsTRC2majPo0oPkYNxYt28on5ovYxsQAP7jIBnDY0NE1GPV9GsdRgGIruBJ1GQcBlBxkemcVZlgilkheWNHeFi8bEZKMVK5HocMR+JoAkorKjv5bO/hstTKnzyRb3KjasrAE7GHZ8An0bBIx0GrQAUUUUAFFFUdQ1jTdNBOo6jZ2gHUzzrHj8zQBeormW+IHg1Vdm8W+HgqNtYnUocKfQ/Nwa6E3EIhExmjERAO8sNuD05oAlrN1HXdL02Ty729hil67M5Ye5A5ArK1bVri/dbPSHMSyDL3OOQn95R2B6A9+3HzCC3sbexi8u2jC55Zjyzn1Y9Sfc0AZnge88OaoEtLTUIxdR3Ul4NLEhTySGONsbYO1QRnb8m75h1zXoNcFqVnFdSWsjjE1rOtxDIByjr6fUZB9QSO9Ovdav4gXk1Mwg8D5IwM+2VNAHd1ymq6pc/bNektrlmsLCwWUFFG1LhGkZl3dzhUDLngYzjdzz6Xl9rl3DYte3D+adoaRfKUYBOcKBuOASOv4da9IaJHhMUgEiFdrBxkMOhz60APooJAGSQB71xfinVdV1Oyks/DEFyol3RG+ClS3HSFiMDv8AvWwBjKiQ8UAXfCd0mq6z4i1OGRJLcXK6fCynIKwLh/yleZcf7Oe9dPWJ4L8P2/hbwxYaPaBNlsnzMowHkYlnbHbLEnHvW3QAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcx8RN1x4fXSo2IfV7iLTzg4Plu377HuIRKR9K6euZ15xN428LWh5MYu78DHTZGsWf/ACZx+NAHSqoVQqgBQMADoBS0UUAFFFFABRRRQBzM1lN4Zc3WjwvLpJYtc6dEu4xZ6yQKPxLRjryVG7IfoLO6gvbWK5tJUmt5lDxyRtlWU9CDU1cteTf8Irqb3Tqw0C9fdOwyVspyeZCO0T/xHgK3zHh2ZQDc1jTLbWNOlsr5GaGQq2UcoysrBlZWHKsrAEEcggGsoWPia3jKW+t6dcqn3Deae3muPR3jlVcn+8IwB/dNdEDkZHSigDGsbnUtShaO7sLvRpkOHkEkMyv/ANc2BJx3yyKcdgejH8K6Tcktqlt/akh6tqB88Z9VRvkT/gKityigDnZ/A/hWeLy5PDej7cYG2zjUgZz1ApdM8E+FdLZW03w1otq64w8NjEjce4XOat3WuQCZ7XTlOoXyko0MDAiJv+mr9Ix9eT2BPFQzW2vzRtKL+zt5QN0dvFCSpOfuvI2SRjjcqKQTnBxggF/UdQstKtka8lSGNiI40AyznsqKOWPsATXP6V5F3eardadNFL51yCWaPa9rthjQxFDhlb5C2GAxvHWtjRLWJokvpbSaK/kUrI10Q0q88ruHAXIyAuF7gc1T8T6fMg/tjSI2OpWwBeJP+XyIfeiYdC2MlCfut3wWBAHx20dsjBMsznc7scs59Sagm7059RtpILeSCQTfaEEkCx/M0qkZBA9Md/zpi2+p3HK2Cwg/895gCPrt3UwKU1YN7dRRyszPZqwGNzzANj8v611g0O9nYefcQW6dxEDIx+hOAPyNUPGVhbaboEi6fEJNZvCLKweb94RO+QHCnj5BukOB91GPagQeBbVri4l1CVS8QQC3l2lVOc7ioPXjHze5x3rtK5LSfDut6M08Wm63ZGwkkEixXVhJK6/KA3zidRliCxO0ZZmOMk5uXmhalqWE1HX7qK3z80OmRi13j0ZyWkH1RlNIZB4r1H7Y66HozpNrBlgmYAbktUWRX3zc8AhTherHpxkjU8NXy3+kxt9nNrLCzW81uW3eU6HaVz3HGQe6kHvU+kaVY6NZC00u1itoAxcqg+8x6sx6sx7k5J71zuoajcaJ4rube2tEkXVLf7XG80whhE0W2OTe5BIyhgwAp+6xxwaAOvorln8SahpJRvFekw2Fo5wb2yuzdW8Jzx5paONkB/vbSo7kd+poAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuWRftXxQkfqNO0dUHsbiYkj6/6Kv6e1dTXLeHyW8d+LCeSFs1HsPLY4/Mn8zQB1NFFFABRRRQAUUUUAFIyhlKsAVIwQehFLRQBxOn22o6Rr2oafpFw02mWcVvcw6e+3CpI0weJHPI2+WGQE7QDs4XBXpYta0+SKRzcrG0eA8coKSIT0BQ4YE4OOOe2ayfDd6k3i7xZabD5sE1u5ckZCtCoC4zkYKM3/A/rU/2C+Hj86gFf+zW0wQMfN+XzRLuHyeu0nn8KAJLvXmijPl6deK8qsLV50CJNIFJVDzuTdjA3qOeOpAMVhp0Os2cV3qV9JqUcgz5QzDbjnlTEDzgjBWQsQQRx0rW1OyW/tVhZ2TbNFMCBnmORXA+hKgGmafp4srvUJkkJW7lE2zsh2Kp799ue1AFq2t4bWBILWGOGFBhY41Cqo9gOlSUUUAFUNW1SHTljVkknupiVgtoQDJKR1wCQABkZYkAdyKyNV8UhdY/sXQbX+1NXXBnVW2w2ano00mDtJ7IMs3pjJGtpmmJZySTyyyXV7KAJLmXG4gdFAAAVR2UD1JySSQCDwvpR0vTFjlit0uGeR2EK4CKzsyR5xyEUqgPGdvQdK16KKAEdlRWZ2CqoySTgAVyfhZZPEWoDxReIy2xVo9JgYY2QHrOR/fkwCPRNo4LOKueM5VntLXRct5msS/ZDt6iHaWmOe37tWAP95l9a6BFVFVUUKqjAAGABQAtFFFABXPeOYimi/2nFH5k+lOL5FC7i6KCJUA7lomkUe7D0roaQgMCCAQeCDQBzln5dnqEekuEudF1CB3tN+GVMAboefvKVbco5wFcdAopfCCNprXvh93aRNOKtbOx3H7NJu8tSfVSrp67UUnk1Q8Pj7NpnhyxkTJsdQnsIywyQkUdwkbH3Maqc/7XWuhtpWfxBfoMGOO3gGf9otKSPy2/nQBo0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcxpcflfEfxEAOJtOsJc8cnfdKePoq8+49K6eubnPk/EazHa70qfJ5/5YzRY7f9Nz39aAOkooooAKKKKAMvUr7ULNXli0pr2BT9y3nXziOOQr7V9eN2emMk4E2k6rZ6tA0tlKSUO2WJ1KSRNjO10bDKcc4IHBzV6srWdBsdWZJZ0kiu4xtiu7aQxTxj0Drg4/2TlT3BoA1aK5aOy8V6WuLXU7LXIV+7HqEf2acj3miBQ/8AfofWn2/jGyjvY7HXYLjRL6RtkSXoURTN6RzKTGxP93Ib1UUAdKFUMWCgM3U460tFFABRTJpY4InlmkSOJAWZ3OAoHUk9hXIyeLLvW2MPgiyS/U8HVbnKWKe6kfNOfaP5exdaAOk1jVbDRdPkvtWu4bS0j+9LKwUZPQD1J7AcmuUa41/xj8tiLnw74fbrdSLsv7pf+maEfuFP95vn9FU81oaR4Pt4dQj1XXLqXW9ajOY7q6UBLf2giHyxfUZY92NdRQBn6Doun6BpyWGkWqW1spLbVySzHkszHlmJ5LEknua0KKKACiiigDl4nN78S7lSoMel6Wiq2P47iViwH0Fuh/4EK6isDwoiTXGuakvP2vUJEGeqiECAj6bonP8AwKt+gCppFw13pVncOQXlhR2x6kAn9at1heEyYhq9ixz9j1GVQfaTbOB9AJgv/Aa3aACiiua0/N54+1e4JzFYWkNlGP7sjlpZfzX7P+VAFWPCeKJI8YJ1kSgYIGDp5GfzVq6DTmzeaoPM34uVGMY2fuY+P6/jXJzM5+LK2xkwBbxXgTP3hsuI+nqD/Out07f9r1TeoC/aRsI7jyY+T+OfyoAvUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFc14mHkeJPCl5kAfa5bRyR0SSB2HPu8UY/Gulrlvid5kfgjUb2BS0+m7NSQL1Jt5FmwPqEI984oA6mikR1kRXRgysMgjoRS0AFFFFABRRRQAVjNZ2t9d6vpmpW8V5bXAjnaGdA8bIy7Nu0jHWIn/gQrZrmvGkr6YdL1m3I823u4rR4yf9dFcSpEyfUMY3HfKY6MaAOb8NaRqtlq3iS08M6sbOz0++S2g0+/Rru3EbWsEuUyyyJ80jjAcrgYC1vGz8bTDY+taBbKerw6XK7/AIbp8D6kH6VdstI1Cykvp7e+tPtN9cfaJ2ktGZchFjAUCQYAVF6k85PfAs+Rrn/QR03/AMAH/wDj1AGRF4HsrmZJ/El5e+IJ0O5Vv3XyEbqCsCBY8jsSpYetdWAFAAAAHAArMSDWg677/TiueQLFwSPr51PJ1dHchLCZBnaNzxk+mThsfrQBo0Vkvca4ACunaa3qPt7j8v3P09Kqvruo274vPDepeWPvTW0kMyqO527xIfwQmgDoKKo6Rq9jq8Dy6fcLKI22SIQUkibGdrowDI2OzAGr1ABSMwVSzEBQMknoBUN9eW2n2c13fTxW9rCpeSWVgqoo6kk9K5yLzPGVtuuIJ7Xw8/SCZCkt+v8AtqeUiP8AdPzOOuFyGAIfhbcwzeG54IX3m3vrnJxjckshnib/AIFFNG3/AALFdhWB4ei2694mk+QL9sijVV7BbaE8/wDfXT0ArfoAwtNby/GWuQDo1taXR47sZY/5Qit2uYsgyfEzWS74WbSLHy0JPJSa73kD28yPP1HtXT0AFc34LkFzN4iuwP8AXatKuc9fKRIf/aVdFNIkMTyzOscSKWZ2OAoHUk9hXKfCxXPgq1u5EKtqM9zqPIwStxcSTLn/AIC6/TpQBVuDs+MduSsREmkBQSPmGJJCT+oH4n1rpdDAMV3KH3iS7m/DaxQj81Nc5eop+M2kHCZ/sG8Y+uRcW4B/J3/Ot/wxn+zZs4B+23fT/r5koA1qKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACsrxWCfC2sAf8+U3/oBrVpCAwIIBB4INAFbSWRtLs2icPGYUKsP4htGDVquJ8O6ra+GrQ6RqImt9Ns3eGyvJEYxLCrlVjkfGEZAABuI3LtIJJYDV/wCE38MGTZHr+mzNjdiG4WTA99pNAHQ0VjWPijQr66S2tdWsnupPuQ+cA7/7qnk/hWzQAUUUUAFchAD4k8bTzSZbSdAYRQr/AAy3rLl39/LRgo/2nfuoxZvLjW9bY2+lxSaPYnh9QuEHnsv/AExiOdp6/NIBj+42cjZ0fTLbR9OisrFGWGMs2XcuzMzFmZmPLMzEkk8kkmgC7RRRQAUUUUAFFFVtQ1Cy02HztRu7e0hzjfPIsa59Mk0AZuv6O9w41LSjHBrcCYhmIwJVHPky46xn/wAdJ3DkVU1fxbHYWmnJDp93c61qMYe30tQFlBIyfMJ+WNV5yx44wMnANyXxHaraz3UVvfTWsEbSyzCAoioq7twL7d4wP4N1cJosPiRPHupIsNmLyWCJp76dxIsCMmWSJAclg5AOcDZHFnJbIAOvs/D9zqE0N74snivLmNhJFZQgi0t2HIIU8yOP779+VVK0r3W7e3uGtreKe/vFODb2qhmTv87EhU45+ZhntmsyTwpcLmW18S67Fdn70rzJKrn3idDGAfRVX2xTLOHxZpcQt4rfw7qEC/cZWl0/Az3QJKCep4IyewoAn8MSMNe8TRTRmGeS6guxExBYRvbRICcEj78Mq8Ej5K6OuHNn40k17+04rbw7Ys9t9mlX7VPchgH3If8AVx/d3Sf99fjWqLDxTMmLnXtNhzjJtNMZWHTIzJM4PfnbQBmfFC3t7m10W3AkTU7vUoLW2uLeVop4kLh59jqQw/dRyEjOOBkHFX4vDuswwNDF4w1Rk/gee3tnkUemREAfqQT7nrT9F8KLZaquqanquoazqSKyQzXpjCwK2NwjjjVVXOBk4LY4ziukoA8w8c+HHW00W21XXNZ1kXmq2ts8N1JFHFKhfdIrxwpGrrsRuGBFenABQAAABwAK4zWXTWPiZoWmx/PHosMmq3JxkJJIrQQKfcq87e20HvXaUAc1dpEfiTpbrEPPXSbsPJt52ma22jP1DHH1q34Rd5NKnaRdrDUL5cYxwLqUA/iADVcsz/ENVCfJFpZJbPd5RgY/4Aam8GStPoKzOAGkublyB0yZ5DQBuUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGV4fIP9pAEHF7ID7dK1a5zwq+zWvFdqx5j1FZFB6lHtoWz/31vH/Aa6OgCnq2l2GsWT2eq2Vte2r8tDcRiRSfXB71hyeGbrTwsvhnV7u1ZOlpeytdW0g/ukOS6egKMAPQgYrqKKAILB7mS0ja+higuSPnjikMiA57MQpI/AVPRRQAUUUUARXUrQW7yRwS3DqMiKIqGb6biB+ZFY1v4t0d51t7y4bTbtjtWDUUNs7n/Y34En1QsK3qhvLW3vbZ7e8giuIHGHjlQOrD0IPBoAmByMjpRXJJ4C0ux3P4bmvfD8x5H9nTFYR/27tuhP8A3xn0IqlqN1400uyuIbvT7XXrd42RbrS2FvcpkEBjBI2xiOuVkHThe1AG1Bc3fiKHzrC4ex0p8+XcRqDNcj++m4EKh7HBLA5G3gm3pnh7S9NuPtFtaK14QQbqZjNOR6GVyXI9s4rF0zx54akiFpBcNaXsKqi6VcQNb3XoqrC4DHsBgEdOcVoJb67qW5ry6j0m2Y/LBagSXAH+1K2VBPcKpx2c9aALfiWfT49HuYNVv4LGC6jeDzJZFT7ykfLu6nnpXPeHrS4XU7/W5bR79rtt8U0I8ksAoUfupNm3AyAxLkg8MAQD0WlaFp2luZbW3BuWGHuZmMs7j/akclj9Ca06AMiS61tpENvpdj5LHn7RfMkij/dWJlz/AMC/Gnpf6htZX0iUTL3E8Zjb/dbO781FalFAHM/23r6LM03hWfagJURXsLlvwJHNLZeJNQuraKdPCurskihlaOezZSD0IPnjIx7V0tYF7b6jpM8t3o0QvbSRi8+nFwjbjkl4WPAYnqjEKTzlTncARv4g1NWUL4P11s5586yAX6/6Rn8gaYbvxZfJi20zTNKVv+Wt5cNcSJ9YowFP/f2p7fxfoUgUXGow2M5O029+fs0oPpskwT9RkHsSK27eeK4iWW3lSWJuQ6MGB+hFAGX4a0KHQ7acCaS6vruU3F5eS433EpAGTjgAABVUcKoAFbFFFAHPWwZ/iDqRJGyLS7XAxyS8txnn/gA/Op/BcxuPC+nzEbfMQvj0yxNZnhrUrLV/G/iG606dZ4obW1spGU8LLFNdhl/DcPzFavgyVZ/B+hSx52SWEDLn0MamgDYooooAKKKKACiiigAooooAKKof2taySNHaF7yRTgi3G8A9wX+6p9iQaCdRmHyLbWgzkb8ysR7gFQp+hYUAX6iubmC1j8y6mjhjzjdIwUZ+pqv9g3f6+7u5j2/eeXj/AL425/HNPttOsraTfb2lvFJ/fSMBvz60AVjrunH/AFE7XQ7m0ie4A+pjBx+NNbWd5xa6bqVxzjiDyv8A0aUrVooAxH1q/VUI8M6uxbqBLafL9cz/AMs1N/al3/0AtS/7+W//AMdrVooAxTrN8JxH/wAI1q5X/np5lrt/9HZ/SpINYmODd6Nqdopz8zrHL+kTuf0rWooAzF17S94jlvYbeUnAiuT5Ln0+V8H9K0gQwBBBB5BFDqrqyuoZWGCCMgish/DOjk7obFLRz1ksma2c/VoypP50AbFFYR0K7hP/ABL9e1OBRysUxjuE/EupkI/4GKRv+Entjx/Y2pA9v3lmV/8ARu79KAN6iufPiKe2x/amg6tbL0MsMS3aE+whLPj3KCrem+IdI1KfyLLUbaS6AybcuFmX/ejOGH4igDVooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOWvc6V4+tLxuLTWLYWEh7LPEXki+m5XmGfVUHcV1NcF4rtLjxX4zXw2081rpVhYJqc8sD7ZHuHkdbbB9EaGST3ZY+wIO14W157uebRta8uDxFZqDPEvCzx5wtxED1RvTna2VPIyQDo6KKKACiiigAooooAKKKKACiiigDO1zQ9K1+z+y61p9rf2/UJcRBwp9Rnofcc1zjeFtZ0X5/COvSiFf+Ybq5a7gI9FkJ82P/vpgP7tdpRQBymkeLydTh0jxLp0miatMSsCvIJbe6IGSIZgAGOOdrBW6/Ljmurqhrmk2WuaZNp+pwia2lAyMkFSDkMrDlWBAIYcggEVj+CdRujHf6NrMxm1TR5BFJcOADcwsN0U5A/vLkN23o+OKAOnorkLz4k+FbWd4jqUs4RtjS2lnPcxK3oZI0ZAfxqh/wALg8DBdzay6ruK5axuBkjr1joA76iuMh+J/hGa3M8WpytGMciyn5+g2ZP4VC/xW8GxyIj6pMrv91TYXALfQeXQB208Uc8TRTxpJEwwyOoII9wa5l/APhxLl7nT9P8A7Jun5abS5Xs2Y+reUVD/APAgaqxfErw7M4S3GtzsfuiHQr5930IhwfwqpffE6ztoy0PhjxrdtjOyHw/cg/8Aj6qP1oA3JNJ1+3GNN8SLJ7anYJPgeg8poT+ZNZ9/ZeLZbeZdQ8RaNp+nCNjPcWlg6zomOSjvMyIQMncVbHpXPL8Sta1N/L0zwtqmlq3SXV9Kvyy/9s4oCp+nmio4LY62yy+Kh4o14b8jT/7LaxsgRzzExBce0juPbIoAn+BFnb22k6lJZWz29pLNvt0YEHyHd5Yic858uVMk9cA13Hg6NIfCGhxRjCJYwKo64AjUCq3hUk6n4mypQDUI8Rn/AJZ/6HbfLxx+XFTeB4Tb+C/D8JO4x6fbpn1xGooA26KKKACiiigAps0iQxPLM6xxIpZnY4CgdST2FVNX1O30q0E90WO5hHFFGNzyueiIvcn+QJOACaxhoMuuypdeKlSSFWDwaUG3QREchpP+er9+flUgbRkbyAMg8Tz625TwrYm7tuP+JnckxWhHrGfvTf8AARsP98Veh0E3AD67eSalJ1MRHlW49hEDgjv85cg962wMDA6UhIUEkgAckmgBERY0VI1CoowqqMAD0FOrFbxToXnNDFqtpcTrwYbaQTSD/gCZP6VrW8y3ECSxiQI4yBJGyN+KsAR+IoAkooooAKKKKACiiigAooooAKKKKACiiigAqnqel6fq0Ah1Sxtb2EHIS4iWRQfoQauUUAc7/wAIuLXB0TVdS00j/lkJvPhPt5cu4Kvsm2mm98Sabj7dpttq8A6zaa/ky/8AfmVsY+kpPoK6SigDJ0nxDpmqXDW1rc7b1F3PaTo0M6DpkxuA2PfGD2Na1UdX0jT9YhSLU7SG4VDujLr80bf3kbqre4INZBs9c0UbtMuG1iyXraXsgFwo9I5v4vpJyT1kFAHS0VmaNrdnq3mpAZIruHAntZ0Mc0JP95T29GGVPUEjmtOgAooooAKKKKACiiigAooooAKKKKAOB1zTp7r4lGfTbwafrEelRPayMu+K6jWWQTRSpkblBeEgghlLZB5IJ4n+y6rbQx+K9N1LR722Yvbarp5aUW792jmRdyLjqJUVT0INbvjDSbq9js9R0YxrrWmSGa18w4SUEYkhc9ldeM9mCtg7cVJ4Y8Uaf4gSRIC9tqMHF1p9yNlxbN6Onp6MMq3UEigDnNG8R65BESjaf4x05OPtujzxpcgf9NIS2wn1KOM9kHStmLx34dDbL+//ALKm6GPVYnsjn0HmhQ3/AAEkHtWpqfh/RtUmE2paTYXcwGBJPbo7j6MRkVT/AOET0xVKwPqUCngJFqNwqDtwm/b36YoA2bS7tryPzLS4hnj/AL0Thh+YqauPT4d6A16txe2lvflc/LdWNq3UEffEQfv13VZPgPw1lTHpawlF2r5EskW0e21hj60AdPRXJP8AD7QyS0UuuW8hUrvg1y9jIH4S8/jWL4ksbTwbpr3p8Y+JLY9ILVrmO8kuZOixRpMjs7E4GAc+460Aej0Vx2jp45Gj2U97daJJevAjTWsttJGySEAsplRyDg5GRH2qRtf8S2Tf8THwfLcJnl9J1CKcAeuJfJb8ACfrQB1tFcvaeO9Bku47S+uJdJvpDtS31SF7VnPohcBX/wCAk1a17xbo2i22+e8inuXwsFnbusk9y5OAkaA5Yk8eg6kgAmgDeorlvDVvqeoytf67qJFwr8aZZSgQWh/uO6/NK4/iydueijqepoAK4vW7O3HxP0SS4t4por/Tbm3kWRAwLxPE8R5GMgPP/wB9Gu0rlfEHzePvCSKMsEvZD7KERSfzZfzoA6O5+zR+XLc+Suw4R5MDafYnpTBqNkTgXltn/rqv+NVNK0ywNhBKbK2MssaPI/lLudto5JxyadLoGjSyF5dJ093PVmtkJP6UAadFYDeDPC7MWbw3opYnJJsIsk/9806Lwf4ZhcPD4d0aNx0ZbGIH/wBBoA3aKwpfB3hmaQvL4d0Z3PVmsYiT+O2srXvBnhOG2gnPhjQvMW6gRW/s+Eld8yKcHbxkHFAHZUVzFl4P8MSwsz+GtDyJJF4sIugcgfw+gqG38KeGf7euoB4b0VRFbwSqRYxcFnlH93/YFAD9EkITxfcxyEyG/kO4Y4KW8SDH0CD8a2vDsJt/D+mQk7vLtYkz64QCuT0xILH4feKGtoo7S1jl1IRrGAiosbyJwB0A2HHsK7i3iWCCOJM7I1CjPXAGKAJKKKKACob26hsrSW5uX2RRruY4JP0AHJJ6ADkmpqyCv9qat83NlYvwOoln9fcJ+PzHsUFADdLsJJ7watqsYW+KlYISQwtYz1Udt5wNxH0BIGToajfWum2cl3fzxwW0Yy0jnAHOAPck4AHUk4FM1fUrbSrJrm7ZggIRERdzyOeFRFHLMTwAKy9N0q4vr2HVvECJ9qjybWzB3R2YOec9GlIOC/QdF4yWAI0utd1obrKIaLYHpNdR77qQeqxZ2x9iC+49igNPTwhpcrCTVRPrE3UtqUhmXPqIj+7U/wC6oroaKAGQxRwxLHCiRxqMKqDAH0Ap9FFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGZrWiWmreU83mQ3kGTBdwNsmhJ67W9DgZU5U45BFUrPVrrT7yLT/ABD5YeUhLa/jG2K4Y9EIP3JP9nJDdVPVV6CoL6zt9Qs5rS9hSa2mUo8bjIYUAT0VhWl1NpWoRaZqDvLbTfLZ3kjZLN/zxkPUuAMhv4gDn5hlt2gAooooAKKKKACiiigAooooAKx9f8NaRrzRSapZJJcQgiG5jZop4c/3JUIdP+AkVsUUAcoPDmuWX/II8WXhjH3YdTto7tF/4EvlyH8XJ96z31Pxla+IYdIJ8O300lq90r7J7UFUdUPGZcHLqf8A9WT3dcxPal/ibY3WBti0i4iJ9C00J/8AZDQA0an4wjP7/wAM6W+OT9m1hnz9N8CfriqGma94w1vSbK+03QNEt7e8gS4jkutVkYhXUMvyLBycEZ+YV3Fcp8Kbb7H8N/DlqVK+TZRx4JzjAx/SgCE6D4r1I/8AE48VJZQH70Gi2SxNj0Mspkb8VCn6VpaD4P0TQ7pruysvM1Fxh766ka4uX9QZZCWx7Zx7Vv0UAFFFFAEF9ZWuoWr21/bQXVu/3opow6N9QeDXAaV4C0U+KNUbT7a20/SbaVI5LGxgS3EsxiRjvZAD5W1kPlggFi5bOcV6NXO+DJVlTWyCTIuq3CuT6ggD/wAd2igDeghit4Uht40ihQBURFCqoHYAdBUlFFABXH61Ns+JekSMpaO10TUJiM9WMtoBj3wr/nXYVwniWRo/GGozoAzWnhydlz0BeTPP18ofkaAOr8OxvD4f0yKQhnS1iViDnJCDNaFR20Qt7eKFSSsaBAT1IAxUlABRRRQAVj+KmRdMgMhAX7dZgZ9TcxAfritisDxx/wAgW2/7Cenf+lkNAFzQ3ZlvwxJCXcqr7DOf5k1Ws5WPjjVojjYunWTD6mW6B/kKd4ei8m915NxYfb9303QxNj9aisv+R+1n/sGWP/o27oAxIiU+GficlDMRJrJ2Y+9/pNx8v9K7quFtefhjdBJQn2l7geYTnd5tw/Pvnf8Ajmu6oAKKKKAGu6xozyMFRQSzMcAD1NZNrLdWFubdNMuLgRklJYpYsS5OdxLMp3HOW46561PqB+13UengExlfNuD22Z4X/gRB47qrD0rRoAxtO0uZ7xNS1lo5b9QfJjTmK1BGCEyASxHBcgE8gADitmiigDLurey+3QxTzXaTTq+wC6lRWxjIGGAzzkDrgHHQ0p0HTH/4+LRbngD/AEljNnHrvJ596vzwRXERjuIkljPJV1DA/ga5q+0Szs717h9Dsb+ykO59tqjTwnuQMfOp64HzA9NwICgGi/hfQHGH0PSmGd2DaRnn16daR/DOl5zbwzWfOcWVzJbDPuI2AP0IqGHw/wCGr5POttL07cPlE0EKxyRn0DKAyMM+oIratIFtreOFGldUG0NK5diPdjkn6mgCOwtpLWAxy3dxdnOQ84TcB6fKq8fXn3qzRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBW1Gyg1GyltLtN8MgwcHBBByCD2IIBBHIIBqpod1OfOsNQbdfWm0NJjAnQ52SjHTOCCOzK3bBOpVK8svOvbO7iYRz25K5IzvjbG5D+Sn6qPegC7RRRQAUUUUAFFFFABRRRQAUUUUAFZsUTnxJczMfkW0iRB7l5C38l/WtKoRCReNMGG14whXHPBJBz/wI/pQBNWF4JRovDsMUg2tFNPHt/uhZnAH4YxW7WX4btltdPmjQghry6k4Pd7iRj+rUAalFFFABRRRQAVzXg8SLqXitJGzt1YleegNtA3/s1dLXK+BcNc+KZQTiTWZeCOm2OJP/AGTP40AdVRRRQAV55qj/AGrxH4/kH3bTRLezB9H23MrfpJH+XvXodeY6IZbjwH4812JQ8urT39xBu/ijij+zxfgVgUj/AHqAPTqKKKACiiigArm/Hsix6VY+bKkMJ1OyaR34AVbhH69vujmukqG7tbe8gaG8ginhbBMcqBlOPY0AVNL1DSby5ul0u9sriclZZ1gmV2GQFDMAeMhMfhVKMxW/i/VriR8E6bakj/ZSS5JIH/Av5Vs21tBapstoYoU/uxoFH6Vxvje4FpLrssaEz/8ACPXMgbJ/5Z5IH5uaAEs4mi+F3huGeIyOy6Wkqg9S0sIcn8yTXcVg+IbYwaDZW8D7RFeWKg46qtzFkfiARW9QAVHczxW1vLPcOI4YkLu7dFUDJJ/CpKxtdYXd3YaSORcMZ5xn/lhGQSPcM5jUjurN6UAWtGSQ2pubiMx3F0fOdG6pkfKp9woAPuCe9X6KKACiiigAooooAq3On2txKJZIgJgMCVCUcD03Lg49s1VuNNuj/wAemr3tuB91Csci/iWQsf8AvrPvWpRQBzpTxXaMWWbRdTj7RtHLZuB7vulBP/AVH0q1Y6/bzagmnXsUun6m6l0trjH71R1MbAlXA7gHIBG4DIrYrE8X+GrHxTpJsr/zI3RxNbXUDbJrWUfdkjb+Fh+vIOQSKANuiuN8La1qen3ieH/GbxnVCzCy1CNNkOoxgZz6JMADuj9iy5GdvZUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFUNFiENnIqkkG5uH59Wmc/1p9hdz3Mk6z6fc2aRttRpnjPm9eVCM2B064PPSrlABRRRQAUUUUAFcn8NQW0fVZiqr5ut6l0OSdt3LHk/98fyrrK5X4YxeT4RRdpXN7fPg9913M2fxzn8aAOqooooAxfG2rHQfB+taqn+stLSWWMf3nCnaPxbA/GqMmlJofwyk0qM5Wy0hrfd/e2Q4yfc4zVf4pEyeHbOyBx9u1Wwtm5x8huoy4/74VhXR65Es2i6hFIMo9vIrD2KmgC6DkZHSiquk/wDIKs/+uKf+girVABRRRQAUUUUAFedfEzyxqc8ZdxJdeG9Tix1AG+2UH8DLXotebfFTCa1YP1LaNqMP4GS0bP8A44PzoA6/xRD58emJu241CB84z91t39K2qytf/wCYd/1+x/1rVoAK57ww51HUdY1c8xyTmyt+f+WUDMhOPUymY57rt9BWh4j1A6T4f1LUVTzHtbaSZU/vsqkhR7kgD8aPDmmjRtA07TQ282tukTP3dgoBY+5OT+NAGjRRRQAUUUUAFFFFABRRRQAUUUUAYfiDTbm7gl8sRX0DkF7G5wFOO8bgZRwcEE5GRxt+8KWiandDTIby2FxqelNlcOP9MtirFXRx/wAtCrBlOPnBXHzk5rqHbarMQSAM4Aya4Lwz4hg0K0u7LW4dQhZtRu7iC5SymmgmhnuJJomWREKj5JACCQQVOeOSAdrp1/a6jb+dYzpNGGKMVPKsOqsOqsO4OCO9Wawr3R7DWli1OwuZLW7kiVodRsXAdkIyueCsi85CuGXnIHes6XX9V8Onb4otPtGnqP8AkLWEbMqj1mh5aP3Zdy9ztFAHXUVDZ3Vve2sVzZTxXFtKoeOWJw6Op6EEcEVNQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeeeFtfg8OXt9o+vSfY7KfUbp9LvLghYplaZy0O7orq+8KpPzJtIzhgPQ65fwcltrXg0fbreO4tr2a5kkhuEDqweeRipU5GOelAHUA5GR0orkovAWl2QI0O71bRVJz5VjeuIV/wB2F90a/goph8F3blxN4z8UyRv/AAedbx4HoGSFWH55oAPF93Dd+J/DGhwnzb37Z/aEqKeYYIkf943oC5RB6kn0ONPU9RvZbCWO20HUJ5JFaMqZYYgpPHLF+nPUBq57wXY2Xhbxjrmi+S6y3+y/tLyd2lmu4wipIjyuSztG4LYJ4WVcd676gCvp0ckWn20cyKkiRKrKr7wpAGQGwM/XA+gqxRRQAUUUUAFFFFABXnXxcRg+mTKF2+Rdwse+GRWx+aD8q9Frzv46C8g8EPqdhbmc6c7zzooy3lGGRCR7KXVyPRDQB1viAuZ9GijUEyXyg5PQLG7n/wBBrXrD1S7tptU8OLFPE7TXDzRhWBLxi3lyw9R8y8/7Q9a3KAOd8cOG0/T7Tq15qVrFj1USrI4+hSNq6KuZ8aiNbrwxPOSIYdXjLEerxSxp/wCPyJXTUAFFFFABRRRQAUUUUAFFFFABRRRQAVmaNIYTLpsuBJa/6sD+KE/cI+g+U+6k9xWnVTULFbvy5Ecw3UJJinUAlM9Rz1U45H06EAgAo+ELeWy0OOznR0a1llgTcCMxrIwjI9im01s1jJri2tylprSCyndgkUxP7icnoFfsx/uNg5zjcBmtmgDBs/DUGm6ub3RpWsIpmLXVnGuYJyf4wn8D55LLjPO4HgjeoooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuOiu5PBt5Jb6igPh25uHkgvlz/AKI8jljHN6IXY7X6DIVsYBbsaZPDHcQyQzxpLDIpR0dQyspGCCD1BoAfRXFD7X4FG1I7i+8KDoEDSz6aPpy0kP0yyf7S/c66xu7a/s4buxuIrm1mUPHNC4dHU9CCOCKAKPiPQrPX7JILzzI5YnE1vcwtslt5R0kRuxGT7EEgggkHE03xBfaRqlvo3i8RiS4cRWOqxLthvG7Rsv8Ayzm/2fut/CeqjsKo65pVnrmk3Om6nCJrS4TY6nqPQg9mBwQRyCARQBeornfh9f3Oo+EbCa/l8+6j8y2lmxjzWikaIuR6ts3fjXRUAFFFFABRRRQAUjqrqyuoZWGCCMgilooAytD8OaLoKbdF0mxsBt2E28CoSuc4JAyeeea1aKKAOX+JqkeCNSuEBL2XlX64GeYJUmB/OOuormfiRME8FanbggS36Lp0QIzl52EK4H1eumoAoajqtvp5AuBLjAJYRnYoJxkuflH0zmq9j4m0K/uEgsdZ064ncbljiuUZmGQMgA5IyQM+tackEUkkbyRI7xnKMyglT7HtTLi1guJIZJow0kLbo36Mp74I556EdxwaAJ6KKYJEMrRB1MqqGZM8gHIBI9Dg/kaAH0UUUAFFFFABRRRQAUUUEgDJIH1oAjuYIbq3kguYo5oJFKvHIoZWB6gg8EVg/wBi3ukpnw3dKIV6afeMzQfRH5eL/wAeUDoldFRQBi2HiCCW7jsdQhl03Un+5b3OMS4GT5Tj5ZOATgHcB94LW1VXU9Ps9Us3tNRtorm3fBMci5GRyCPQg8gjkHkVzLvq/hJwZDc614dHDOcyXtmPU45njHr/AKwf7fJAB2FFQWN5bahZw3djPFcWsyh45YmDK6noQR1qegAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK5qbwpHa3U154bu5NGupmMkscSB7aZz1Z4Txk9SyFGPdjXS0UAc3LP4wt12xWGgX7D/lo19NZg/8A8mXHb+I1WmtvGGrx+RdT6XoNu3Ej6fM95OR3CO8caofco3sO9dbRQBU0jTrXSNLtdP0+PyrW2jEcalixAHqTyT3JPJPJq3RRQAUUUUAFFFFABRRRQAUUVxWr+ILnXtQuPD/AIPm/fRsY7/VlG6KxHdEPR5/ReQvVugVgBXP/CU+OYRH82jeHZCzt/DPflSoUeoiRmz/ALbjuhroUn+3a08UMh8mwOJtpI3SsuQh9gjBiPVl9DVRY7PwloFnp+l2xcg/Z7S33EtNKctlm5OT8zs5zwGY5pyaCyaCthFeyw3Jk86W8jUCQyltzyKDkAkk4BDKBwQRxQBVsfFei2Ua6fq+tafaanbfuZYbu6SOU4JUPtYg4cDcD3BrpIpEljWSJ1eNhlWU5BHqDXzz4m0n4jfDy+l1bTfE9jqumCGYLZ6jFukaJA0oQlUG7kuByCu4AZGcdN8OvGFnfahYJe6TeeDdRuiD9mePOn6jnP8AqnwEEhPPG1j0O8DgA9irnPGEUllHF4gsw5uNMVnmjQZNxbdZY8dyAN6/7SgdGNdHSEBgQQCDwQaAEikSWNJImDxuAyspyCD0IqHULg2tq04UMqFS/smRuP4DJ/CsL4ZvJJ8PPDbSjDf2fAB7qEAB/EYro5Y1lieORQyOCrKehB6igB1FZ/h2Z7jw/pk0rs8klrE7O3ViUBJNaFABRRRQAVU1a3kutNuIYCqzshMTN0WQco34MAfwq3SEhQSSABySaAK+mXiahp9vdxAqsyB9rdVPdT7g8EeoqzXMm5/4R3xB5NydukarLmCQ/dt7pusZ9BIfmX/b3Dq6iumoAKKKKAOXvNEu9IvJdS8LLGDK5ku9MdtkNyT1dD/yzl9/ut/EMneuvoms2msQSPal0mhbZPbzLslgf+669j+hHIJGDWjWPrWgwajcR3kEstjqsK7Yr2DAcDOdjg8On+y2R3GDggA2KK5mPxDc6U3k+K7dLUD7upW4Y2jj1YnJhPs/yjoHaukjdJY1kjZXRgGVlOQQehBoAdRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFVNX1Oy0fTbi/wBTuY7WzgXfJLIcBR/U9gByTwKdqd9b6Zp13f3sgitbWJ55pD0VFBZj+ABrjPC2hTeI5LTxT4wh8y8ci407TZOYtNjPKfL0afGCznkE4XAHIBHHZ6945Jl1Vrvw/wCGW+5p8TGO9vF9Z3HMKn/nmp3f3mH3a7bS9Os9JsIbHTLWG0s4V2xwwoFVR7AVaooA53xoZrGzj1y0y02mZkeMuFWSA480EnphRvB45Qdia34FdII1mk82VVAd9u3cccnHbPpSzRpNE8UyLJE6lWRhkMD1BHcVleGd8FpPp8ru7afKbdXcklo8BoySeSQjKCT1KmgDnfG/hnX9enh+yX9hHBbO00KzRHlipTawHVdrNnnknoOCOk0nTDHoUWn6nFbTKE2PEBvQj0O4fN69B9K1aKACsvxPeS2GgXs9tj7V5fl24P8AFM52Rr+Lso/GtSuatZ18SazFcwEPo2nSFopQcrdXGCu5exRAWGehc8Y2ZIBt6VYw6ZpdnYWwxBawpBGPRVUKP0FWqKyfF1w9p4V1ieIgSx2czJnu2w4H54oAXwoS3hbRyRgmyhOMf7ArVqO1hS2tooI87IkCLn0AwKkoAKKKKACkIDAggEHgg0tFAGBqmm7dOuLKW0Gp6NMhSSzY5kRT1CEn5h7EgjsTwo5zTvE0nhpXg1S4m1LQIMKup7Wa4shjhLyPG8Y7S46ffAwXb0KqOo6TZai6SXMP7+MERzxsY5Yx3CupDAeoBwe9AFi0uYL22iubOeK4t5VDRyxOHRwehBHBFTVwFn8PJdMu7mfQ9dudLkc71a2iRVkbnPnQ48p85+8iRt6knmtEX/jHSiBf6RY65AOs+mTfZ5j7+RMdv5S/hQB11Fc3a+NNGeZLe/lm0m7c7Vg1OFrYufRGbCv/AMAZq6QHIyOlABSIqoqqihVUYAAwAKWigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOe8Y+JR4eisIrezk1DVNRuBa2VnG4TzH2lmLMeFVVVmLYPA6E8VFaa3rlqbt/Eugx2lrDEJFn0y5k1DeSQNgjWFZSec8IRgdaZ458PXuryaNqOi3FvBrOj3Rubb7SCYpAyNHJG+OQGRz8wyQQODXEXXw+8RzarrutaVFoXhrUr61htxFpc7/AL8i482WSScQoVd1JTcEYjrk0Ad7Y+NdBvYPNiu5Uxepp7RT2s0MqTvgojRugdchgQSAMHOakv8AxdpNl9s3tfzmzuPstwLTTri5MUnlpLhhFG2BskQ7unOM5BFcFZfD7xBBBqVyGsFvZNVstStrebU7m8UiAKDG9xKhk5wcNtOOOMUuq+EPGt9pOs2x/sNRresC91C3jv5og1oLeGPyFl8kkFjEQzbRlemN2FAOqPxL8Kf2bZX6ajPLbXlu13EYrG4kYQK20yuioWjjyD87gL710Go61p+naQNUu7lV08+XidAXUiRlVD8oPBLLz0AOTxzXneu+BNWv9SXVIbCxSefTY9Om0+DxBe2cECxPIUKvBGplUrJgoyLjHB5JPXal4XS++G83hjbDAH0z7CnlsxSJhHtUqWy2FIBBOTxzk0ATr4x0F7u4tU1BWuLe/TTJUWNyVuHAZU6c8HO4cDByRg4pW3xC8P3kc0li2rXkUTtG8lpo95OgZW2ldyREEg9QK5Hwt8LtR0vxP4c1e+vrWYwRPc6siFv9J1AmYiZflGQPtU4ycHATjjjRm8H+I7bwPo+k6ZfQpcWt/LPdxRXstot1C7yt5YnRDJH99CSq5+UjI60Ab8nxB8Npp1he/bZ3ivppLe3SKynklaWMkPGYlQurAg5UqDW3oOsWGv6VDqWk3AuLOXIV9rKcqSrAqwBUgggggEEYNeUWHhbxP4bvfDP2WytL+9XVdQvHD3tw8MaSxNgSXDRu+ecbmU5PHfI9E8BaDc+H9Emh1CeKa/u7y4v7loQRGsk0jOVTPO0Zxk8nGeM0AdHRRRQBz/xC0u41vwL4g0yyAN1d2E0MSnozlCFB9icA/WrnhjW7XxHoFjq1iT5F1GH2n7yN0ZGHZlIKkdiDWpXHX3hS90/VrnVvBt/FYXF3J5t5Y3MZktLp+74BDRyHjLr1x8yseaAOxorzibxHrIEviDzDDBpZS11nQ9qyGHBYyzo4G5sI8Ui9mRT8u4jHaXev6VaLC09/AFli86MhtwaP++CP4ffpQBp1mWpjPiHUPL3bxbwBz/DnMv8A49gjPttqhc+L9OFuW0yO81WdgfLhsbd33t6F8BE+rsoHrU/hKwvbTT5rjWDH/at9Mbq6WJtyRsQFWNT3CoqLnjJUnjNAGreW0d5btBNv2Nj7jlGBByCCCCCCByKzZbTW0kxZ6raeRt/5e7EyybvXckiDHttz71sUUAczd+G7zV5APEOsSXNj/FYWcX2aCUeknzM7D1XeFPdSOK6OGKOCGOKGNI4o1CoiDCqBwAAOgp9FABXPeO3CaDFuJCNqNhG3urXkKkH2wTmuhrO8R6TFruhX2l3DvHHdQtF5ifejJHDr/tKcEe4FAGjRXGWviDxFpVstv4g8N31/PEApvtJaKSKfH8Xls6uhPUrtIHQMank8cW0AL3ui+I7aEDJkOlyyBR6kRhiB74oA6yiqOi6vp+uWCXukXkF5aOSBLC4YZHUH0I7g8ir1ABRRRQAUUVBfJcPauLORI7jgozruXIOcEeh6evPFAEWm6hHfm7EWM21w1u/OfmXB/DqKuVxFgdSsfiCk01oYbXWrZvtEYlWTyrmDADgjHyNHxnGeFyFOBWtJ4x0TzpIbO5l1GWNtjrp1vJdhG/us0asFPsxFAG7cQRXMDw3ESSwuNro6hlYehB61m6ToFjpFwX0tZbW3KlfscbkW45zlY+iHr93AOTnPGMxvGIDEDw74jYA9RY8H9aW38c6Q9zb297HqemS3DiOM6hp09vGzngL5jLs3E8Absk9M0AdRRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAedW3xDv2vUkutBhh0R9ck0EXa3++bzVmeFH8rywNjOqj7+QW6EDJig+ImrS6LBqf8AwjdusF9e/wBnafH/AGlmSefzSgLjysRx4R2LZZhtxtOan8OfDt7a+mudb1W7uYV1q71a20+N0+zI8kzvG5/diQsocHaXKhuQDwa2JfA2mv4VttCW4vo47W5N5bXSSKJ4JvNaQOp27cgsRgqQRwQaAOU1zxz4kOp6Pp2n6bY2mrRa4NPv7aW9JhlRrSSaPZL5BOxgAd20MGTbjBJC3/xgtLLxBNp88GlCO1votOuV/tdBd+a5VWaK3KbpI0Z8FiVJAYheK6CT4eWT2uTqurf2r/aC6mdV3Qm5M6xmIHBj8vaIyU27MYPTPNWl8G+VfSTWniDW7WCadbm5tYHhWO4lAUM7Hyt67tg3KjKp54GTkA57UPHHiDUfDGs6v4e0KBNKhivUt9QmvgsqtAsg80wGIjYXQgfMSeMqBkiKDxlqNlJYz69pcZ1H/hH7rUwbXVZXhkSIQnDRmNEDsXPO07AMAkMRW9a/D6xtXuoINU1dNGuHuJH0hZkFtunVhJjCeZgl2YLv2hjkDgVHD8OrPy41vdY1e+aPTbjSY3naEMlvMIwR8kS5I8sYY5PJznjABnD4k3VjBNJr+graM2ljVLSO1vRcNMpdY/LbKIEfdJGBgsPm68Vv+GvEOq33iPUNF1zSLTT7q1s7e8DW18blXWV5VAOYkwQYT69ar6/4FsNRtHI8+aePSH0qGN7jyVZSyOrF1QsrBo0+YA45O09KrfD7wxrml61q+seJ9RN3e3sFvaopuFn2RxGRh86wwjkyngRjGMkkk0AY/iHxB4n/ALW+INlEloulafpglhmW7aOe3LW8rB0URfMxZR1cbcAgnpTI/iLqWh+HJ313RI/tNroH9sQbNQMpuUTarCQmMbHyynjePm68V1ereC7bUdW1O+XU9StV1Sz+xX1tA0RinQI6Kx3ozKwEhwVZc4GQaTU/Amkamnl3rXUkR0iTRWTeAGgcoSTgZ3/IOQcdeKAKvjLxw/h241WCLS/tkljZWt2o+0eX5pmuGhCfdO3G3Oec5xx1rF1P4ja9pX9unUfC1mkehxRXN+8WrFwIXGQYh5ILuAHypCj5eGOa1z8ObSc6g+p63repXF7DbwSTXMkO5UglMqBQkaqPmJzxz9ea0db8F6drEPiWO5mu0XX7VLS68t1BREVlBTKnBw5657UAcbd+MdY8OeJPH17NY/b/AA/pl9amd5L8o9tE1pblvJiKEMAWZyNyZycZJNbmk+P5NS8cT6DDZaeiwXUttIsupql6Ai584WpQFomOAGVz1zjri3qHw/s77WNXvJtV1QWmrTRTX2mgwm3nMcaRqDmMyAERrna4zz24qf8A4QqCTxDb6pfaxq98lrdyXtrZXMkTQ28rqykoRGJMAMwClyoz04GADq6KKp6zqVto+k3mpX8nl2lpE00rAZIVRk4Hc+g70AZtpZCPxvql2hVVm0+1SRR/GyyT4Yj6HGe/HoKdpVpaaXrLafp1vDb2yWisIo1AEY8xyAB2BLNx044pPDCXYsZ9U1lRbXl6RPJAzDFrGFAWIn/ZHLHpuZiOMCjwyGvJLzWpAR9vKi3BGCLZM+Xn/eLO/qPMAPSgDdooooAKKKKACiiigAoorH1/xPovh/yl1fUYLeaX/VQZLSy/7ka5ZvwBoA2KK4+bxrM0aSWHhbxDcRO6RrLLDHajLMFGVmdJO/8Ac+uKnOq+LCQ6eGLAR/xK+rYk/ACIqT9WFAFfxB4TmTVH1/wlNHp2vEfv0bIttQA6JOo7+kg+ZfcfLWr4X8RQa7DNG0MtlqloQl7YT/6y3c9PZkOCVcfKw6dwDR/EltfXx067t7nTNWCl/sV4FDuo6tGykrIo7lScZGcU3xJ4at9ZkhvIZ5tO1i2Ui21C2wJYwTkqwPDxkgZRgQevBAIAN6iuQj1/XNFxF4n0eW7iXj+0tHiaZGHq8AzKh9lEg/2u1aVh4v8ADt/L5NtrVgbjqYHmCSr9Y2ww/EUAbtFFFAHM+IPCket6kst1czfZZE8m4iDYLQ8EwqRgqjsAznOW2Kv3eBNruv6D4L0u1S9eKzgY+TaWdtCWeUjokUSAlj7KOPaugrz74cxW3iLV9X8ZXTxXN7LczWFlhg32S0ikKBQP4Wcq0jdzuUdAKALK/E7Q4biCPWbbWdDjnISO41XTpbeFmJ4UyEbVP+8RXXajY2er6bPZX8MV1ZXMZjkjcZV0IqS8tYL21mtbyCK4tplKSRSqGV1PUEHgiuM+HMUmg6prvhFpJHs9LMNzpxkOWWzmDbY8nkhHjlUH+6FFAG/4TW6t9LOn6hO9zc2EhtjcOctMgAMbse7FGXcf7watqsW3dl8Z38eGKNYW7Z7KRJMPzOf/AB2tqgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDkbnQdf0u4kufDOtmeJ2LtpusFpoiSc4jmH7yP8fMUdAopIPHFtaTpa+K7Ofw7ds21XuyGtZTnjZcD5DnIwrbW/wBmuvqO4giuYJILmJJYZFKvHIoZWB6gg9RQA8EMAQQQeQRS157faLpnhyQv4W8SQ+HZBk/YJJFmsmOc/wCoZgU/7ZMnvmiP4gzWVtINcsYY9oyuo2Exu7LGcbnKDzIvfeoUdN/egDub2+trJVNzKqFuFXqzfQdTXHePtZgm8MSyPbz/AGa2u7S4ufut+4juYnlOFYkgICT7AinWDG7Rr5L9r5ZVzHdQkNG5PQIycbR0wCw696uNG6F/LEpcbYVZlQ8YyT65wT+VAFnxd9l1Pw9b/wCmxCyuJ4HIDFlu4d4ZowFyX3IGwo+90PBNdGDkAjPPqMV4jd+HtV0eaa++H0wQurmbRJH8uFoiefsznm3dtvQfLn+7gGuh+HmuweM9OlTw9LN4fgtZCt5bhVe78/owYyBgAMYJILE91wCwB6bRXEeHNb1Sa71WwsVl1uCzujDHqF0yW6cIpZCyJhyHLLlU7YbBGW6rStQj1GxtbhVaJ5ohJ5MhG9PUHHoeCRxQBcbO07QC2OATgViXen61cK00Os/YrkcxwJbpLbj0D7gHb3Kun4VuUUAc74Z8TLqd7d6RqUIsfEFkAbizLZDoek0Tcb4j64yDkMARW3fXdtYWkt1fXEVtawrukmmcIiD1JPAFcn4g8MaP4q8TXdvrNq0rWtnbS288cjxSwMz3AJSRCCpO0ZwecDI6VnX3wu0l44rqZ9Q169s2ElvFrd/LdQkj+Eq5KjP97aSDg84wQBkPirVfHdwbbwOJLHQQSs/iGeL/AFmOq2kbD5z28xhtHYNXXeHvDWl6AsjWFv8A6VN/r7yZjJcTn1kkb5m/PA7ACrWh6ja6ppsdxY5WMZjaJgFaF14aNlH3WUjBHtV+gDB8dyNbeE9Rvo5EimsIzfRvIMrui+cAgc4O3acc4JxTWh8VS4Zb7RLTjHlmzluOfXf5sf5bfxqjcsnjO9S3t23eHrK4DXEo6Xs0bAiJT3jVgCx6FlC8gOK66gDg/i4jDwCbyV0ttWtJreW1uIhuMFwZEQFMjOPmII7qSDwTW14W8V2GteE4Namura3VYgb0NIFW1lA/eI5P3dpz17YPQ153478RL4q1H7Hp53aNp8x/fA8XU65UkeqJkgHu2T/CCeSm8P2E9yLiaxtZLgEESvCpbjpzjPFMD1Sb4s+GhKVtf7RvIR/y3gtHMZ91LY3D3UEHtmt/S9X8OeMrRhbPaahGnL288Xzx5/vRuAy/iK8Y+xe1RSRPZTQXlsJBexSKts0R2uZGYKqqf9okLjoc4ORRYD21PCOgW7/6DYR6e5ycafI1oW9SfKK57Vt20XkQJEZJJdoxvkOWP1PeuVtZ9Str2Sys4INT1tYklv7y4lMMERbO2NMKxxwSEAGB8zHc2W2dF1WS8FxDqFstlf20gjlhEvmIcjKsjkKWUjvgHIYY4pAateOWfgyHTvCcviLwnCLHxTpkt1ueH5F1AQzyBoZ1XhwwUgMRuU7SCMYr2Osa/uoPDHhe/vr2QPFaRTXczBQoY5aRsD3JIA5PTkmgC5oepQazoun6paZ+zXtvHcxZ67HUMP0IrBsAJfijrUiAYg0myiZvVmluW2/gMH/gQq54DsZNF8BeHdPvSElsdMt4JS3GGSJVbPpyDXODxBB4Z8Fa34z1BGd9SmN3bwL9+VSFitYlH95kWMkdmdvegDpdHvVv/E+v+SAYrPyLJ2x1lCtKwz6BZo/xzW7XMfDbRLvQvCVrFqzB9Yume91Bx0a5lYvIB7AnaPZRXT0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVHcTxW0DzXEiRRIMs7sAAPc1k6/4itdJZYFV7vUJP9XaQ8u3uf7o9zWEmn3eqTLd+I3SVlO6KyT/Uw/Ufxt7n8KALs/iK81H5dAt1W3P/AC+3SkKf9xOC31OB9apSaQbo7tXvbu/Y9VdykX4IuB+ea1LiaK3iMk8iRRr1Z2Cgfiax21+CY4063ur89N0EfyZ/32wPyNMC5b2FpaKBa2sEWOmyML/KsLSVul1a9K4Z5J086VWIyQqgLxzsVmI/2unGDVyfUdUjheebT7e2gjG5vMuNzkegCqRn2zT9Ft2trdriRQss8wdgzZCktkLn0BJbj2PekAk/g61MzXukz3Gi6lKd8lxp+I1lPXMsJBjkPTll3Y6EVeit7mLS0+3gT3aKQ8sMflrK2cAhC7FSR2yetW7a7eacBHiYHLbfM7dFHT0BP41LNdIrlZFbeg3CMDO49sfrxQBlTxRwwW8Ecg82QESOScDjv/d6KAeoxXH6LeWuhfGDUrgNDaxavoP2oLKwijaeCQIcnoCVKZ9lrrJ58lpoyjOmZJnY5jcEYUAdyM4xxjHNeaeOYnTx74CmMm4vBfI3uPLTv6DYKAPT7XxPZ6lbNp/hN4bXqpu5otkEDE5IT+GWTLZwDt5J3HoZ9S8K6NY+GLiOw0qGS5SAiCZEH2hpsYRxKBuDlsHfng81wcsMUq4ljRx6MoNOt0Ftdpc2+YrhMAPGSp4GB068etAHqO7XLeON2WyvDwHiTdEy+4Ykhvphf6G1ZXzywzve2stiYSd3nMpUr13BgSMfXBHcCvPtL8Uatp0LI7jUlyNguW2Mo5yN6qc9uoNdPpvjGwvbq3s54Li3muAFG9A0Zc/wbh/UAGgC5MBH40syuMz6fPv5Gf3ckW33/wCWrVt1z8emWNj4uspLKztrZ5LG4VzDGELASQYzjrjJ/OugoAw9Q8NWdzqD6haTXem6jJjzLiyl2GTAwC6EGNyAAAWUkAYHFVrnwxdX0JtdT8Rapc2LcSQqIYTKv913jRWx67SuenTOejV1Z2UH5l6inUARWtvDaW0VvaxRw28KCOOONQqooGAABwAB2rm/Hs15c2cGg6RM8Go6tvj89PvQQKMyyD0OCqA9mkU9q6muX8OONT8WeItSPMdrImlW5x2jUSSMPq8hU/8AXIUAeeJocMNnFaQI1vDAoSNYmK7ABgDj09DWa91HpN4bXW7q3iidS9vdTMsYkAwGVs4G4ZB4xkHgcGvUNZ0wx3sjqv7uQ7gfc9RVD7F7UxHBW1/Bf3scGlRm7TrNOuRFGvP8WMMx/ujtyccZ1Ps0cN/pc8oO2K/tm9hmVRk+wzn8K6n7F7VBe6VBeW0lpdxrJDcgwsjHG8Nxj8aAO0tdP+zavf3iSfJdrFuj29HQMC2c912DHbb71zGtvHf+NLTTbGRZLhzb3N7t628FvI7puPYvKwUDuokPODTdI1nXdK0Sy0q68PatqWs20KwNOJIhDcMo2+aZWfgNjccjdyflJp2jeCZ4/tV5qmsXy6lqM32nUVsJBDHI+AqorbfMCIgVBhhkLkjJNIZ2NzcQ2kDzXU0cMKDLSSMFVfqTXBvNJ8Q9Vtkto2HgyylWeS4YEDVZkOUWMd4FYBi/RyABlQSegk8F+HJ7iO4vdHtL64j5Sa+X7S6n1DSbjn3roQMDA6UAV9RsodRsZ7O7UtbzoY5FBI3KeoyOxHFcFZW48d+Nk1aX5vDPh6do9PT+G7vVyrz+hWPlEP8Ae3nsK0vF+rXWp3reFfDUzLqUyj7dexHjTIG6sT/z1YZCL1/iPC89RpOnWukaZaadp0KwWdrEsMUa9FVRgCgC3RRRQAUUUUAFFFFABRRRQAUUUUAFFQX93DYWU93dPsghQu7YJwB6Ack+w61haTpVzqF8useIRmdW3WVieUslxwSOjTEdW525KrxksAdJRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVX1C+tdOtnuL6eOCFerucD6e59qALFcjfa9davcyWXhxlSBDtm1FhuVT3WMfxN79BUN9cXvijEMKzWOiE5kd8pNcj0A6qh9Tyaiu7lvtKaFoCpCY1HnzKvy2yHoAO7nt+ZoAVX0vw+TEhkuNQm+ZguZbiY+rd/wA8Ckc65f8A+rWDS4D3fE02Pp90frWlpumWumxFbZDvbmSVzueQ+rN1Jq0aYGJB4ds1lE14Zb+4HSS6bfj6L90flWqeBgDAqRqy9dvzYWWYtpuJT5cQbpnGSx9gASfYUAVLgtqWriEcWdowMjE4DSdRz/s8f8CI/u1NJLG8nyCaRVyESCPI59Wb5fbGRx19Kl0qHytPiVgcfeG8fMc8kt/tEkk/XFWsADAGAKAKY1KzVfKuzcWxZsg3kY2FvdxwPzFNuWmhDRIHdN4ZtvLBv9k+mBx3yMetWpFV0ZHUMrDBBGQRVHSXisbi7s52JtraNZodx+4j7htz6AqcZ7NikBBqDFYIyJYYrZZSFJbjBwx+Y9QCQPqcV5vr8j6t8V9LRYHS00TS5GR2GCTMwRcjtkRuRn69CK6i/wBfU30bWIiuBYADzM5iSUrtXpycDJ46nHPy5NDQdC1KMvczW19f6lqUgnubzyGVXb7oxnhUUAALngD3yQC3RVw6TqgeZW0y8HlAktsyGwf4cHn8KYmm6pJCJI9KvmyxXaY9jfXDEce9AFakEcs0kMNvMIJ5ZEjjkLFdrFgAcjnqa04fD+sy3UcP9mSxqwBaV5IwiZGecNn24Bqvp+kapeav9l0+W2a6s5QZr1FL29k4BBXJx50oyCFACqRlz0VgDurG6/tLxrfGEE2+lW4tTIDw00pWR0+qqkJ/7aY9a6Ks/QdItdD0uGwsg/lR5Znkbc8rsSWkdv4nZiWJ7kmtCgDNspt2talF/cEZ/wDHf/1VpVy2hXPm+MNYT0H8iBXS3E8NtC0tzLHFEvV5GCgfiaAHSOscbO5CooLEnsBXlngvxSbHwhYR2Vm11qF15l/dM77I4pbh2mZGbkllMmCB0xjPFa+v+LJdTjez8Plkgb5ZL5hgY7iMdz79K5bw5Ismi2zRoEA3LgeoYgn9KAOlHiu4F5BcatpsbRRhlL2shZlVsZyrD5hkKeDngV19vbWt5bx3NpKHglUOjDkEGvOjXS/D0mTT9SsHZ/IhuMx7XKlQ6hiARgj5sn8aYCa/a25ufs11qN67HDJp+lgrPIM8b3B3KuR94GNR3NaWl6Yh0Sa11K1NnDM+EV7555lyQVJkY5Vw2MBWIUgYJrctLS3s4ylrBFCpO4iNQuT6nHU+9R6pa/btNurUOEM0TRh8Z2kjAOPY80gMDwBe3MlvqulXqytNo989mJ2XaJoyqyRkDoMJIikDjIzxnA6muCuI9RbVzeacLzRNbn2JcwS2j3lhdlRgMWTG044D5RsAblIUAaEjeObpPs4g8O6bng3qXU12wHqsJijGfTLkfXpQBva1rGnaHYte6xe29laqceZM4UE9gPUnsBya5aTUvEPi391oMM+g6O3DapeQ7bmVf+mEDD5M/wB+QDHZD1q5pvhXS9Iv4tS1Fr3WNaOQNQvUaeRPUIFXZCPZFXPvWje+I4bdjHBp+r3c/aOGwkXP/A3Cp+bUAT+HNA0/w5pwstKhMcZYySO7F5JpD96SRzyzHuTV+e4ht/L8+WOLzHEab2C7mPRRnqT6VzRl8W6s2Ibez8PWh6yXDC7uiPZFPlofffJ9KvaT4YsNPuxeymfUNTxj7dfSebKM9Qv8MYPdUCj2oA3Kx71pNJu5L2OJ5bGYg3KRqWeNgMeYqgZYYADAegIHXOxRQBHbzw3UEc9tLHNDINySRsGVh6gjgioNUvF0+0a6lH7iMgyt/cTu30HU+wNVptDtTPJPaNPY3DsXZ7WTYGY9WZOUYn1ZSarT+GLS9bOr3N7qad4bmbELD0aJAqOP95TQBoadqtnqTziwmFwkJCtLGCYy3OQr/dYjGCATg8HBq7XMvouqaQAPC13bLaDppt8jNCg9InX5ox7EOoHCqoqCbU/GwTbF4Z0TzjxubWn8se+fs24j8BQB1tc94n8V2OhSRWgWW/1m4Um20y1Aeeb3x0VB3dsKPWsl9N8V6pPHba14gg0yKVWYwaJb4faMAgzykn+IfdRT7+mtp2j6H4O0+7urS18othri4bdPcXLdBuc5eRiSABknJAFADfCuk6hHPPq/iGZZNYulC+RExMNnFnIhj9exZzyxHYBQOjrnIrfxDqpE13eDRLY8rbWqJLOP+ukjhkB9VVeOznrVmPw3aj5pbvVppD95m1Kdc9f4VcKOvYDt6CgB2sxfbdV0qycAwK7XsgPR/K27B9RI6OP9ytis3UUktfslzaxPItv+7kjUksYmxnA7kEK3qQpA5OK0gcgEZ59RigAooooAKKKKACiiigAooooAKKKKACiiigDivFViur+P/D+m3N3qUNk2mahcNHZahPab5Els1UsYXUtgSPgE4+Y15B4K8baR4l1rRLH7Dq8f9qXM1t5dt441Ce5tfL/5aTQ7l2oex3V614s1vStB+JPhu61zU7HTbZ9J1KNZby4SFGczWJCgsQM4BOPY15X4f8P+EdPtPDunX/xV8K3OlaJqp1eCOB4YJ3m3FgrSm4YbMnoFGfWgD174fwmz1Dxfp63N9PbWerJHB9su5bp40aytZCoeVmbG53OM/wARrsK4r4calY6vqnja+0q9tr6yl1lPLuLaVZY3xYWYOGUkHBBH1BrtaACimSyCNQSrNk4AUZqnJeXJ4gsm3es0iqv5ruP6UAX6r317bWEDT3txFBCOryMFH61nSpqlx/rL2O0Q/wANtGGcf8DfI/8AHRUMGi2UUwneI3FyOk9yxlcfQtnH4YoAgm1+91AFPD9izIf+Xy8Bji+qr95vyA96htdBQ3K3mrXEmpXy/dkmACR/7idF/nW4azdY1NbBY440869nO2CAHBc+p9FHc9qYFfXdQlg8uz08K+pXAIiU9I17yN6KP1PFSaNpkWlWfkxFndiXllf70rnqx96NI05rNZJrqQT38+DNNjAPoqjso7D8epq+aAGGmGnmmGgQ1q5W7/4mXihITzDb/Lj6BWf9WiX6bhXVNXLeFU8y8vrjrhmXPqzSO5/8dMf5UDOjaszVNYstOJW5kO8DcVRCxAPTOOmfetNqpNp9qb03ZhU3BwdzEnBAxkDoDjjIoAzX1C/uggsrP7Okhwst3kHpn7g5/MiqCaJqQllkmvba4MmN6yxuysBnAK78EcngjHNbmqSNBHDcBXZIpAXVFLEqQVJwOeN2foKzft90YI5Vt7h5bc7biMRkeYp/jjJ4Y8BsA5wSMZ4oAvxXmvwoEiutMRV7LaEAfgHoF1r4k3NrMZGMbRZqF+vXP61mGfUJmN5p1oQkoMflXWYzkH5ZcEZA65U4JG3pjFbJoAYL/XFIJ1OA+xtBz/49Tm1fXUHyXGnv7SWzD9Q9NNMagROuv62A26PTSccYDjH61UOq64yeXHPp9nHkkC3tiTzyfvNjrntQaaaAK0h1GU5n1rUWP+w6xj8lUVA1s7Y82/1KXHTfeyn/ANmqW/u4bK3M1y+yIEAtjpk4p4YMoZSCpGQQcg0Actpuy71e5ikeUqNxBEzBjhh1YHJ/GtUaTZB97QeYwOcysz8/8CJrlfCV35uvtznejn+tdle3MNnA81zIscS9WNAMWRljjZmIVFGSewArI8LxmPw9YbgQzx+aQeuX+b+tJ4im+06VFbW7EtqLLApHXYwy7fggY/lWqFVFVUACqMADsKAGscDnius+G9uV0We9ZcG8uGlUnqUACr+i5/GuRtLGbXtR/s21JWEYN3MOkaf3R/tHpXq1vDHbwRwwIEijUIijooAwBQBJRRRSGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAZkUqy+JrmEkFrezidR3AkeQH8/KX8q0JYo5dolRXCsHAYZwR0P4Vy2i6lbXnxL8UWkDEz2Nhp8UwKkYZmuXGD3+VhXWUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFADZPu1Aank+7UBpgNNNNOY4GTWJNqkt6xh0NFmPRrt/wDUx/Q/xn2HHqRQBJrOqLY+XBBGbm/m4ht1OCfVieyjuaj0jS2tZJbu9kFxqUwxJLjAVeyIOyj9epqfTNLisPMkLvPeTczXEn339vYDsBwKumgBhpppxppoAYaYaeaYeKBGR4o1RdI0a4usjzcbYh6uen5dfoKreDrF7Dw/bJMCJ5B5smeuT0z74wPwrLdT4n8Qox50y0O5fR+ev/AiP++R/tV15oGMamGntTDQBFMnmRum5l3AjcpwR7j3qnpVybzS7S5YgtLErkgcEkdval1uV4NHvpYTiVIHKc/xbTj9adY2qWNhbWkP+rgiWJfoowP5UCJTTDTzTDQAw0xqeaY1AEZpppxppoAztbtPt+lXVsPvSIQv+8OR+oFeaaT4xn07TprKaMy4UrCxODGfQ+or1S4migQvPIkaf3nYAV4T47WK08R3LWzhrac+cjL0564/HNA0XNA1pdL1aG6kVnjTIZV6kEEVrNqs/i7xBbWoBisw27yweijqSfXHH415011713/w70CXUtMuruSdobec+ThB8zqPvDPYE4/KkB2djPFeX8upu6pY26m3tWY4VufncexICj2U+tXrWWXWbyGy0wsvnts+1MvyrwSSo/iOAfbimW2iWVuEzGZigCqZTu2gdgOg/Kui8IxNP4oTA/dWtu0hx0DMdqj8t9MR2OhaRa6Jp6Wlkp2j5nduWkbuzHua0aKKQwooooAKKKKACiiigAooooAKKKKACiiigAoorlfH2tXNnaQ6PobA+ItW3QWYxkQD+O4b/YjBz7navU0Ac54R0iXW/EXivxPY6reWDXOovZwmBIXjlit0jhy29GJHmRy8qRwa09Y8Sa74NT7V4mtYdT0FT+91LTYmSW0X+/LAS2UHd0Y4wTsArqfDuj2vh/QrHSdPUra2cKwpu5ZsDlie5JySe5Jq+6LIjJIoZGBDKwyCPQ0ARWN3b39nBd2M8dxazoJIpY2DK6kZBBHUVPXmXwvt28K+LvE/glWb+zLfy9V0pGP+rt5yweMf7KSI2P8Aer02gAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBkxwhJzxzwKzpJ7mTItrbA/vzttH1AGSfocVpSfdqA0wMx9LFyQdSma6HXysbIv++B1/wCBFqvBQqhVACjgAdqeaaaAGGmmnGmmgBhpppxppoAYa5vxjfmK3jsItxlushwh+by8gED0LEhR/ve1dIa4rT2GreO76U/NDY4Ud8MuVA/MyH8BQB0Wk2I0+xSL5TIfmkZRgFvb2HAA7ACrZp7Uw0AMamGntTDQBkeKgx8N6mYwTIttI6gdSQpIH6VoAhlBUggjII70+RVdGVwGVhgg9xWJ4anK28umXDk3WnkQtk8vH/yzf3yuOfUMO1AjWNMNPNMNADDUbVIax7/XbS3uGtYfMvL0f8u1su9x/vHon1YigC47zH7kSgf7b4/kDVG/kW2hMuoahHbQjqQVjH4ls/pioTBrF/zc3Eemwn/lnbYkl/F2GB+Cn60+00PT7WYTiDzrkf8ALe4Yyyf99Nkj8KAMtby3lfdpOlT38nQXEwKIP+2knJH+6DXG/FvStSm0JNWvZLbdaOF8q3Q4RGIBJc8tzt7Dqa9WNZ+t6fFquk3lhP8A6u4iaMn0yOv4daAPldJmlkWOMFnchVUdST0FfT3h/Tl0nRLKwXB8iMKxHdurH8Tk18+fDLRprn4kQ2V4mDpsjyzj+6Yzgf8Aj+2voCa/lupo7bSVWSaWQRLK33Nx7D+9jqT0GKENlqeYrLHBDG091KcRQpyzH+g9SeBXfeF9HOk2LeeyveTkPO69M9lHsBx+Z707QNAs9FRjAGlupB+9uJeXf8ew9hxWvSAKKK8++IN54n8O3b61pEy3Wl7R51rIm4RY43cc7T6g8E+lAHoNFeZ+HvjBol6Vi1hJNMnPG5syRE/7wGR+Ix716LY3trf2y3FjcQ3MD/dkicOp/EUAT0UUUAFFFFABRRRQAUUUUAFFQ3dzBZW0tzeTxW9vEpaSWVwiIB1JJ4ArjX1fWvF+YfC/maVorcPrU8X72Uf9OsTDof8Anq4291V+tAGh4n8XRaZfJpGk2z6t4jmXdFYQtgRr/wA9Jn6RR+55PRQx4qTwp4ck06afVdZnjvvEd4gW5ulXakaDkQwg8rEpJwOpOWbJNXfDXh3TfDlk9vpcBUyt5k88jF5riTu8jnl2PqfwwOK16ACiimTSxwRPLNIkcSAszucBQOpJ7CgDzLWbo2XxxttQRh9lg0u30+9OeIxczy+ST6HzIVX6SZr1CvM/CEOn+J/GPjbVrK3lufD2rWlnafa5OIrqSLzlkMPcoFeMbxgFg2M9a7PQbyRZZtJv5TJqFmqne3WeI5CS/U4Ib/aB4wRkA2aKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAbJ92oDU8n3agNMBppppxppoAYaaacaaaAGGmmnGmmgCNiFBJOABkmuK+GSmWw1G+cYkubpifpgH+bGup1yXyNGv5enl28jfkpNYXw6Tb4YicDAkldh9Ado/wDQaAOlamGntTDQAxqYae1MNADDWXqmkWuoSJNL50VzGu1J4JWikUemVIyPY5FahphoEYg0m8i4h13UNv8AdlSF/wBdmfzNRvYavtO3WgG9TaKf61uGmGgDCOiS3C41XU7u7HeNCIIz+CYJ+hYir9raW1hbCGzgjghXkJEmB+Qq2aY1AFN7uNRkrP8AhA5/pUDalbj73nr9beQf+y1fNNNAGYdWtc4/0gn/AK9pP/iaibUyxxBY3sjHpmLYPzbFahqvd3EdrC0szYUfiSewA7mgDirfwrDZ+JNW1y6BV9T8tBZwHJdxxtzxnccHA716Fp+gTaasV+dTtbTVkUhYJIhLBEh/g2ghs/7SsPxHFXvCGgzG4XWNWjKXBGLa2b/lgp/iP+2f0HFdiQCMEZFIZy2n+Loy80WrW32WSLBEsMnnQy/7hwGz67lHsTUk3jXR4jgyzN9IzW/Ja28n+sgif/eQGuR1zwYPtsmpaF5H2h+ZbC8y9tP7A8tC3+0ny9yrUANn+JOiwjPlXz+yxr/Vqyr/AOLekojrHpt7MCMbZNig/Xk1e0TS/C/iI3FvPo72Oq2uPtVhLIySQk5wflbDIcHDrlTg9wQGa58OfC0dhPcXDT2UUSlmlE3Cj1+bNAHznrTxT3lxLBCIIZJGZIgchFJyFz3wOKyrTWNS0W5M+k39zZzd2gkKZ9jjqPY1q6okazyrAzPEGIRmGCVzwSO3FGi+C/EHiZwNH02aaInBmYbIh/wM4H4DmgZ0uhftAeItL2x61aWuqwjq/wDqJT+Kjb/47Xpvhn4++DdXkjgvZrnSblztC3UWUJ9A65H4nFcj4f8A2dnmZJfE2rhF6m3sVyf+/jDj/vk/WvXvCfw98L+FNr6Lo9tFcL/y8yDzJv8AvtskfQYFAjqI3SWNZI2Do4DKwOQQehp1FFABRRWJr/ijTdFmjtZpHudSlGYdPtV824lHqEHRfVjhR3IoA265vV/FcMF/Jpei20msaymN9tbthIM9DNKfljHfByxHRTVP+zvEHiQ51udtD0s/8w+xm/0mQektwv3P92LB/wBsjiuk0jS7HRrCOy0q0gtLSP7sUKBVBPU8dSepPU96AOdtfCc2p3MV94zuY9TuI2Dw2MalbK2YdCEP+sYf33zyMqE6V11FFABRRXC3fim/8SXk2meA/KaOJzHda7Mu+2tyOCkQz+/lHoPkU/eJPykA3PEviez0N4rVYp7/AFe4Um2060XfNKM43Y6IgPV2IUeueK5+PwhqPii4S8+IFxFLaqweHQLVibOM5yDMxANww46gJ6KetdJ4a8N2Ph+GX7KJZ7ychrq+uW33Fyw/id+/sBhR0AA4raoAaiLGipGoVFGFVRgAegrkPiXb3trpcXiPRIml1bRN1wsKnH2q3OPPgP8AvKoYf7aJXY0UAUNB1az17RbLVdMlE1leRLNE47qRnn0PYjsav15d8JVPhnxV4s8CvlbSymGqaWp6fZbgklF9kkDD8a9RoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBsn3agNTyfdqA0wGmmmnGmmgBhpppxppoAYaaacaaaAOd8eT/Z/CeoNnlkEY/wCBMB/WrPhm1+x+HtPgIwywqWHoSMn9SaxvH5+2z6Ro6ctdXIeQDsi9f55/CusPAwOlADWphp7Uw0AMamGntTDQAw0w080w0CGGo3YKCWIAHcmpDUUsaSKVkVXX0YZFAFR9Qs1OGu7cH3kUf1pg1CzY4W7tyfQSL/jVgW8KjCwxgegUVDJZ2r5320LZ65QGgByyJIMo6t9Dmop54YBmaWOMersBVWXQ9LkbLWFuD/spt/lUFzY6Rp8BmltLZFXjJjBJPoPU0AC6xbXF0lrp+69upDhI4RnJxn7x4H511XhzwzLFdJqOttHJdrzDbocxwe+f4m9+3ameC9EmimbVtRh8md02W9vj/URnk5/2jxn06V19IYUUUUAFFFFAGB4r8PDWEgu7Kc2Ot2WWsr1RkoT1Rx/FG2AGU9eCMEAjjpNN1H4ibxqN+NMisZPs93pkYLvFOoBbJ4DA5DK3dWU4GTXqFcjrqf2J4x0vWovktdRZdLvwBwWOTbyH3Dkx+/nD0GABuifDjw1pTLJ9hF5OP+Wl2fM/8d+7+ldeqhVCoAqgYAAwAKWigAoorE13xRpmjXCWk8klxqUib47C0jM1w65xkIuSFz/EcKO5FAG3WLr/AIm0vQ5IoLudpL6YZhsrZDNcTe6xrlserdB3IrJ+z+KvEBzdTr4a01v+WFuVmvXH+1JzHF7hQ59HBrb0Dw9pegxyrpdosUkx3TTuxkmnb+9JIxLOfdiaAMXyvFHiHm4k/wCEZ01v+WULJNfSD/afmOL6LvPoymtvQdA03QYZI9MthG0p3TTOxklnb+9JIxLOfdia1KKACiiigAqjrWrWGh6bNqGrXUVrZwjLySHjngADqSTgADJJIA5qj4i8RQ6S8VpbwS6hrFwpNvYQEeZJ/tMTwkYPV24HQZJAOfpHhea41KHWvFk0V/q8R3W0EYP2Wwz/AM8lPV+xlb5j22g7aAMprDWfHzE6ylzonhQ/d04MUu79fWdgcxRn/nmPmP8AER92u6srS3sLSG0sYIre1hUJHDEgREUdAAOAKnooAKKKKACiiigDznx5B/ZHxJ8E+JoxtSaaTQrwjqyTjdDn2EqD8Xr0auX+JumTat4F1aGzUNfQxi7tR/03hYSx/wDjyKPxre0m/h1TSrPULU7re7hSeM+qsoYfoaALVFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQA2T7tQGp5Pu1AaYDTTTTjTTQAw0004000AMNNNONc9411D7Fo7RI+yW5zGGHVUwS7fgoP44oAwvDsn9veNdQ1Xra2aeRbn65GR+G4/8CFdsaxfBen/ANn6BAHTZLPmd1/ulug/AYH4VtGgBrUw09qYaAGNTDT2phoAYaYaeaYaBDDTDVe/1G0scC5mVXb7sY5dvoo5NNhj1q/x9h0owRnpLfP5f/jgy38qAJzVO4vbWBd09zDGvqzgVrWvhKWchtb1F51729sDDH9CQdzfmK6Gy0qwsVVbOytoAvTy4gv9KLhY4GO4u9QOzRbGa6J/5bOpjhX33Hr9Bmug0Dwkttcpf6zMt9qC8xgDEUP+4vc+55rqqKQwooooAKKKKACiiigArnfiLayXngfW0thm6itmuLb2mi/eRn8HRTXRUjosiMjqGVhgg9CKAINNvI9Q061vYDmG4iSZD/ssAR/OrFcf8KJWTwPZ6dO3+kaO8mlSg9R5DmNSfqio30YUSX134wd7fQ7iWz0AHbNqkRxJdeqWx7L2Mv4Jz8ygE+q65eahfzaP4UEb3kTbLvUJF3QWPtj/AJaS4ORGOB1YrwG0/Dug2ehW0qWvmS3E7eZc3c7b5rl8Y3O3c44A4AGAAAAKuaXp9ppVhDZadbx29rCNqRoMAf4knkk8k8mrVABRRRQAUUVX1C9tdOspry/uIra0gUvLNKwVEUdSSelAFiuVvNeutXu5tN8JeVI8TGO61ORd1vasOqqMjzZR/dBwv8RHCnPik1Px0QyfadJ8JsODgxXeor/6FDCfwdh/cHXs7GzttPs4bSxgit7WFQkcUShVRR0AA6UAUNA0Gz0RJmg8ye8uCHuby4bfNcMO7t6DsoAVRwoA4rWoooAKKKKACiiigAooooAK4v4ZTfY7XVfDUvE2g3jW8YPe1f8AeW5HsEYJ9YzXaV5/48f/AIRbxTpPjIErp5C6XrHoIHbMMx/65yNgn+7I3pQB6BRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUANk+7UBqeT7tQGmA00004000AMNNNONNNADDXA64f7b8Zx6cp3QQgJJjkBRh5Ppn92v513c8iwwvLIcIilmPoB1rzrwNqFusl/ql2zS315Iyw28SmSUrnccKOcEnGTx8tID0M0w1Sjg13UOUit9LhPRp/30v/AHyp2j8Sasp4WgkH/Ewv9Ru2PUGcxKf+Ax7aYDmphqxH4X0ePO20Jz/eldv5mhvC2isxLafESe5Lf40XAozSxxDMjog9WOKzbjXdLgO17+3Lf3UcO35DJrei8JaBE2V0izJ/24w3861bWytbQYtLaCAekcYX+VFwOKS+vLzjS9JvbjPSSVfIjPvl8E/gKuQeHNVvcHVdRW1jPWCxHzfjI3P5AV2FFIDM0nQtN0nLWNqiSn70rfNI31Y81p0UUAFFFFABRRRQAUUUUAFFFFABRRRQAU2R0ijaSRlRFBZmY4AA6kmnVybg+MLySM4Phi3cpICM/wBoyKeR/wBcVIwf77Aj7g+cAzrHTIfFl1e3cEclr4bvZhNMoLA6uyoqByP4YdqqMdZQoz8nD93GiRRrHGqoigKqqMAAdABTgMDA6UUAFFFFABRRWR4m1618P2Cz3KyTTyuIba1hG6W5lPSNF7k4Jz0ABJIAJoAXxN4g07w1pbX+qzFI9wjijQbpJ5D92ONBy7k9AP5VzOl6BqPii+g1rxtEIreJhLYaFuDR257SzkcSTeg5VO2T81XPDXhq8m1RfEXi5orjXMMLa3jbdBpsbfwRZ+85AG6QjJ6DC8V2FABRRRQAUUUUAFFFFABRRRQAUUUUAFVtTsbbVNOurC/hWe0uomhmibo6MMEH8DVmigDh/hleXVjFe+EdYmaXUtD2pFO/W6s2z5E3ucAo3+0hPcV3Fcj44sJra80zxRpsTvfaUxW4jjUlrizfHmpgcsVwJFH95MD7xrrqACiiigAooooAKKKKACiiigAooooAKKKKACiiigBsn3agNTyfdqA0wGmmmnMcDJrOl1SEkrZxzXsgONtsu4Z9C3Cj8SKALhqjf6jb2bLHIzPO/wByCJS8j/RRzj36UgsdWvz/AKVOmnW5/wCWdud8p+rkYX8AfrWnpumWmmowtIQrPy8jEs8h9WY8n8aQHD+On1VPDN1PO6WEUmIkgUh5HB6726KNoY4XPTrXTeCNKi0rw3YxrBHHcPCrzMFwzMRk5PfGcVkeOIjq2vaJowyY2fzpx6Lz/NVkH412tABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRVfUbyLT7C4vLjd5UEZkbaMkgDOAO5PQD1oAxvEEkuqXq6BZSPEJEEt/OjFWigJICKRyHkIZQR0UOcghc7ttBFa28VvbRJFBEgjjjRQqooGAAB0AHas/w9YS2dm8l5tOoXbm4umU5G8gAKP9lVCoPZQepNalABRRRQAUUVV1TULTStOub/UZ0t7O2jMssrnARQMk0AV/EOs2mg6XJfX5k8tSESOJS8k0jHCxoo5ZmOABWN4X0S8k1FvEXiYRnWpo/LhtkO6PToTz5SHu543v/EQAPlUVF4d0+613VY/E2v27wFAw0rT5Rg2kbDBlcf8APZx1/uKdo5Lk9hQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAyYOU/dhS3oxwP5VSe3vZTgTQ2699qGRvwJwB+RrQooAzl0i2Y5uzJeN/08NuX/vgYX8cVoKAqgKAABgAdqWigAooooAqwWaRXlzcn5pJmXkj7qhQNo9s5P41aoooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKytWU3WoabZf8szIbqTn7yxEFR658xoz9FNatY9wRZa8948oa3mhjglUt/qCGcq+M8K24gn1Ve2SADYooooAKKKKAEZgqlmICgZJPQCuF0/Pj3VotTlz/wiljKHsI8nGoTKf+Phh3iUj5B/Ew39AlJq80njnV7jQbGRl8N2cnl6vdRnBupB1s0Pp08xh2OwcltvdQxpDEkUKLHEihVRRgKB0AHYUAOooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAMjxRqk2l6fGbKJJb66mS1tlkOEEjnAZz/dAySBycYHJFWNM0yKysjBIftMsozczyKN1w+MFnxxz0x0AwBgACl1nSrTWbBrPUIy8JdJBtYoyOjBkZWGCCGAII9KvUAZcch0qaO3uHJspWCQSscmNicCNj6HgKe5+U87d2pVLW9Nt9Y0m7068DeRcxtGxQ7WXPRlPZgeQexANcr4W8XR2emDTfG1/aafr9hmK4a5kWBLlV4FxGWIDI4wTj7pJU4IoA7euN8R6le67qkvhnw3cNA8e3+1NSjIzZxtz5cZ/57sOn9wHcedoMU/iG+8VMbLwWXisWyJ9ekj/AHSD0tw3+uf/AGv9WvUlj8p6bQNGstB0yKw02IpAhLFmYs8jk5Z3Y8szHJLHkk0AS6Npdnoul2unaZAtvZWyCOKNf4QPc8k9yTyTyauUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFMlijlAEqI4ByAwzg+tPooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Position of the patient, assistant, and physician in preparation for reduction.",
"    <br>",
"     (B) Application and direction of forces in the reduction of an anteriorly dislocated temporomandibular joint.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced with permission from: Pratt A, Loiselle JM. Reduction of temporomandibular joint dislocation. In: Textbook of Pediatric Emergency Procedures, 2nd Edition, King C, Henretig FM (Eds). Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"     </div>",
"     <div class=\"contractual\">",
"      <br/>",
"      <a href=\"file://www.lww.com\">",
"       file://www.lww.com",
"      </a>",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_8_23687=[""].join("\n");
var outline_f23_8_23687=null;
var title_f23_8_23688="Epidemiology and pathogenesis of varicella-zoster virus infection: Herpes zoster";
var content_f23_8_23688=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology and pathogenesis of varicella-zoster virus infection: Herpes zoster",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/8/23688/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/8/23688/contributors\">",
"     Mary A Albrecht, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/8/23688/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/8/23688/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/8/23688/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/8/23688/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/8/23688/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Varicella-zoster virus (VZV) infection causes two clinically distinct forms of disease: varicella (chickenpox) and herpes zoster (shingles). Primary VZV infection results in the diffuse vesicular rash of varicella or chickenpox.",
"   </p>",
"   <p>",
"    Clinical resolution is followed by the establishment of latent infection within the sensory dorsal root ganglia. Reactivation of this neurotropic virus leads to herpes zoster, or shingles, a painful, unilateral vesicular eruption in a restricted dermatomal distribution [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23688/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis, epidemiology, and sequelae of herpes zoster will be reviewed here. The clinical manifestations, treatment and prevention of this infection, manifestations during pregnancy, and issues related to chickenpox are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/6/21608?source=see_link\">",
"     \"Postherpetic neuralgia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/22/36200?source=see_link\">",
"     \"Prevention of varicella-zoster virus infection: Herpes zoster\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33225?source=see_link\">",
"     \"Varicella-zoster virus infection in pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/20/2378?source=see_link\">",
"     \"Clinical manifestations of varicella-zoster virus infection: Herpes zoster\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overall, the CDC estimates that 32 percent of persons in the United States will experience zoster during their lifetimes [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23688/abstract/3\">",
"     3",
"    </a>",
"    ]. In the United States, herpes zoster occurs in nearly one million individuals annually, causing substantial morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23688/abstract/4\">",
"     4",
"    </a>",
"    ]. The cumulative lifetime incidence is approximately 10 to 20 percent of the population [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23688/abstract/5\">",
"     5",
"    </a>",
"    ]. Incidence rates progressively increase with age, presumably due to the decline in VZV-specific cell-mediated immunity [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23688/abstract/4,6-10\">",
"     4,6-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of herpes zoster has been well studied:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Using data from 1996 to 2005, one population-based study of adult patients from Minnesota found that the incidence of herpes zoster, adjusted to the US adult population, was 3.6 per 1000 person-years [",
"      <a class=\"abstract\" href=\"UTD.htm?23/8/23688/abstract/4\">",
"       4",
"      </a>",
"      ]. A temporal increase from 3.2 to 4.1 per 1000 person-years was noted from 1996 to 2001.",
"     </li>",
"     <li>",
"      Similar findings were noted in a large study of veterans, where the annual incidence rates significantly increased from 3.1 episodes per 1000 veterans in 2000 to 5.2 in 2007 [",
"      <a class=\"abstract\" href=\"UTD.htm?23/8/23688/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Age is the most important risk factor for the development of zoster (",
"    <a class=\"graphic graphic_figure graphicRef79262 \" href=\"UTD.htm?7/14/7406\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23688/abstract/3,12\">",
"     3,12",
"    </a>",
"    ]. One study demonstrated that zoster incidence increased 10-fold with age when comparing children less than 10 years of age to persons aged 80 to 89 years; a dramatic increase in disease rates begins to occur after 50 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23688/abstract/13\">",
"     13",
"    </a>",
"    ]. It is estimated that approximately 50 percent of persons who live to age 85 will have an episode of zoster [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23688/abstract/7\">",
"     7",
"    </a>",
"    ]. Other studies from the United States and Europe also demonstrate that older patients with VZV account for the majority of medical consultations and hospitalizations for this diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23688/abstract/6,8,9\">",
"     6,8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, among persons with zoster, the risk for postherpetic neuralgia (PHN) increases with age. In one study, the risk for experiencing PHN increased 27-fold among patients aged &gt;50 years compared with those &lt;50 years [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23688/abstract/14\">",
"     14",
"    </a>",
"    ]. In another study, PHN occurred in 18 percent of all adult patients with herpes zoster, but in more than one-third of those aged 79 years or older [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23688/abstract/4\">",
"     4",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    Physical trauma appears to be a risk factor for herpes zoster, particularly cranial herpes zoster. In an age-matched case-control study that used Medicare data, patients &ge;65 years of age who developed herpes zoster were 3.4 times more likely than controls to have experienced trauma during the week prior to herpes zoster onset [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23688/abstract/15\">",
"     15",
"    </a>",
"    ]. Patients who had cranial herpes zoster were more than 25 times as likely as controls to have had cranial trauma during the week prior to herpes zoster onset.",
"   </p>",
"   <p>",
"    Other risk factors for developing herpes zoster include underlying malignancy, disorders of cell-mediated immunity, and chronic lung or kidney disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23688/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A careful history and physical examination should be performed in a patient who presents with herpes zoster; however, an episode of herpes zoster itself should not prompt an evaluation for an occult cancer in an otherwise healthy individual. HIV serologic testing may be considered in patients who have never had routine testing and are at risk for HIV acquisition [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23688/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Immunocompetent hosts",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of herpes zoster varies depending on the host. Reactivation appears to be influenced by age-related immunosenescence, disease-related immunocompromise, or iatrogenic immunosuppression. As noted above, increasing age is the leading risk factor for the development of herpes zoster. The following observations have also been made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An excess of zoster cases has been observed among women, even when controlling for age [",
"      <a class=\"abstract\" href=\"UTD.htm?23/8/23688/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      One study suggested that the incidence of herpes zoster was significantly lower in black versus white study participants [",
"      <a class=\"abstract\" href=\"UTD.htm?23/8/23688/abstract/19\">",
"       19",
"      </a>",
"      ]. However, these findings may be partially explained by the results of one survey that demonstrated a higher proportion of elderly black persons have not had primary varicella and thus are not at risk for zoster [",
"      <a class=\"abstract\" href=\"UTD.htm?23/8/23688/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Approximately 1 to 4 percent of individuals will experience a second episode of herpes zoster, although this is more common in the immunocompromised host [",
"      <a class=\"abstract\" href=\"UTD.htm?23/8/23688/abstract/4,5,8\">",
"       4,5,8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Immunocompromised patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunocompromised patients are at increased risk of VZV reactivation, including transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23688/abstract/21-28\">",
"     21-28",
"    </a>",
"    ], patients receiving selected immunomodulator therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23688/abstract/29-35\">",
"     29-35",
"    </a>",
"    ], and HIV-infected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23688/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. The rate of complications (eg, disseminated disease, ocular involvement) is also significantly higher in those who are immunosuppressed [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23688/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Transplant patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of herpes zoster in solid organ transplant recipients is 10- to 100-fold higher than in the general population, ranging from 1 to 12 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23688/abstract/23\">",
"     23",
"    </a>",
"    ]. The risk of reactivation is also higher in older immunocompromised patients, as noted in immunocompetent populations [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23688/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective review of 239 patients undergoing lung transplantation, 29 patients developed zoster with a calculated incidence of 55 per 1,000 person-years of follow-up [",
"      <a class=\"abstract\" href=\"UTD.htm?23/8/23688/abstract/39\">",
"       39",
"      </a>",
"      ]. Postherpetic neuralgia occurred in 20 percent of patients. No clear risk factor for the development of herpes zoster was identified; CMV prophylaxis with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"       ganciclovir",
"      </a>",
"      was protective.",
"     </li>",
"     <li>",
"      In another retrospective review of 612 renal transplant recipients, 37 subjects developed herpes zoster for a time-adjusted incidence of 11 percent at four years of follow-up [",
"      <a class=\"abstract\" href=\"UTD.htm?23/8/23688/abstract/40\">",
"       40",
"      </a>",
"      ]. Patients who were VZV-seronegative at the time of transplant had a threefold increased risk of developing herpes zoster compared to those who were seropositive.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Autoimmune disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is an increased risk of herpes zoster in patients with underlying autoimmune disease (eg, rheumatoid arthritis, inflammatory bowel disease), particularly due to the use of immunosuppressive therapies such as glucocorticoids, nonbiologic disease-modifying antirheumatic drugs (DMARDs), and tumor necrosis factor (TNF)-alpha inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23688/abstract/30-34,41-44\">",
"     30-34,41-44",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A multicenter cohort study performed in the United States compared the incidence of herpes zoster in 25,742 patients with rheumatoid arthritis or another autoimmune disease initiating nonbiologic DMARDs and 33,324 patients initiating a TNF-alpha inhibitor [",
"      <a class=\"abstract\" href=\"UTD.htm?23/8/23688/abstract/44\">",
"       44",
"      </a>",
"      ]. Baseline use of glucocorticoids at a dose of &ge;10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      equivalents was associated with an increased risk of herpes zoster (adjusted hazard ratio 2.13, 95% CI 1.64-2.75) compared with no baseline use.",
"     </li>",
"     <li>",
"      In the same study, patients who initiated a TNF-alpha inhibitor were not at higher risk for herpes zoster than patients initiating nonbiologic DMARDs, and no differences in risk were observed among",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      recipients [",
"      <a class=\"abstract\" href=\"UTD.htm?23/8/23688/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, an earlier smaller study showed that use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      was associated with a moderately increased risk of herpes zoster (hazard ratio 1.82, 95% CI 1.05-3.15) compared with nonbiologic DMARDs [",
"      <a class=\"abstract\" href=\"UTD.htm?23/8/23688/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A nested retrospective case-control study included 18,000 patients with inflammatory bowel disease who were treated with glucocorticoids",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the nonbiologic DMARDs,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      or 6-mercaptopurine [",
"      <a class=\"abstract\" href=\"UTD.htm?23/8/23688/abstract/42\">",
"       42",
"      </a>",
"      ]. The incidence of herpes zoster was significantly increased with both glucocorticoids and",
"      <span class=\"nowrap\">",
"       azathioprine/6-mercaptopurine",
"      </span>",
"      (adjusted odds ratio 1.5 and 3.1, respectively).",
"     </li>",
"     <li>",
"      A retrospective Veterans Affairs cohort study, involving 20,357 patients with rheumatoid arthritis, found that those who received treatment for either moderate disease (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      ) or severe disease (eg, TNF-alpha inhibitors) were at increased risk of developing herpes zoster [",
"      <a class=\"abstract\" href=\"UTD.htm?23/8/23688/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk of herpes zoster in patients receiving a TNF-alpha inhibitor is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32538?source=see_link&amp;anchor=H12#H12\">",
"     \"Tumor necrosis factor-alpha inhibitors: Risk of bacterial, viral, and fungal infections\", section on 'Herpes zoster'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The interaction of VZV with HIV-1 was evaluated in a cohort of 786 men who have sex with men (MSM), 287 HIV-positive and 499 HIV-negative [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23688/abstract/36\">",
"     36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of zoster was higher in HIV-infected men (29.4",
"      <span class=\"nowrap\">",
"       cases/1000",
"      </span>",
"      person-years versus 2.0",
"      <span class=\"nowrap\">",
"       cases/1000",
"      </span>",
"      person-years).",
"     </li>",
"     <li>",
"      Overall age-adjusted relative risk (RR) for developing zoster in HIV- seropositive men was 16.9 (95% CI 8.7-32.6).",
"     </li>",
"     <li>",
"      The risk of herpes zoster was not associated with the duration of HIV infection and did not predict more rapid progression to AIDS.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another prospective study from the Netherlands also found a higher incidence of herpes zoster in HIV-infected MSM (51.51 per 1000 person-years versus 3.31 per 1000 person-years), and recurrences were only documented in HIV-infected individuals (26 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23688/abstract/37\">",
"     37",
"    </a>",
"    ]. Herpes zoster was also not an independent predictor for HIV disease progression in this cohort. The incidence of zoster rose with decreasing CD4 cell counts (31.2 per 1000 person-years for a CD4 count &gt;500",
"    <span class=\"nowrap\">",
"     cells/microL,",
"    </span>",
"    47.2 per 1000 person-years for 200 to 499",
"    <span class=\"nowrap\">",
"     cells/microL,",
"    </span>",
"    and 97.5 per 1000 person-years for &lt;200",
"    <span class=\"nowrap\">",
"     cells/microL).",
"    </span>",
"   </p>",
"   <p>",
"    The development of herpes zoster suggests the need for assessment of HIV-1 seropositivity in populations at risk for HIV-1 infection [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23688/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HIV-infected children who develop chickenpox have a higher incidence of developing herpes zoster and are more likely to have recurrent zoster; a lower CD4 cell count enhances this risk as shown in a prospective study of VZV infection in 61 HIV-infected children with CD4 cell ranges between 20 and 24 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23688/abstract/38\">",
"     38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Of 30 children who had primary varicella after the age of one year, 8 (27 percent) developed zoster.",
"     </li>",
"     <li>",
"      Zoster developed an average of 1.9 years after varicella occurred.",
"     </li>",
"     <li>",
"      Children with CD4 cells &lt;15 percent when they developed chickenpox were at a higher risk for zoster, with an incidence of 467 cases per 1000 person-years.",
"     </li>",
"     <li>",
"      Four of eight children with zoster (50 percent) experienced recurrences.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Impact of varicella vaccine on incidence of herpes zoster",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the licensure of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    , concerns were raised that immunization might lead to an increased risk of vaccine-associated herpes zoster, particularly in immunocompromised children. Other clinicians raised the possibility that widespread varicella immunization in childhood may increase the incidence of herpes zoster in the general population due to decreased circulation of wild-type virus and a decline in T-cell immunity [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23688/abstract/46\">",
"     46",
"    </a>",
"    ]. Neither of these concerns has materialized.",
"   </p>",
"   <p>",
"    The incidence of post-vaccination zoster was examined in a study of 548 children with acute lymphocytic leukemia who received the Oka live attenuated VZV vaccine. Zoster developed in 13 subjects (2.4 percent) during a mean follow-up interval of 4.1 years [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23688/abstract/47\">",
"     47",
"    </a>",
"    ]. In a subgroup analysis that matched 96 vaccinated subjects to those who had prior natural varicella infection, the incidence of zoster was lower in the immunized group (4 compared to 15 cases in those subjects with natural infection).",
"   </p>",
"   <p>",
"    Emerging data also suggest that the vaccine-induced decline in varicella disease has not led to an increase in herpes zoster in the general population. The Centers for Disease Control and Prevention has collaborated with an HMO in Washington State to monitor the incidence rates of varicella and herpes zoster before and after vaccine licensure [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23688/abstract/48\">",
"     48",
"    </a>",
"    ]. The incidence of varicella decreased between 1995 and 2002 (from 2.63 cases to 0.92",
"    <span class=\"nowrap\">",
"     cases/100",
"    </span>",
"    person-years), but the incidence of herpes zoster remained stable.",
"   </p>",
"   <p>",
"    Other issues related to varicella vaccination are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/26/37289?source=see_link\">",
"     \"Prevention of varicella-zoster virus infection: Chickenpox\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the early 1900s, many viewed &ldquo;shingles&rdquo; as a viral illness that was acquired from person-to-person contact, similar to &ldquo;chickenpox&rdquo;. The hypothesis that zoster was secondary to reactivation of latent varicella-zoster virus (VZV) infection was first proposed in 1965 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23688/abstract/49\">",
"     49",
"    </a>",
"    ]. The precise mechanisms involved in the establishment of viral latency following primary VZV infection have been an ongoing focus of investigation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Dissemination and immune evasion",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the initial phase of varicella, VZV inoculates the nasopharyngeal lymphoid tissue through airborne viral droplets in a susceptible host. This is followed by rapid spread to regional lymphoid tissue with preferential infection of tonsillar memory CD4+ T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23688/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. Susceptibility of tonsillar T cells to VZV suggests that this cellular population may be an important target during initial infection.",
"   </p>",
"   <p>",
"    The exact mechanism by which VZV is transported from the nasopharynx to regional lymph nodes has not been elucidated, but appears to involve cell-associated viremia in the form of migrating T-cells [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23688/abstract/52\">",
"     52",
"    </a>",
"    ]. VZV causes productive infection of activated CD4+ T cells, resulting in downregulation of major histocompatibility complex (MHC) class I expression [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23688/abstract/50,52,53\">",
"     50,52,53",
"    </a>",
"    ]. Downregulation of MHC class I expression enables the virus to evade the immune system. Preferential infection of CD4 T cells, expressing skin homing markers, may enhance transport of VZV to cutaneous epithelia. The prolonged incubation period, prior to the onset of skin lesions, may reflect the time required for VZV to overcome local immune-mediated barriers, including alpha interferon (IFN-a) production by epidermal cells [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23688/abstract/50,53\">",
"     50,53",
"    </a>",
"    ]. During acute infection, viremia uniformly occurs as shown by detection of VZV DNA in serum, peripheral blood mononuclear cells, and in the characteristic lesions of herpes zoster [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23688/abstract/54\">",
"     54",
"    </a>",
"    ]. VZV DNA has also been demonstrated in human saliva among patients with acute symptoms of herpes zoster [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23688/abstract/55\">",
"     55",
"    </a>",
"    ] and persists for many years after clinical illness [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23688/abstract/56\">",
"     56",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    VZV-specific cell-mediated immune responses play a critical role in controlling VZV latency and limiting the potential for reactivation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23688/abstract/2,47,57,58\">",
"     2,47,57,58",
"    </a>",
"    ]. A decline in cell-mediated VZV-specific immunity has been documented in older individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23688/abstract/57,58\">",
"     57,58",
"    </a>",
"    ] and in patients with lymphoproliferative malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23688/abstract/59\">",
"     59",
"    </a>",
"    ] who experience higher rates of herpes zoster. In contrast, children with hypogammaglobulinemia do not experience severely protracted or fulminant primary varicella infection, or increased rates of zoster [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23688/abstract/60\">",
"     60",
"    </a>",
"    ]. These combined observations indicate that a decline in cell-mediated, rather than humoral, immunity is linked directly to reactivated VZV syndromes. These epidemiologic observations are supported by in vitro data that demonstrate reduced VZV T cell responder cell frequency in aging patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23688/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Latency and reactivation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cell-free virus, which is present only in skin vesicles, infects nerve endings in skin and migrates along sensory axons to establish latency in neurons within the regional ganglia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23688/abstract/52,62-64\">",
"     52,62-64",
"    </a>",
"    ]. VZV proteins accumulate preferentially in the cytoplasm of neurons during latency, but migrate to the nucleus during productive infection [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23688/abstract/65\">",
"     65",
"    </a>",
"    ]. Once reactivation occurs, virus can spread to other cells within the ganglion to involve multiple sensory neurons and thereby establish infection of the skin [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23688/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A guinea pig model has been developed to examine viral latency and reactivation in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23688/abstract/62\">",
"     62",
"    </a>",
"    ]. In this model, infection of sensory neurons with cell-associated virus leads to lytic infection; in contrast, cell-free virus establishes latency [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23688/abstract/62\">",
"     62",
"    </a>",
"    ]. During latency, the virus only expresses a limited number of viral proteins, such as immediate early protein 63 (IE63) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23688/abstract/66\">",
"     66",
"    </a>",
"    ]. Immunity to this protein may play a role in maintaining the virus in a latent state [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23688/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following varicella-zoster virus (VZV) reactivation, the dorsal spinal ganglion typically exhibits intense inflammation, accompanied by hemorrhagic necrosis of nerve cells [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23688/abstract/49\">",
"     49",
"    </a>",
"    ]. The ganglion undergoes eventual neuronal loss with subsequent fibrosis of afferent nerve fibers, particularly type C nociceptors [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23688/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The dermatomal distribution of the vesicular rash of herpes zoster corresponds to the sensory fields of many infected neurons within a specific ganglion [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23688/abstract/2\">",
"     2",
"    </a>",
"    ]. Mapping of the involved sensory areas, related to each ganglion, was first conducted in 1900 in detailed autopsy studies of persons who had recent zoster [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23688/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Varicella-zoster virus (VZV) infection causes two clinically distinct forms of disease: one is a diffuse vesicular rash known as varicella, or chickenpox. Clinical resolution of varicella is followed by the establishment of latent infection; reactivation of this neurotropic virus may lead to herpes zoster, or \"shingles\", a painful, unilateral vesicular eruption in a restricted dermatomal distribution. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      During the initial phase of varicella, VZV infects the nasopharyngeal lymphoid tissue through airborne viral droplets in a susceptible host. This is followed by rapid spread to regional lymphoid tissue via migrating T-cells. Cell-free virus, which is present only in skin vesicles, infects nerve endings in skin and migrates along sensory axons to establish latency in the regional ganglia. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Following VZV reactivation, the dorsal spinal ganglion typically exhibits intense inflammation, accompanied by hemorrhagic necrosis of nerve cells. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Pathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Reactivation appears to be influenced by age-related immunosenescence, disease-associated immunocompromise, or iatrogenic immunosuppression. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/1\">",
"      Gnann JW Jr, Whitley RJ. Clinical practice. Herpes zoster. N Engl J Med 2002; 347:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/2\">",
"      Oxman MN. Immunization to reduce the frequency and severity of herpes zoster and its complications. Neurology 1995; 45:S41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/3\">",
"      Harpaz R, Ortega-Sanchez IR, Seward JF, Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008; 57:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/4\">",
"      Yawn BP, Saddier P, Wollan PC, et al. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007; 82:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/5\">",
"      Straus SE, Ostrove JM, Inchausp&eacute; G, et al. NIH conference. Varicella-zoster virus infections. Biology, natural history, treatment, and prevention. Ann Intern Med 1988; 108:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/6\">",
"      de Melker H, Berbers G, Hahn&eacute; S, et al. The epidemiology of varicella and herpes zoster in The Netherlands: implications for varicella zoster virus vaccination. Vaccine 2006; 24:3946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/7\">",
"      Schmader K. Herpes zoster in older adults. Clin Infect Dis 2001; 32:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/8\">",
"      Donahue JG, Choo PW, Manson JE, Platt R. The incidence of herpes zoster. Arch Intern Med 1995; 155:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/9\">",
"      Gil A, San-Mart&iacute;n M, Carrasco P, Gonz&aacute;lez A. Epidemiology of severe varicella-zoster virus infection in Spain. Vaccine 2004; 22:3947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/10\">",
"      Weinberg A, Lazar AA, Zerbe GO, et al. Influence of age and nature of primary infection on varicella-zoster virus-specific cell-mediated immune responses. J Infect Dis 2010; 201:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/11\">",
"      Rimland D, Moanna A. Increasing incidence of herpes zoster among Veterans. Clin Infect Dis 2010; 50:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/12\">",
"      Ragozzino MW, Melton LJ 3rd, Kurland LT, et al. Population-based study of herpes zoster and its sequelae. Medicine (Baltimore) 1982; 61:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/13\">",
"      Hope-Simpson RE. Postherpetic neuralgia. J R Coll Gen Pract 1975; 25:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/14\">",
"      Choo PW, Galil K, Donahue JG, et al. Risk factors for postherpetic neuralgia. Arch Intern Med 1997; 157:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/15\">",
"      Zhang JX, Joesoef RM, Bialek S, et al. Association of physical trauma with risk of herpes zoster among medicare beneficiaries in the United States. J Infect Dis 2013; 207:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/16\">",
"      McDonald JR, Zeringue AL, Caplan L, et al. Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis. Clin Infect Dis 2009; 48:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/17\">",
"      Friedman-Kien AE, Lafleur FL, Gendler E, et al. Herpes zoster: a possible early clinical sign for development of acquired immunodeficiency syndrome in high-risk individuals. J Am Acad Dermatol 1986; 14:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/18\">",
"      Opstelten W, Van Essen GA, Schellevis F, et al. Gender as an independent risk factor for herpes zoster: a population-based prospective study. Ann Epidemiol 2006; 16:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/19\">",
"      Schmader K, George LK, Burchett BM, et al. Racial differences in the occurrence of herpes zoster. J Infect Dis 1995; 171:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/20\">",
"      Dworkin RH. Racial differences in herpes zoster and age at onset of varicella. J Infect Dis 1996; 174:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/21\">",
"      Feldman S, Hughes WT, Daniel CB. Varicella in children with cancer: Seventy-seven cases. Pediatrics 1975; 56:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/22\">",
"      Feldhoff CM, Balfour HH Jr, Simmons RL, et al. Varicella in children with renal transplants. J Pediatr 1981; 98:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/23\">",
"      Patti ME, Selvaggi KJ, Kroboth FJ. Varicella hepatitis in the immunocompromised adult: a case report and review of the literature. Am J Med 1990; 88:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/24\">",
"      Carby M, Jones A, Burke M, et al. Varicella infection after heart and lung transplantation: a single-center experience. J Heart Lung Transplant 2007; 26:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/25\">",
"      van de Beek D, Patel R, Daly RC, et al. Central nervous system infections in heart transplant recipients. Arch Neurol 2007; 64:1715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/26\">",
"      Kim DH, Messner H, Minden M, et al. Factors influencing varicella zoster virus infection after allogeneic peripheral blood stem cell transplantation: low-dose acyclovir prophylaxis and pre-transplant diagnosis of lymphoproliferative disorders. Transpl Infect Dis 2008; 10:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/27\">",
"      Miller GG, Dummer JS. Herpes simplex and varicella zoster viruses: forgotten but not gone. Am J Transplant 2007; 7:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/28\">",
"      Hovens MM, Vaessen N, Sijpkens YW, de Fijter JW. Unusual presentation of central nervous system manifestations of Varicella zoster virus vasculopathy in renal transplant recipients. Transpl Infect Dis 2007; 9:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/29\">",
"      Korelitz BI, Fuller SR, Warman JI, Goldberg MD. Shingles during the course of treatment with 6-mercaptopurine for inflammatory bowel disease. Am J Gastroenterol 1999; 94:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/30\">",
"      Antonelli MA, Moreland LW, Brick JE. Herpes zoster in patients with rheumatoid arthritis treated with weekly, low-dose methotrexate. Am J Med 1991; 90:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/31\">",
"      Lyon CC, Thompson D. Herpes zoster encephalomyelitis associated with low dose methotrexate for rheumatoid arthritis. J Rheumatol 1997; 24:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/32\">",
"      Kinder A, Stephens S, Mortimer N, Sheldon P. Severe herpes zoster after infliximab infusion. Postgrad Med J 2004; 80:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/33\">",
"      Baumgart DC, Dignass AU. Shingles following infliximab infusion. Ann Rheum Dis 2002; 61:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/34\">",
"      Choi HJ, Kim MY, Kim HO, Park YM. An atypical varicella exanthem associated with the use of infliximab. Int J Dermatol 2006; 45:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/35\">",
"      Chanan-Khan AA, Cheson BD. Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol 2008; 26:1544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/36\">",
"      Buchbinder SP, Katz MH, Hessol NA, et al. Herpes zoster and human immunodeficiency virus infection. J Infect Dis 1992; 166:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/37\">",
"      Veenstra J, Krol A, van Praag RM, et al. Herpes zoster, immunological deterioration and disease progression in HIV-1 infection. AIDS 1995; 9:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/38\">",
"      Gershon AA, Mervish N, LaRussa P, et al. Varicella-zoster virus infection in children with underlying human immunodeficiency virus infection. J Infect Dis 1997; 176:1496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/39\">",
"      Manuel O, Kumar D, Singer LG, et al. Incidence and clinical characteristics of herpes zoster after lung transplantation. J Heart Lung Transplant 2008; 27:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/40\">",
"      Arness T, Pedersen R, Dierkhising R, et al. Varicella zoster virus-associated disease in adult kidney transplant recipients: incidence and risk-factor analysis. Transpl Infect Dis 2008; 10:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/41\">",
"      Smitten AL, Choi HK, Hochberg MC, et al. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum 2007; 57:1431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/42\">",
"      Gupta G, Lautenbach E, Lewis JD. Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2006; 4:1483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/43\">",
"      Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009; 301:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/44\">",
"      Winthrop KL, Baddley JW, Chen L, et al. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA 2013; 309:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/45\">",
"      Melbye M, Grossman RJ, Goedert JJ, et al. Risk of AIDS after herpes zoster. Lancet 1987; 1:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/46\">",
"      Whitley RJ. Changing dynamics of varicella-zoster virus infections in the 21st century: the impact of vaccination. J Infect Dis 2005; 191:1999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/47\">",
"      Hardy I, Gershon AA, Steinberg SP, LaRussa P. The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. Varicella Vaccine Collaborative Study Group. N Engl J Med 1991; 325:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/48\">",
"      Jumaan AO, Yu O, Jackson LA, et al. Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992-2002. J Infect Dis 2005; 191:2002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/49\">",
"      HOPE-SIMPSON RE. THE NATURE OF HERPES ZOSTER: A LONG-TERM STUDY AND A NEW HYPOTHESIS. Proc R Soc Med 1965; 58:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/50\">",
"      Ku CC, Besser J, Abendroth A, et al. Varicella-Zoster virus pathogenesis and immunobiology: new concepts emerging from investigations with the SCIDhu mouse model. J Virol 2005; 79:2651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/51\">",
"      Dworkin RH, Johnson RW, Breuer J, et al. Recommendations for the management of herpes zoster. Clin Infect Dis 2007; 44 Suppl 1:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/52\">",
"      Ku CC, Padilla JA, Grose C, et al. Tropism of varicella-zoster virus for human tonsillar CD4(+) T lymphocytes that express activation, memory, and skin homing markers. J Virol 2002; 76:11425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/53\">",
"      Ku CC, Zerboni L, Ito H, et al. Varicella-zoster virus transfer to skin by T Cells and modulation of viral replication by epidermal cell interferon-alpha. J Exp Med 2004; 200:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/54\">",
"      Satyaprakash AK, Tremaine AM, Stelter AA, et al. Viremia in acute herpes zoster. J Infect Dis 2009; 200:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/55\">",
"      Mehta SK, Tyring SK, Gilden DH, et al. Varicella-zoster virus in the saliva of patients with herpes zoster. J Infect Dis 2008; 197:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/56\">",
"      Nagel MA, Choe A, Cohrs RJ, et al. Persistence of varicella zoster virus DNA in saliva after herpes zoster. J Infect Dis 2011; 204:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/57\">",
"      Burke BL, Steele RW, Beard OW, et al. Immune responses to varicella-zoster in the aged. Arch Intern Med 1982; 142:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/58\">",
"      Arvin AM. Aspects of the host response to varicella-zoster virus: a review of recent observations. Neurology 1995; 45:S36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/59\">",
"      Arvin AM, Pollard RB, Rasmussen LE, Merigan TC. Cellular and humoral immunity in the pathogenesis of recurrent herpes viral infections in patients with lymphoma. J Clin Invest 1980; 65:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/60\">",
"      GOOD RA, ZAK SJ. Disturbances in gamma globulin synthesis as experiments of nature. Pediatrics 1956; 18:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/61\">",
"      Hayward AR, Herberger M. Lymphocyte responses to varicella zoster virus in the elderly. J Clin Immunol 1987; 7:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/62\">",
"      Chen JJ, Gershon AA, Li ZS, et al. Latent and lytic infection of isolated guinea pig enteric ganglia by varicella zoster virus. J Med Virol 2003; 70 Suppl 1:S71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/63\">",
"      Lungu O, Annunziato PW, Gershon A, et al. Reactivated and latent varicella-zoster virus in human dorsal root ganglia. Proc Natl Acad Sci U S A 1995; 92:10980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/64\">",
"      Kennedy PG, Grinfeld E, Gow JW. Latent varicella-zoster virus is located predominantly in neurons in human trigeminal ganglia. Proc Natl Acad Sci U S A 1998; 95:4658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/65\">",
"      Lungu O, Panagiotidis CA, Annunziato PW, et al. Aberrant intracellular localization of Varicella-Zoster virus regulatory proteins during latency. Proc Natl Acad Sci U S A 1998; 95:7080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/66\">",
"      Debrus S, Sadzot-Delvaux C, Nikkels AF, et al. Varicella-zoster virus gene 63 encodes an immediate-early protein that is abundantly expressed during latency. J Virol 1995; 69:3240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/67\">",
"      Sadzot-Delvaux C, Kinchington PR, Debrus S, et al. Recognition of the latency-associated immediate early protein IE63 of varicella-zoster virus by human memory T lymphocytes. J Immunol 1997; 159:2802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/68\">",
"      Fields HL, Rowbotham M, Baron R. Postherpetic neuralgia: irritable nociceptors and deafferentation. Neurobiol Dis 1998; 5:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23688/abstract/69\">",
"      Head H, Campbell AW. The pathology of herpes zoster and its bearing on sensory localization. Brain 1900; 23:353.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8292 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-61DB87C3C4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_8_23688=[""].join("\n");
var outline_f23_8_23688=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Immunocompetent hosts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Immunocompromised patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Transplant patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Autoimmune disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - HIV infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Impact of varicella vaccine on incidence of herpes zoster",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Dissemination and immune evasion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Latency and reactivation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/8292\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8292|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/14/7406\" title=\"figure 1\">",
"      Zoster and PHN by age",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/20/2378?source=related_link\">",
"      Clinical manifestations of varicella-zoster virus infection: Herpes zoster",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/6/21608?source=related_link\">",
"      Postherpetic neuralgia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/26/37289?source=related_link\">",
"      Prevention of varicella-zoster virus infection: Chickenpox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/22/36200?source=related_link\">",
"      Prevention of varicella-zoster virus infection: Herpes zoster",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32538?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: Risk of bacterial, viral, and fungal infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33225?source=related_link\">",
"      Varicella-zoster virus infection in pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_8_23689="Overview of cervical spinal cord and cervical peripheral nerve injuries in the young athlete";
var content_f23_8_23689=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of cervical spinal cord and cervical peripheral nerve injuries in the young athlete",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/8/23689/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/8/23689/contributors\">",
"     Jason E Decker, MD, FAAP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/8/23689/contributors\">",
"     Albert C Hergenroeder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/8/23689/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/8/23689/contributors\">",
"     Joseph Chorley, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/8/23689/contributors\">",
"     Richard G Bachur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/8/23689/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/8/23689/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/8/23689/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An overview of cervical spinal cord injuries and cervical peripheral nerve injuries in the young athlete will be presented here. The anatomy of the cervical spine, the diagnostic approach to the athlete with neck pain or injury, the management of the athlete with an acute neck injury, musculoskeletal injuries of the neck and the evaluation of cervical spine injuries in children and adolescents are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/25/41368?source=see_link\">",
"       \"Approach to the young athlete with neck pain or injury\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/28/15815?source=see_link\">",
"       \"Field care and evaluation of the young athlete with acute neck injury\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/49/11033?source=see_link\">",
"       \"Overview of musculoskeletal neck injuries in the young athlete\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/7/32889?source=see_link\">",
"       \"Evaluation of cervical spine injuries in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CERVICAL SPINAL CORD INJURIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The annual incidence of traumatic spinal cord injury is estimated to be between 30 and 46 cases per million populations in the United States and Canada [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23689/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The majority of injuries occur in young adults: 57 percent of cases occur in people 16 to 30 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23689/abstract/4\">",
"     4",
"    </a>",
"    ]. Most injuries (&gt;80 percent) occur in males. Motor vehicle crash is the most common mechanism of injury and accounts for approximately 35 percent of cases. The next most common mechanisms (in descending order) are gunshot wounds, falls, and recreational sporting activities, particularly diving and in the United States, American football [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23689/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a retrospective study of 1016 cases of traumatic spinal cord injury in Germany, 14 percent were caused in sport or diving accidents [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23689/abstract/7\">",
"     7",
"    </a>",
"    ]. The sporting activities during which the injuries were sustained included downhill skiing, horseback riding, air sports (eg, hang-gliding, paragliding), gymnastics, and trampolining. Spinal cord injuries can also occur in ice hockey, where the typical mechanism involves being body-checked from behind and falling head-first into the boards [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23689/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Spinal cord injuries may be complete or partial. Partial spinal cord injuries include the central cord syndrome, anterior cord syndrome, Brown-S&eacute;quard syndrome, cervical cord neurapraxia, and spinal cord injury without radiographic abnormality (SCIWORA).",
"   </p>",
"   <p>",
"    SCIWORA is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4951?source=see_link\">",
"     \"Spinal cord injury without radiographic abnormality (SCIWORA) in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of athletes with cervical spinal cord injuries should be directed by a neurosurgeon. The use of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/63/17401?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    in patients with spinal cord injury is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/11/26810?source=see_link&amp;anchor=H21#H21\">",
"     \"Acute traumatic spinal cord injury\", section on 'Glucocorticoids'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Complete cord syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trauma is the most common cause of complete transection of the spinal cord. Other causes include infarction, hemorrhage, and acute disc herniation.",
"   </p>",
"   <p>",
"    Transection of the spinal cord results in complete loss of motor, sensory and autonomic function below the level of the lesion (",
"    <a class=\"graphic graphic_table graphicRef63597 \" href=\"UTD.htm?23/43/24253\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef53006 \" href=\"UTD.htm?21/8/21634\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef72447 \" href=\"UTD.htm?35/7/35958\">",
"     figure 2",
"    </a>",
"    ). Acute spinal cord transections can cause spinal shock via the removal of ascending and descending cerebral impulses. Spinal shock is manifested by flaccid paralysis with absent deep tendon reflexes in the first day or two after injury. This period of flaccid paralysis is followed by spasticity with hyperactive reflexes. Transection at or above the C3-C5 level can result in diaphragmatic paralysis and respiratory failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/28/42439?source=see_link\">",
"     \"Respiratory complications of spinal cord injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sympathetic interruption in complete spinal cord interruption can cause neurogenic shock. The sudden loss of sympathetic tone leads to decreased systemic vascular resistance and increased vagal tone, which result in hypotension with paradoxical bradycardia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23689/abstract/9\">",
"     9",
"    </a>",
"    ]. Other symptoms of neurogenic shock include gastrointestinal dysmotility, bowel and bladder dysfunction, and problems with temperature regulation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23689/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42901?source=see_link&amp;anchor=H9#H9\">",
"     \"Physiology and classification of shock in children\", section on 'Distributive shock'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of the athlete with an acute cervical spine injury involves cervical spine immobilization and transport to an emergency medical facility for specialty care. The prognosis for functional improvement in patients with complete cervical spinal cord transection is poor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6854?source=see_link\">",
"     \"Pediatric cervical spine immobilization\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/28/15815?source=see_link\">",
"     \"Field care and evaluation of the young athlete with acute neck injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Central cord syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The central cord syndrome is the most common of the partial cord syndromes. It is typically seen in older patients with degenerative spine disease and cervical spondylosis. In athletes, the central cord syndrome is usually caused by hyperextension injury during which the ligamentum flavum is thought to buckle, resulting in increased pressure on the central cord [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23689/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. It may also occur after traumatic disc herniation, trivial trauma, or in hyperflexion injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23689/abstract/11,13-15\">",
"     11,13-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The characteristic physical finding of central cord syndrome is bilateral motor paresis greater in the upper than in the lower extremities. The paresis is usually greater distally than proximally, and there is variable sensory involvement (",
"    <a class=\"graphic graphic_figure graphicRef72447 \" href=\"UTD.htm?35/7/35958\">",
"     figure 2",
"    </a>",
"    ). This pattern occurs because the most central portions of the spinal tracts contain fibers from the upper extremities (",
"    <a class=\"graphic graphic_figure graphicRef71763 \" href=\"UTD.htm?43/15/44275\">",
"     figure 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/25/41368?source=see_link&amp;anchor=H2#H2\">",
"     \"Approach to the young athlete with neck pain or injury\", section on 'Anatomy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with central cord syndromes have a relatively good prognosis for recovery when compared with patients with the other spinal cord syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23689/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Anterior cord syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anterior cord syndrome is caused by direct or indirect injury to the anterior spinal cord. Direct injury may occur secondary to a crush injury or compression from a hematoma; indirect injury result from ischemia secondary to compression of the anterior spinal artery [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23689/abstract/9\">",
"     9",
"    </a>",
"    ]. In athletes, anterior cord syndrome is typically seen after hyperflexion injuries with bony instability, acute disc herniation, or hematoma formation.",
"   </p>",
"   <p>",
"    The anterior cord syndrome, which involves injury to the spinothalamic tract, is characterized by loss of motor, pain, light touch, and temperature sensation (",
"    <a class=\"graphic graphic_figure graphicRef72447 \" href=\"UTD.htm?35/7/35958\">",
"     figure 2",
"    </a>",
"    ). Because the posterior columns are preserved, the patient retains fine touch, vibration, pressure, and proprioception sensation distal to the injury (",
"    <a class=\"graphic graphic_figure graphicRef71763 \" href=\"UTD.htm?43/15/44275\">",
"     figure 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/25/41368?source=see_link&amp;anchor=H2#H2\">",
"     \"Approach to the young athlete with neck pain or injury\", section on 'Anatomy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to the usual care for spinal cord injury, treatment of the anterior cord syndrome involves stabilization or removal of any structure that exerts increased pressure on the anterior aspect of spinal cord. Laminectomy may be necessary to decompress the spinal cord.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Brown-S&eacute;quard syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Brown-S&eacute;quard syndrome is a rare spinal injury that results in hemisection of the spinal cord. It is usually caused by penetrating trauma; other causes include blunt trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23689/abstract/16\">",
"     16",
"    </a>",
"    ], disc or bone herniation, hematoma, and tumor. The Brown-S&eacute;quard syndrome can also occur as a complication of decompression sickness [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23689/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Brown-S&eacute;quard syndrome is characterized by ipsilateral loss of motor function, vibration, and proprioception below the level of the lesion with contralateral loss of pain and temperature sensation beginning approximately two levels below the lesion (",
"    <a class=\"graphic graphic_figure graphicRef72447 \" href=\"UTD.htm?35/7/35958\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef71763 \" href=\"UTD.htm?43/15/44275\">",
"     figure 3",
"    </a>",
"    ). This pattern of deficits occurs because the spinothalamic tract travels on the ipsilateral side of the cord before crossing over to the contralateral side. In addition, ipsilateral loss of pain and temperature sensation may occur at one or two levels below the lesion. Most cases of Brown-S&eacute;quard syndrome are partial cases with varying degrees of paresis and analgesia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23689/abstract/10\">",
"     10",
"    </a>",
"    ]. The Brown-S&eacute;quard syndrome also may be associated with Horner syndrome (ptosis, miosis, and anhydrosis) if there is coexistent injury to the cervical paravertebral sympathetic chain and inferior cervical (stellate) ganglion [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23689/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/32/32262?source=see_link\">",
"     \"Horner's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As with other spinal cord injuries, the prognosis for functional improvement in the Brown-S&eacute;quard syndrome tends to be poor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Cervical cord neurapraxia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical cord neurapraxia (CCN), also known as transient quadriparesis or transient neurapraxia, is a rare cervical spine injury that is often considered a \"concussion\" of the cervical spinal cord [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23689/abstract/21\">",
"     21",
"    </a>",
"    ]. It is thought to be caused by axial loading of the neck in flexion or extension. CCN occurs most commonly in football players who lead with their heads when hitting an opposing player. In the National Collegiate Athletic Association (NCAA), the incidence is 1.3 per 10,000 athletes per season [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23689/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The affected athlete has sudden posttraumatic onset of",
"    <strong>",
"     bilateral",
"    </strong>",
"    sensory, motor, or combined neurologic deficit. Sensory findings include burning, numbness, tingling, or loss of sensation; motor findings include weakness or complete paralysis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23689/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Burning hands syndrome, a variant of this central cord injury, consists only of upper-extremity symptoms, most notably temporary burning dysesthesias and weakness of the arms and hands [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23689/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. By definition, the symptoms of CCN are transient and completely resolve within 10 minutes to 48 hours. CCN should be distinguished from cervical \"burners\" (unilateral paresis of an upper extremity, often associated with neck pain) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23689/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Cervical burners'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Mechanism of injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathophysiology and mechanism of injury in CCN are incompletely understood. CCN is thought to result from compression",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    contusion of the spinal cord. One hypothesis is that the cervical cord is compressed between the posterior margin of one vertebral body and the anterior margin of the spinous process of the vertebra below it (the pincer mechanism, (",
"    <a class=\"graphic graphic_figure graphicRef67314 \" href=\"UTD.htm?1/24/1423\">",
"     figure 4",
"    </a>",
"    )) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23689/abstract/29\">",
"     29",
"    </a>",
"    ]. Such compression is most likely to occur in a hyperextension injury with axial loading. Compression of the spinal cord is postulated to cause prolongation of the absolute refractory period of the long tract axons [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23689/abstract/30\">",
"     30",
"    </a>",
"    ]. Reversible magnetic resonance imaging (MRI) and electrophysiologic abnormalities have been documented in patients with burning hands syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23689/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cervical spinal stenosis is a risk factor that can predispose athletes to CCN [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23689/abstract/31\">",
"     31",
"    </a>",
"    ], although it is inconsistently present in children with CCN [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23689/abstract/32\">",
"     32",
"    </a>",
"    ]. Functional spinal stenosis is defined as the loss of cerebrospinal fluid from around the spinal cord or deformation of the spinal cord (as seen on contrast-enhanced CT, MRI (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52011 \" href=\"UTD.htm?37/1/37919\">",
"     image 1",
"    </a>",
"    ), or myelography) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23689/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. The stenosis is most common at the C3-C5 levels and is usually congenital, although it can be acquired (eg, in disk herniation, cervical spine instability, etc).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of athletes with CCN have spinal stenosis or some other cervical spine abnormality. Burning hands syndrome is associated with a bony or ligamentous spinal abnormality in approximately one-half of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23689/abstract/35\">",
"     35",
"    </a>",
"    ]. Thus, the initial evaluation consists of cervical spine radiographs [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23689/abstract/36\">",
"     36",
"    </a>",
"    ] to evaluate for evidence of spinal canal stenosis, cervical instability, or congenital anomalies, such as Klippel-Feil syndrome (a disorder in which there is congenital fusion of variable numbers of cervical vertebrae and associated defects including scoliosis, renal anomalies, elevated scapula, congenital heart disease, and deafness).",
"   </p>",
"   <p>",
"    Plain radiographs are usually followed by MRI to better identify and clarify the extent of any associated pathology (eg, congenital spinal stenosis, herniated disk, intrinsic cord abnormalities, or ligamentous injury) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23689/abstract/21,36\">",
"     21,36",
"    </a>",
"    ]. If the MRI is inconclusive, contrast-positive computed tomography (CT) or myelogram can be used to better delineate the anatomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Return to play",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether spinal stenosis increases the risk of permanent neurologic injury in the young athlete is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23689/abstract/32,37-40\">",
"     32,37-40",
"    </a>",
"    ]. Some studies indicate that spinal stenosis predisposes to spinal cord injury [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23689/abstract/39,40\">",
"     39,40",
"    </a>",
"    ], but clear evidence of permanent injury is lacking. Thus, it is difficult to establish guidelines for returning to play.",
"   </p>",
"   <p>",
"    We do not permit our patients with proven spinal stenosis to participate in contact or collision sports [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23689/abstract/36\">",
"     36",
"    </a>",
"    ]. The decision regarding return to play for athletes who have CCN and no evidence of cervical spine stenosis or abnormality after a thorough evaluation must be individualized for each athlete in consultation with an experienced neurosurgeon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CERVICAL PERIPHERAL NERVE INJURIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral nerve injuries are classified into three categories according to severity [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23689/abstract/41-45\">",
"     41-45",
"    </a>",
"    ]. Within each grade, and across the categories, there is a spectrum of clinical severity.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Grade I injury, or neurapraxia, describes a disturbance of physiologic function without significant damage to or degeneration of the nerve [",
"      <a class=\"abstract\" href=\"UTD.htm?23/8/23689/abstract/43\">",
"       43",
"      </a>",
"      ]. Transient alteration of motor or sensory function usually lasts seconds to minutes, but more severe cases can last up to a few weeks. By definition, electrophysiologic evidence of denervation is absent when tested 18 to 21 days after the injury. The prognosis for full recovery for all grade I injuries is excellent.",
"     </li>",
"     <li>",
"      Grade II injury, or axonotmesis, describes an injury resulting in some axonal and myelin degeneration within an intact neurilemmal sheath. Motor or sensory losses persist for at least two weeks. At 18 to 21 days, the electromyogram (EMG) is abnormal, and it may remain so up to one year [",
"      <a class=\"abstract\" href=\"UTD.htm?23/8/23689/abstract/46\">",
"       46",
"      </a>",
"      ]. Full recovery is often seen, but it may be incomplete and unpredictable.",
"     </li>",
"     <li>",
"      Grade III injury, or neurotmesis, is the most severe injury and is rarely seen in athletic competition. Grade III injuries are characterized by complete disruption of the nerve with complete degeneration [",
"      <a class=\"abstract\" href=\"UTD.htm?23/8/23689/abstract/23\">",
"       23",
"      </a>",
"      ]. EMG changes are permanent. Some motor units may attempt to regenerate, resulting in as much as 30 percent recovery of motor function. However, prognosis for good functional outcome is generally poor.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Cervical burners",
"    </span>",
"    &nbsp;&mdash;&nbsp;The \"burner,\" or \"stinger,\" is a brachial plexus injury resulting from trauma to the neck and shoulder. It is one of the most common injuries among football players, occurring at least once in 50 to 65 percent of football players during a four-year college career [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23689/abstract/47\">",
"     47",
"    </a>",
"    ]. Burners or stingers are seen less commonly in hockey, wrestling, and gymnastics. The incidence is unknown since the injury, unless severe or prolonged, often goes unreported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Mechanism of injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;The burner is a brachial plexopathy caused by injury to the upper brachial plexus or nerve roots, usually affecting the C5-C6 levels (",
"    <a class=\"graphic graphic_figure graphicRef50576 \" href=\"UTD.htm?34/25/35222\">",
"     figure 5",
"    </a>",
"    ). Most burners are caused by one of three mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stretch injuries to the brachial plexus are more common among high-school football players [",
"      <a class=\"abstract\" href=\"UTD.htm?23/8/23689/abstract/37\">",
"       37",
"      </a>",
"      ]. Stretch injuries occur when the athlete makes a tackle with the shoulder depressed and simultaneous lateral flexion of the neck toward the opposite side, causing traction on the upper trunks of the brachial plexus on the side of the depressed shoulder [",
"      <a class=\"abstract\" href=\"UTD.htm?23/8/23689/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Nerve compression injuries are more common among college and professional athletes [",
"      <a class=\"abstract\" href=\"UTD.htm?23/8/23689/abstract/37\">",
"       37",
"      </a>",
"      ], who typically have preexisting radiological evidence of arthritic changes or degenerative disk disease. Compression of the nerve roots at the intervertebral foramen occurs when the athlete undergoes collision with the neck extended and laterally flexed toward the side with symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?23/8/23689/abstract/48\">",
"       48",
"      </a>",
"      ]. Athletes with nerve compression injuries usually have a positive Spurling's test (",
"      <a class=\"graphic graphic_picture graphicRef52401 \" href=\"UTD.htm?11/45/11999\">",
"       picture 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/25/41368?source=see_link\">",
"       \"Approach to the young athlete with neck pain or injury\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Direct blows to the supraclavicular fossa at Erb's point, where the brachial plexus is most superficial, can also result in cervical burners [",
"      <a class=\"abstract\" href=\"UTD.htm?23/8/23689/abstract/49\">",
"       49",
"      </a>",
"      ]. This type of injury is more common among athletes who wear less protective padding (eg, rugby, as opposed to football, players).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The athlete with a burner usually becomes symptomatic immediately after an injury with the appropriate mechanism. Symptoms are primarily sensory, and include unilateral shoulder",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    arm pain with burning dysesthesias in the C5-C6 nerve root distribution with associated weakness of the deltoid, biceps,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the external rotators of the shoulder (",
"    <a class=\"graphic graphic_table graphicRef63597 \" href=\"UTD.htm?23/43/24253\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef53006 \" href=\"UTD.htm?21/8/21634\">",
"     figure 1",
"    </a>",
"    ). The player is often observed to be shaking or holding the affected arm to his side after the injury. The symptoms usually resolve within minutes of the injury. In some cases, however, the symptoms may develop hours or days later [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23689/abstract/50\">",
"     50",
"    </a>",
"    ]. Severe cases result in more persistent symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sideline management of the patient with a suspected burner begins with a history and physical examination. The focus is to rule out more serious conditions, such as a spinal cord injury. If the athlete remains on the playing field, spinal cord injury must be ruled out before the athlete is permitted to walk [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23689/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/28/15815?source=see_link\">",
"     \"Field care and evaluation of the young athlete with acute neck injury\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H2\">",
"     'Cervical spinal cord injuries'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A detailed history, including the mechanism of injury, exact symptomatology (distribution and duration of symptoms), and previous history of burners should be noted. Examination of the neck and shoulder should be performed [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23689/abstract/51\">",
"     51",
"    </a>",
"    ]. The examination should include active cervical range of motion within pain tolerance, palpation for muscle spasm and bony tenderness, and a detailed neurologic examination, including special attention to the motor function of the C5-C7 myotomes (",
"    <a class=\"graphic graphic_table graphicRef63597 \" href=\"UTD.htm?23/43/24253\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/25/41368?source=see_link\">",
"     \"Approach to the young athlete with neck pain or injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The brevity of symptoms and presence of a full, pain-free range of motion are key features in the diagnosis of cervical burners [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23689/abstract/52\">",
"     52",
"    </a>",
"    ]. The presence of neck pain or stiffness, posterior midline neck tenderness, bilateral neurologic symptoms, or symptoms involving a lower extremity are not consistent with a simple burner [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23689/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The athlete with any signs or symptoms of spinal cord injury (",
"    <a class=\"graphic graphic_table graphicRef76379 \" href=\"UTD.htm?20/20/20811\">",
"     table 2",
"    </a>",
"    ) should be assumed to have a cervical spinal cord injury, and must be immobilized and transferred to an appropriate facility for further evaluation and management. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6854?source=see_link\">",
"     \"Pediatric cervical spine immobilization\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/7/32889?source=see_link\">",
"     \"Evaluation of cervical spine injuries in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The athlete with a burner must have serial examinations (initially every 10 to 15 minutes) to evaluate evolution and resolution of symptoms. Most burners last no more than a few minutes, allowing for safe return to play provided the following criteria are met:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Absence of neck pain and symptoms",
"     </li>",
"     <li>",
"      Normal neck examination (no tenderness, normal range of motion, normal strength, and negative axial compression and Spurling tests, (",
"      <a class=\"graphic graphic_picture graphicRef52401 \" href=\"UTD.htm?11/45/11999\">",
"       picture 1",
"      </a>",
"      )) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/25/41368?source=see_link\">",
"       \"Approach to the young athlete with neck pain or injury\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      An intact neurologic exam (normal strength and sensation of the upper extremities) (",
"      <a class=\"graphic graphic_table graphicRef63597 \" href=\"UTD.htm?23/43/24253\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef53006 \" href=\"UTD.htm?21/8/21634\">",
"       figure 1",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Athletes who have persistent symptoms must be held out of competition until symptoms resolve and strength returns to normal. Additional evaluation is indicated if symptoms persist for more than two weeks.",
"   </p>",
"   <p>",
"    Depending upon the symptoms and duration of symptoms, the evaluation may include cervical spine radiographs or MRI. EMG and nerve conduction studies should be performed in patients who have symptoms for more than three weeks. These studies can be helpful in differentiating brachial plexus injury from cervical radiculopathy and may also help to qualify the severity of the nerve injury [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23689/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because burners tend to recur, any player who suffers a burner should consider taking steps that may reduce the risk of recurrence. Although suggested, none of these interventions has been proven to reduce the risk of cervical burners [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23689/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An exercise program to improve strength and flexibility of the neck, shoulder, and upper extremity may be helpful, although the efficacy of this intervention has not been established [",
"      <a class=\"abstract\" href=\"UTD.htm?23/8/23689/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Maintenance of good posture (ie, reduced cervical flexion and extension) can decrease encroachment of the spinal nerves at the intervertebral foramen.",
"     </li>",
"     <li>",
"      The athlete should wear properly fitting shoulder pads.",
"     </li>",
"     <li>",
"      Several types of protective equipment, including neck rolls, cowboy collars, and custom orthoses, have been developed to limit cervical extension and lateral neck flexion [",
"      <a class=\"abstract\" href=\"UTD.htm?23/8/23689/abstract/53,55\">",
"       53,55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The athlete's blocking and tackling techniques should be reviewed and changed if indicated [",
"      <a class=\"abstract\" href=\"UTD.htm?23/8/23689/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If recurrences persist, despite the above interventions, consideration may be given to changing the athlete's position",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    discontinuing the causative athletic activity [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23689/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Atraumatic cervical radiculopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atraumatic cervical radiculopathy is caused by impingement of the nerve root near the intervertebral foramen. The most common causes of nerve root impingement include a bulging disk or degenerative changes at the intervertebral foramen such as osteophytes or local inflammation. Less common causes include tumors and abscesses. Long-term",
"    <span class=\"nowrap\">",
"     contact/collision",
"    </span>",
"    athletes may have accelerated degenerative changes that predispose them to atraumatic cervical radiculopathy at a relatively younger age than individuals who did not participate in these sports.",
"   </p>",
"   <p>",
"    Characteristic symptoms include sharp arm pain and paresthesias in a dermatomal pattern (",
"    <a class=\"graphic graphic_figure graphicRef53006 \" href=\"UTD.htm?21/8/21634\">",
"     figure 1",
"    </a>",
"    ). The pain is exacerbated by neck movements that cause further nerve impingement, such as extension and lateral flexion. There may or may not be associated neck pain or weakness of the associated myotomes(s) with diminished deep tendon reflexes (",
"    <a class=\"graphic graphic_table graphicRef63597 \" href=\"UTD.htm?23/43/24253\">",
"     table 1",
"    </a>",
"    ). The Spurling test (",
"    <a class=\"graphic graphic_picture graphicRef52401 \" href=\"UTD.htm?11/45/11999\">",
"     picture 1",
"    </a>",
"    ) or axial compression test may reproduce symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/25/41368?source=see_link\">",
"     \"Approach to the young athlete with neck pain or injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cervical radiculopathy is a symptom of pathology, not a diagnosis. Management depends on making the correct diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23689/abstract/56\">",
"     56",
"    </a>",
"    ]. Radiographs are useful in identifying arthritic changes of the cervical spine or other bony abnormalities. If the diagnosis is in doubt, an MRI should be performed.",
"   </p>",
"   <p>",
"    Treatment for disk or arthritic nerve root pain consists of techniques to relieve the pressure on the nerve. These include maintenance of proper posture and the use of in-line cervical traction devices. Anti-inflammatory and analgesic measures such as nonsteroidal antiinflammatory drugs (NSAIDs), ice, heat, and transcutaneous electric nerve stimulation (TENS) may be a helpful adjunct. Physical therapy for mobilization and improving strength and flexibility may also reduce pain. Surgery remains an option for those who fail to make improvement with conservative measures. The management of cervical disc disease in the young athlete is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/49/11033?source=see_link&amp;anchor=H22#H22\">",
"     \"Overview of musculoskeletal neck injuries in the young athlete\", section on 'Cervical disc disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Acute brachial neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute brachial neuropathy (ABN, also called brachial plexus neuritis, shoulder girdle syndrome, and Parsonage-Turner syndrome) is an uncommon cause of shoulder pain that can affect athletes as well as relatively inactive people. The cause is unknown, but it is often preceded by viral infection, radiation or chemotherapy, pregnancy, or strenuous activity [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23689/abstract/46\">",
"     46",
"    </a>",
"    ]. The condition is bilateral in approximately 25 percent of cases and may recur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because ABN is uncommon, the clinician must have a high index of suspicion to make the diagnosis. The hallmark clinical presentation is severe, acute, burning pain in the shoulder and upper arm with no apparent cause [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23689/abstract/57\">",
"     57",
"    </a>",
"    ]. The pain can last from several hours to several weeks. It may radiate proximally toward the neck or distally to the elbow and forearm [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23689/abstract/23\">",
"     23",
"    </a>",
"    ]. Weakness of the shoulder usually occurs four to five days after the onset of the pain; the delayed onset of motor deficit distinguishes this disorder from cervical radiculopathy or brachial plexus injury (see above). Cutaneous sensation is often diminished. Multiple nerves of the brachial plexus are usually involved (",
"    <a class=\"graphic graphic_picture graphicRef52401 \" href=\"UTD.htm?11/45/11999\">",
"     picture 1",
"    </a>",
"    ), instead of the single nerve root that is typically involved in a cervical radiculopathy.",
"   </p>",
"   <p>",
"    On examination, any movement of the shoulder exacerbates the pain. The position of maximal comfort is usually with the shoulder adducted and the elbow flexed [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23689/abstract/23\">",
"     23",
"    </a>",
"    ]. In fact, it may be difficult to perform an adequate motor examination because of the patient's pain. Deep tendon reflexes may be diminished depending upon the degree of neuromuscular involvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRI of the clinically weak muscles may reveal high signal intensity of the affected muscles on the T2 study [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23689/abstract/58\">",
"     58",
"    </a>",
"    ]. EMG can differentiate ABN from traumatic upper trunk or other brachial plexus injuries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial treatment involves analgesics and the use of a sling to rest the arm. Corticosteroids have not been shown to be beneficial in treating ABN. After the pain has subsided, the treatment shifts to rehabilitation of the shoulder and arm. Recovery of range of motion, strength, and endurance are the main goals of physical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23689/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The course of ABN is usually one of gradual improvement and recovery of muscle strength in three to four months [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23689/abstract/58\">",
"     58",
"    </a>",
"    ]. Some patients, however, experience several years of motor dysfunction or some permanent residual weakness. In general, a longer duration of pain will result in a longer delay in recovering strength [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23689/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Return to play",
"    </span>",
"    &nbsp;&mdash;&nbsp;Return to play for athletes should be based on individual sport needs and the degree of functional limitation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18835726\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recreational sports are a relatively common cause of cervical spine injury, especially in older adolescents and young adults. Spinal cord injuries may be complete or partial. Partial spinal cord injuries include the central cord syndrome, anterior cord syndrome, Brown-S&eacute;quard syndrome, cervical cord neurapraxia, and spinal cord injury without radiographic abnormality (SCIWORA). Once identified, cervical spinal cord injuries warrant emergent consultation with a neurosurgeon. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Cervical spinal cord injuries'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cervical cord neurapraxia (CCN), also known as transient quadriparesis or transient neurapraxia, is a rare cervical spine injury that is often considered a \"concussion\" of the cervical spinal cord. The majority of athletes with CCN have spinal stenosis or some other cervical spine abnormality upon radiologic evaluation. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Cervical cord neurapraxia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Burning hands syndrome, a variant of CCN, consists only of upper-extremity symptoms, most notably temporary burning dysesthesias and weakness of the arms and hands. By definition, the symptoms of CCN are transient and completely resolve within 10 minutes to 48 hours. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The cervical burner is a brachial plexopathy caused by injury to the upper brachial plexus or nerve roots, usually affecting the C5-C6 levels (",
"      <a class=\"graphic graphic_figure graphicRef50576 \" href=\"UTD.htm?34/25/35222\">",
"       figure 5",
"      </a>",
"      ) and is the most common cervical peripheral nerve injury in athletes, especially American football players. Symptoms are primarily sensory, and include unilateral shoulder",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      arm pain with burning dysesthesias in the C5-C6 nerve root distribution with associated weakness of the deltoid, biceps,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the external rotators of the shoulder (",
"      <a class=\"graphic graphic_table graphicRef63597 \" href=\"UTD.htm?23/43/24253\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef53006 \" href=\"UTD.htm?21/8/21634\">",
"       figure 1",
"      </a>",
"      ). The symptoms usually resolve within minutes of the injury and many players can immediately return to play (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Cervical burners'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Atraumatic cervical radiculopathy is caused by impingement of the nerve root near the intervertebral foramen. The most common causes of nerve root impingement include a bulging disk or degenerative changes at the intervertebral foramen such as osteophytes or local inflammation. Characteristic symptoms include sharp arm pain and paresthesias in a dermatomal pattern (",
"      <a class=\"graphic graphic_figure graphicRef53006 \" href=\"UTD.htm?21/8/21634\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Atraumatic cervical radiculopathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute brachial neuropathy (ABN, also called brachial plexus neuritis, shoulder girdle syndrome, and Parsonage-Turner syndrome) is an uncommon cause of shoulder pain that can affect athletes as well as relatively inactive people. The hallmark clinical presentation is severe, acute, burning pain in the shoulder and upper arm with no apparent cause. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Acute brachial neuropathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Careful history, physical examination, and, in patients with persistent or concerning findings, radiologic evaluation help determine the type of peripheral nerve injury, its management, and prevention. Return to play is based upon the underlying etiology and whether symptoms have resolved. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Cervical peripheral nerve injuries'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23689/abstract/1\">",
"      Lasfargues JE, Custis D, Morrone F, et al. A model for estimating spinal cord injury prevalence in the United States. Paraplegia 1995; 33:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23689/abstract/2\">",
"      Johnson RL, Gabella BA, Gerhart KA, et al. Evaluating sources of traumatic spinal cord injury surveillance data in Colorado. Am J Epidemiol 1997; 146:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23689/abstract/3\">",
"      Dryden DM, Saunders LD, Rowe BH, et al. The epidemiology of traumatic spinal cord injury in Alberta, Canada. Can J Neurol Sci 2003; 30:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23689/abstract/4\">",
"      Little, NE. In case of a broken neck. Emerg Med 1989; 21:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23689/abstract/5\">",
"      Good RP, Nickel VL. Cervical spine injuries resulting from water sports. Spine (Phila Pa 1976) 1980; 5:502.",
"     </a>",
"    </li>",
"    <li>",
"     National athletic trainers' association position statement: Acute management of the cervical spine-injured athlete. www.ncbi.nlm.nih.gov/pmc/articles/PMC2681208 (Accessed on December 14, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23689/abstract/7\">",
"      Schmitt H, Gerner HJ. Paralysis from sport and diving accidents. Clin J Sport Med 2001; 11:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23689/abstract/8\">",
"      M&ouml;ls&auml; JJ, Tegner Y, Alaranta H, et al. Spinal cord injuries in ice hockey in Finland and Sweden from 1980 to 1996. Int J Sports Med 1999; 20:64.",
"     </a>",
"    </li>",
"    <li>",
"     Emergency Management of Skeletal Injuries, Ruiz E, Cicero JJ.  (Eds), Mosby, St. Louis 1995. p.71.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23689/abstract/10\">",
"      Wagner R, Jagoda A. Spinal cord syndromes. Emerg Med Clin North Am 1997; 15:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23689/abstract/11\">",
"      Saleh J, Raycroft JF. Hyperflexion injury of cervical spine and central cord syndrome in a child. Spine (Phila Pa 1976) 1992; 17:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23689/abstract/12\">",
"      McVeigh, JF. Experimental cord crushes with special reference to mechanical factors involved and subsequent changes in the areas of the cord affected. Arch Surg 1923; 7:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23689/abstract/13\">",
"      Dai L, Jia L. Central cord injury complicating acute cervical disc herniation in trauma. Spine (Phila Pa 1976) 2000; 25:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23689/abstract/14\">",
"      Lee KS, Doh JW, Bae HG, Yun IG. Delayed central cord syndrome after a handstand in a child: case report. Paraplegia 1996; 34:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23689/abstract/15\">",
"      Riviello JJ Jr, Marks HG, Faerber EN, Steg NL. Delayed cervical central cord syndrome after trivial trauma. Pediatr Emerg Care 1990; 6:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23689/abstract/16\">",
"      Oller DW, Boone S. Blunt cervical spine Brown-S&eacute;quard injury. A report of three cases. Am Surg 1991; 57:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23689/abstract/17\">",
"      Kimbro T, Tom T, Neuman T. A case of spinal cord decompression sickness presenting as partial Brown-Sequard syndrome. Neurology 1997; 48:1454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23689/abstract/18\">",
"      Levin HS, Goldstein FC, Norcross K, et al. Neurobehavioral and magnetic resonance imaging findings in two cases of decompression sickness. Aviat Space Environ Med 1989; 60:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23689/abstract/19\">",
"      Edwards A, Andrews R. A case of Brown-Sequard syndrome with associated Horner's syndrome after blunt injury to the cervical spine. Emerg Med J 2001; 18:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23689/abstract/20\">",
"      Shen CC, Wang YC, Yang DY, et al. Brown-S&eacute;quard syndrome associated with Horner's syndrome in cervical epidural hematoma. Spine (Phila Pa 1976) 1995; 20:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23689/abstract/21\">",
"      Allen CR, Kang JD. Transient quadriparesis in the athlete. Clin Sports Med 2002; 21:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23689/abstract/22\">",
"      Torg JS, Pavlov H, Genuario SE, et al. Neurapraxia of the cervical spinal cord with transient quadriplegia. J Bone Joint Surg Am 1986; 68:1354.",
"     </a>",
"    </li>",
"    <li>",
"     Current Therapy in Sports Medicine, Torq JS, Shephard RJ.  (Eds), Mosby, St. Louis 1995. p.52.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23689/abstract/24\">",
"      Torg JS. Cervical spinal stenosis with cord neurapraxia and transient quadriplegia. Clin Sports Med 1990; 9:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23689/abstract/25\">",
"      Maroon JC, Bailes JE. Athletes with cervical spine injury. Spine (Phila Pa 1976) 1996; 21:2294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23689/abstract/26\">",
"      Maroon JC. 'Burning hands' in football spinal cord injuries. JAMA 1977; 238:2049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23689/abstract/27\">",
"      Wilberger JE, Abla A, Maroon JC. Burning hands syndrome revisited. Neurosurgery 1986; 19:1038.",
"     </a>",
"    </li>",
"    <li>",
"     Loder RT. The cervical spine. In: Lovell and Winter's Pediatric Orthopaedics, 6th, Morrissey RT, Weinstein SL.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.903.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23689/abstract/29\">",
"      PENNING L. Some aspects of plain radiography of the cervical spine in chronic myelopathy. Neurology 1962; 12:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23689/abstract/30\">",
"      Zwimpfer TJ, Bernstein M. Spinal cord concussion. J Neurosurg 1990; 72:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23689/abstract/31\">",
"      Torg JS, Corcoran TA, Thibault LE, et al. Cervical cord neurapraxia: classification, pathomechanics, morbidity, and management guidelines. J Neurosurg 1997; 87:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23689/abstract/32\">",
"      Rathbone D, Johnson G, Letts M. Spinal cord concussion in pediatric athletes. J Pediatr Orthop 1992; 12:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23689/abstract/33\">",
"      Cantu RC, Bailes JE, Wilberger JE Jr. Guidelines for return to contact or collision sport after a cervical spine injury. Clin Sports Med 1998; 17:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23689/abstract/34\">",
"      Cantu RC. Functional cervical spinal stenosis: a contraindication to participation in contact sports. Med Sci Sports Exerc 1993; 25:316.",
"     </a>",
"    </li>",
"    <li>",
"     Sports Injury Assessment and Rehabilitation, Reid DC.  (Ed), Churchill Livingstone, New York 1992. p.765.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23689/abstract/36\">",
"      Cantu RC. The cervical spinal stenosis controversy. Clin Sports Med 1998; 17:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23689/abstract/37\">",
"      Proctor MR, Cantu RC. Head and neck injuries in young athletes. Clin Sports Med 2000; 19:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23689/abstract/38\">",
"      Torg JS, Naranja RJ Jr, Pavlov H, et al. The relationship of developmental narrowing of the cervical spinal canal to reversible and irreversible injury of the cervical spinal cord in football players. J Bone Joint Surg Am 1996; 78:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23689/abstract/39\">",
"      Eismont FJ, Clifford S, Goldberg M, Green B. Cervical sagittal spinal canal size in spine injury. Spine (Phila Pa 1976) 1984; 9:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23689/abstract/40\">",
"      Matsuura P, Waters RL, Adkins RH, et al. Comparison of computerized tomography parameters of the cervical spine in normal control subjects and spinal cord-injured patients. J Bone Joint Surg Am 1989; 71:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23689/abstract/41\">",
"      Clancy WG Jr, Brand RL, Bergfield JA. Upper trunk brachial plexus injuries in contact sports. Am J Sports Med 1977; 5:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23689/abstract/42\">",
"      FIELDING JW. Cineroentgenography of the normal cervical spine. J Bone Joint Surg Am 1957; 39-A:1280.",
"     </a>",
"    </li>",
"    <li>",
"     Seddon H. Surgical Disorders of the Peripheral Nerves, Churchill Livingstone, Edinburgh 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23689/abstract/44\">",
"      HOHL M. NORMAL MOTIONS IN THE UPPER PORTION OF THE CERVICAL SPINE. J Bone Joint Surg Am 1964; 46:1777.",
"     </a>",
"    </li>",
"    <li>",
"     Sunderland S. Nerves and Nerve Injuries, 2nd, Churchill Livingstone, Edinburgh 1988.",
"    </li>",
"    <li>",
"     Reid, DC. Sports Injury Assessment and Rehabilitation, Churchill Livingstone, New York 1992. p.739.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23689/abstract/47\">",
"      Sallis, RE, Jones, K, Knopp, W. Burners: Offensive strategy for an under-reported injury. Phys Sportsmed 1992; 20:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23689/abstract/48\">",
"      Watkins RG. Neck injuries in football players. Clin Sports Med 1986; 5:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23689/abstract/49\">",
"      Markey KL, Di Benedetto M, Curl WW. Upper trunk brachial plexopathy. The stinger syndrome. Am J Sports Med 1993; 21:650.",
"     </a>",
"    </li>",
"    <li>",
"     Hershman EB. Injuries to the brachial plexus. In: Athletic Injuries to the Head, Neck, and Face, 2nd, Torq JS.  (Ed), Mosby, St. Louis 1991. p.345.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23689/abstract/51\">",
"      Weinstein SM. Assessment and rehabilitation of the athlete with a \"stinger\". A model for the management of noncatastrophic athletic cervical spine injury. Clin Sports Med 1998; 17:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23689/abstract/52\">",
"      Vegso JJ, Lehman RC. Field evaluation and management of head and neck injuries. Clin Sports Med 1987; 6:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23689/abstract/53\">",
"      Cantu RC. Stingers, transient quadriplegia, and cervical spinal stenosis: return to play criteria. Med Sci Sports Exerc 1997; 29:S233.",
"     </a>",
"    </li>",
"    <li>",
"     Watkins RG, Dillin WM. Cervical spine and spinal cord injuries. In: Sports Injuries: Mechanics, Prevention, Treatment, Fu FH, Stone DA.  (Eds), Williams &amp; Wilkins, Baltimore 1994. p.854.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23689/abstract/55\">",
"      Hovis WD, Limbird TJ. An evaluation of cervical orthoses in limiting hyperextension and lateral flexion in football. Med Sci Sports Exerc 1994; 26:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23689/abstract/56\">",
"      Malanga GA. The diagnosis and treatment of cervical radiculopathy. Med Sci Sports Exerc 1997; 29:S236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23689/abstract/57\">",
"      Miller JD, Pruitt S, McDonald TJ. Acute brachial plexus neuritis: an uncommon cause of shoulder pain. Am Fam Physician 2000; 62:2067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23689/abstract/58\">",
"      Helms CA, Martinez S, Speer KP. Acute brachial neuritis (Parsonage-Turner syndrome): MR imaging appearance--report of three cases. Radiology 1998; 207:255.",
"     </a>",
"    </li>",
"    <li>",
"     Current Therapy in Sports Medicine, Torq JS, Shephard RJ.  (Eds), Mosby, St. Louis 1995. p.66.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23689/abstract/60\">",
"      Dillin L, Hoaglund FT, Scheck M. Brachial neuritis. J Bone Joint Surg Am 1985; 67:878.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6528 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-6A22C7A760-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_8_23689=[""].join("\n");
var outline_f23_8_23689=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18835726\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CERVICAL SPINAL CORD INJURIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Complete cord syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Central cord syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Anterior cord syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Brown-S&eacute;quard syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Cervical cord neurapraxia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Clinical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Mechanism of injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Return to play",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CERVICAL PERIPHERAL NERVE INJURIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Cervical burners",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Mechanism of injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Clinical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Atraumatic cervical radiculopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Acute brachial neuropathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Clinical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Return to play",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18835726\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6528\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6528|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?37/1/37919\" title=\"diagnostic image 1\">",
"      Cervical spinal stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6528|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/8/21634\" title=\"figure 1\">",
"      Cervical dermatomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/7/35958\" title=\"figure 2\">",
"      Sensory syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/15/44275\" title=\"figure 3\">",
"      Cervical spinal cord anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/24/1423\" title=\"figure 4\">",
"      Pincer mechanism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/25/35222\" title=\"figure 5\">",
"      Trunks and cords of the brachial plexus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6528|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/45/11999\" title=\"picture 1\">",
"      Spurling test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6528|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/43/24253\" title=\"table 1\">",
"      Neurologic deficits in spinal injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/20/20811\" title=\"table 2\">",
"      Signs and symptoms of spinal cord injury",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/11/26810?source=related_link\">",
"      Acute traumatic spinal cord injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/25/41368?source=related_link\">",
"      Approach to the young athlete with neck pain or injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/7/32889?source=related_link\">",
"      Evaluation of cervical spine injuries in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/28/15815?source=related_link\">",
"      Field care and evaluation of the young athlete with acute neck injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/32/32262?source=related_link\">",
"      Horner's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/49/11033?source=related_link\">",
"      Overview of musculoskeletal neck injuries in the young athlete",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6854?source=related_link\">",
"      Pediatric cervical spine immobilization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42901?source=related_link\">",
"      Physiology and classification of shock in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/28/42439?source=related_link\">",
"      Respiratory complications of spinal cord injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4951?source=related_link\">",
"      Spinal cord injury without radiographic abnormality (SCIWORA) in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_8_23690="Ovarian and fallopian tube torsion";
var content_f23_8_23690=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Ovarian and fallopian tube torsion",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/8/23690/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/8/23690/contributors\">",
"     Whitfield B Growdon, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/8/23690/contributors\">",
"     Marc R Laufer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/8/23690/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/8/23690/contributors\">",
"     Howard T Sharp, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/8/23690/contributors\">",
"     Deborah Levine, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/8/23690/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/8/23690/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/8/23690/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ovarian torsion refers to the complete or partial rotation of the ovary on its ligamentous supports, often resulting in impedance of its blood supply. It is one of the most common gynecologic emergencies and may affect females of all ages [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/1\">",
"     1",
"    </a>",
"    ]. The fallopian tube often twists along with the ovary; when this occurs, it is referred to as adnexal torsion. Prompt diagnosis is important to preserve ovarian",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tubal function and to prevent other associated morbidity. However, making the diagnosis can be challenging because the symptoms are relatively nonspecific.",
"   </p>",
"   <p>",
"    Isolated torsion of the fallopian tube is less common, but may also occur and adversely impact tubal function [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/2\">",
"     2",
"    </a>",
"    ]. Tubal torsion may occur either in the mid-portion of the tube itself or around the ligamentous supports of the tube.",
"   </p>",
"   <p>",
"    Torsion of paratubal or paraovarian cysts may also occur [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will focus mainly on ovarian torsion, but isolated fallopian tube torsion and torsion of paratubal or paraovarian cysts will also be reviewed. An overview of the approach to an adnexal mass and to acute pelvic pain is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24601?source=see_link\">",
"     \"Approach to the patient with an adnexal mass\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/44/17095?source=see_link\">",
"     \"Evaluation of acute pelvic pain in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H327777\">",
"    <span class=\"h1\">",
"     RELEVANT ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ovary is suspended by the infundibulopelvic ligament (also referred to as the suspensory ligament of the ovary), and is not fixed, but may be positioned lateral",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    posterior to the uterus, depending upon the position of the patient. The infundibulopelvic ligament is a fold of the broad ligament that is attached laterally to the pelvic sidewall. The ovarian vessels, which originate in the upper abdomen, travel through the infundibulopelvic ligaments. Other support structures of the ovary include the utero-ovarian ligament, which attaches the ovary to the uterus, and the broad ligament, one area of which is the mesovarium (",
"    <a class=\"graphic graphic_figure graphicRef83001 \" href=\"UTD.htm?24/52/25412\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The fallopian tubes are attached to the broad ligaments with a condensation of connective tissue called the mesosalpinx.",
"   </p>",
"   <p>",
"    Ovarian and fallopian tube anatomy are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/27/41400?source=see_link&amp;anchor=H25506258#H25506258\">",
"     \"Surgical female pelvic anatomy\", section on 'Adnexa'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H849034\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Mechanism of torsion",
"    </span>",
"    &nbsp;&mdash;&nbsp;When ovarian torsion occurs, the ovary typically rotates around both the infundibulopelvic ligament and the utero-ovarian ligament. The fallopian tube often twists along with the ovary; when this occurs, it is referred to as adnexal torsion.",
"   </p>",
"   <p>",
"    In adults, an ovarian physiologic cyst (functional cyst, corpus luteum) or a neoplasm is the most likely factor to predispose to ovarian torsion (",
"    <a class=\"graphic graphic_table graphicRef52066 \" href=\"UTD.htm?7/29/7643\">",
"     table 1",
"    </a>",
"    ). The presence of an ovarian mass makes it more likely for the ovary to rotate on the axis of the infundibulopelvic and utero-ovarian ligaments and to become fixed in a torsed position. As the size of the mass increases, the risk of torsion increases, until the mass becomes large enough to be fixed in place in the pelvis. In addition, masses that are fixed in place due to adhesions (eg, endometrioma, tuboovarian abscess) or malignancy appear to be less likely to torse. (See",
"    <a class=\"local\" href=\"#H14908185\">",
"     'Ovarian mass'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H14908713\">",
"     'Size'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H14908739\">",
"     'Benign versus malignant masses'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Ovarian torsion may also occur in patients with normal ovaries (no mass and not enlarged). The mechanism of torsion of normal ovaries is unclear. This has been found in patients of all ages, but particularly in premenarchal girls. The utero-ovarian ligament is normally elongated in the premenarchal girl and then shortens as girls mature through puberty [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. One hypothesis of the etiology of adnexal torsion in children with normal ovaries is that the elongated utero-ovarian ligament facilitates ovarian torsion by permitting excessive ovarian movement, but this has not been proven. (See",
"    <a class=\"local\" href=\"#H1942422\">",
"     'Normal ovaries'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The right ovary appears to be more likely to torse than the left, possibly because the right utero-ovarian ligament is longer than the left",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    that the presence of the sigmoid colon in the left side of the colon may help to prevent torsion [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some data suggest that ovarian torsion may occur following strenuous exercise or a sudden increase in abdominal pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/10-12\">",
"     10-12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Mechanism of ovarian or tubal injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rotation of the infundibulopelvic ligament causes compression of the ovarian vessels and impedes lymphatic and venous outflow and arterial inflow. However, the arterial supply to the ovary is not initially interrupted to the same degree as the venous drainage since the muscular arteries are less compressible than the thin walls of the veins. Continued arterial perfusion in the setting of blocked outflow leads to ovarian edema with marked ovarian enlargement and further vascular compression. Ovarian ischemia then occurs and can result in ovarian necrosis, infarction, and local hemorrhage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H327826\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complete occlusion of the ovarian blood supply will ultimately result in loss of ovarian function and necrosis of the torsed tissues. Additional potential adverse effects are hemorrhage or peritonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. However, hemorrhage requiring blood transfusion or sepsis have rarely been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/17-21\">",
"     17-21",
"    </a>",
"    ]. The necrotic tissue will involute over time, but there may be pelvic adhesion formation, which can result in pelvic pain or infertility.",
"   </p>",
"   <p>",
"    Unrecognized tubal torsion will result in loss of tubal function, and likely hydrosalpinx or necrosis with eventual resorption of the damaged tissue.",
"   </p>",
"   <p>",
"    Intermittent adnexal torsion may occur, and may have few, if any, adverse effects if perfusion is not persistently compromised and, in the case of isolated tubal torsion, the tube is not damaged.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of adnexal torsion is unknown. There are some data regarding the rate of torsion among patients presenting for gynecologic care to an acute care setting. In a classic report of a 10-year review of patients at a women's hospital, ovarian torsion accounted for 2.7 percent of emergency surgeries [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/22\">",
"     22",
"    </a>",
"    ]. Torsion was the fifth most common surgical emergency, preceded by (in descending order) ectopic pregnancy, corpus luteum rupture with hemorrhage, pelvic inflammatory disease, and appendicitis. In a 10-year review of surgically treated adnexal masses, torsion accounted for 15 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The primary risk factor for ovarian torsion is an ovarian mass, particularly a mass that is 5 cm in diameter or larger [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/24-27\">",
"     24-27",
"    </a>",
"    ]. Many of the risk factors for ovarian torsion, therefore, are related to the likelihood of developing an ovarian cyst or neoplasm. Since many of these masses are associated with the reproductive cycle or reproductive hormones (eg, corpus luteum, ovulation induction), the risk of torsion is increased in women of reproductive age, during pregnancy, and in women undergoing ovulation induction for treatment of infertility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14908185\">",
"    <span class=\"h2\">",
"     Ovarian mass",
"    </span>",
"    &nbsp;&mdash;&nbsp;An ovarian mass (physiologic cyst or neoplasm) is the primary risk factor for ovarian torsion. In three case series, each with 80 or more patients with ovarian torsion, 86 to 95 percent had an ovarian mass [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/24,27,28\">",
"     24,27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Torsion usually occurs infrequently in premenarchal girls, but when an ovarian mass is present, torsion is a common complication. Torsion accounts for 20 to 30 percent of ovarian surgeries in the pediatric population [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/25,29\">",
"     25,29",
"    </a>",
"    ]. As an example, in a 15-year retrospective series of girls age 19 years or younger (average age of 9 years), torsion was the indication for 97 of 328 (30 percent) of ovarian surgical procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similarly, when an ovarian mass is present in a fetus or neonate, there is an increased risk of ovarian torsion [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/30\">",
"     30",
"    </a>",
"    ]. As an example, a series of 12 of 66 fetuses with ovarian cysts followed with serial ultrasound examinations developed sonographic changes consistent with torsion while still in-utero [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/31\">",
"     31",
"    </a>",
"    ]. In addition, a series of 30 neonates with prenatally diagnosed ovarian cysts that persisted after birth found that 30 to 40 percent required surgical intervention due to torsion in the first weeks after birth [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14908713\">",
"    <span class=\"h3\">",
"     Size",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, torsion is most likely to occur when the ovary is 5 cm in diameter or larger. In three case series, each with 80 or more patients, 83 to 93 percent of torsed ovaries were 5 cm or larger [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/24,25,27\">",
"     24,25,27",
"    </a>",
"    ]. This represents an average; however, torsion may occur with a mass of any size. Although it has been postulated that very large ovaries are less likely to torse because the size impedes movement within the pelvis, the upper limit of size has not been defined. The wide range of sizes of ovarian masses that are in cases of torsion was illustrated in a series of 87 cases of torsion, in which ovarian size ranged from 1 to 30 cm (mean 9.5 cm) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Mechanism of torsion'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14908739\">",
"    <span class=\"h3\">",
"     Benign versus malignant masses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Torsion is more likely to occur with benign cysts or neoplasms rather than malignant lesions, possibly because malignant masses are more likely to be fixed in place. Case series have reported malignancy in 2 percent or fewer of cases of torsion [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/25,28,33\">",
"     25,28,33",
"    </a>",
"    ]. However, the rate of malignancy in a torsed ovary is higher among postmenopausal women (20 to 25 percent in two series), since the overall rate of a malignant adnexal mass is highest in this population [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1942422\">",
"    <span class=\"h3\">",
"     Normal ovaries",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to note that torsion may occur in the presence of normal ovaries, particularly in the pediatric population [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/36\">",
"     36",
"    </a>",
"    ]. In children under the age of 15 years, normal ovaries have been demonstrated in over 50 percent of patients with ovarian torsion [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. As an example, one large series of patients with adnexal torsion reported that 23 of 103 patients (22 percent) had no identifiable adnexal lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/24\">",
"     24",
"    </a>",
"    ]. In another study, 12 of 22 patients under the age of 15 years with adnexal torsion had normal ovaries visualized at laparoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/37\">",
"     37",
"    </a>",
"    ]. Asynchronous bilateral torsion of normal ovaries has also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28078997\">",
"    <span class=\"h2\">",
"     Reproductive age",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of cases of ovarian torsion occur in women of reproductive age [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/24,27,28\">",
"     24,27,28",
"    </a>",
"    ]. For example, in 10- to 15-year retrospective series at single institutions, the average age of a patient with torsion was in the late-20s to mid-30s and the majority of cases occurred between the ages of 20 and 50 years [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/27,28,33\">",
"     27,28,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ovarian torsion may occur in females of all ages, even fetuses and neonates, particularly if an ovarian mass is present, as noted above [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/25,31,32\">",
"     25,31,32",
"    </a>",
"    ]. As an example, in a series of 216 cases of torsion, the age range was 3 months to 77 years (mean 29 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/33\">",
"     33",
"    </a>",
"    ]. There are no data to establish the incidence of torsion in premenarchal girls. (See",
"    <a class=\"local\" href=\"#H14908185\">",
"     'Ovarian mass'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/34/21033?source=see_link\">",
"     \"Ovarian cysts and neoplasms in infants, children, and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similarly, torsion appears to occur infrequently in postmenopausal women. As an example, in a series of 301 postmenopausal women with ovarian neoplasms, 19 (6 percent) had ovarian torsion [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20600973\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy is associated with an increased risk of ovarian torsion, accounting for 10 to 22 percent of cases of torsion in series of 80 or more patients (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef67110 \" href=\"UTD.htm?33/59/34736\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/27,28,33\">",
"     27,28,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of torsion during pregnancy is uncertain; one five-year retrospective study reported 7 cases out of 4274 deliveries (0.2 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/42\">",
"     42",
"    </a>",
"    ]. In a series of 174 pregnant women with a persistent adnexal mass &ge;4 cm, the incidence of torsion was 15 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/43\">",
"     43",
"    </a>",
"    ]. Torsion was most likely between 10 and 17 weeks of gestation, but occurred through term and the postpartum period. Ovarian masses 6 to 8 cm in diameter were more likely to undergo torsion than larger masses, although torsion occurred in women with masses that were 10 to 20 cm. Other series in pregnant women with an adnexal mass have reported a much lower incidence of torsion (1 to 6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/44,45\">",
"     44,45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14908210\">",
"    <span class=\"h2\">",
"     Ovulation induction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ovulation induction for treatment of infertility results in the formation of large ovarian follicular cysts and, in some patients, massive ovarian enlargement due to hyperstimulation. As an example, among women with ovarian hyperstimulation syndrome, the incidence of torsion was 8 percent in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/10/13482?source=see_link\">",
"     \"Overview of ovulation induction\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20600912\">",
"    <span class=\"h2\">",
"     Prior ovarian torsion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent torsion occurs in some patients, but the rate is not known. In one series, 23 of 216 cases (11 percent) of torsion were recurrent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some data suggest that patients with normal ovaries are at higher risk of recurrent torsion than those with abnormal ovaries. In one study, for example, torsion recurred in 7 of 11 patients (64 percent) with normal adnexa compared with 4 of 46 patients (9 percent) with abnormal adnexa [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prevention of recurrent torsion is discussed below. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Prevention of recurrence'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20603472\">",
"    <span class=\"h2\">",
"     Other risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some data suggest that tubal ligation is associated with an increased risk of ovarian torsion, but the degree of this risk is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/27,33\">",
"     27,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are a few case reports of ovarian torsion associated with enlarged ovaries in the setting of polycystic ovarian syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/47,48\">",
"     47,48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H327710\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic presentation of ovarian torsion is the acute onset of moderate to severe pelvic pain, often with nausea and possibly vomiting, in a woman with an adnexal mass [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/13,25,49\">",
"     13,25,49",
"    </a>",
"    ]. However, the presentation may vary and many symptoms and signs that accompany torsion are also associated with other conditions. In addition, torsion may also occur in the absence of an adnexal mass. Thus, a high index of suspicion is required to make the diagnosis. This is of particular importance since torsion may result in the loss of ovarian function or other adverse sequelae. (See",
"    <a class=\"local\" href=\"#H850103\">",
"     'Differential diagnosis'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H1942422\">",
"     'Normal ovaries'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H327826\">",
"     'Natural history'",
"    </a>",
"    above.) &nbsp;",
"   </p>",
"   <p>",
"    The frequency of presenting symptoms and findings of ovarian torsion were as follows in series of 50 or more patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/27,28,33,50\">",
"     27,28,33,50",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pelvic pain (90 percent)",
"     </li>",
"     <li>",
"      Adnexal mass (86 to 95 percent)",
"     </li>",
"     <li>",
"      Nausea and vomiting (47 to 70 percent)",
"     </li>",
"     <li>",
"      Fever (2 to 20 percent)",
"     </li>",
"     <li>",
"      Abnormal genital tract bleeding (4 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Fever may be a marker of adnexal necrosis, particularly in the setting of leukocytosis. (See",
"    <a class=\"local\" href=\"#H850127\">",
"     'Laboratory evaluation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Pregnant women with torsion present in a similar fashion with lower abdominal pain, nausea, vomiting, and possibly a low grade fever, leukocytosis, or a palpable mass [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infants with ovarian torsion present with feeding intolerance, vomiting, abdominal distension, and",
"    <span class=\"nowrap\">",
"     fussiness/irritability",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/13,52-55\">",
"     13,52-55",
"    </a>",
"    ]. In most instances, ovarian cysts in this patient population have already been visualized on a prenatal ultrasound and are being followed with serial sonography to track growth of the cyst or presence of hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/32\">",
"     32",
"    </a>",
"    ]. Parents or other caregivers should be made aware of the signs and symptoms of torsion so they can contact the child's clinician without delay.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H295749\">",
"    <span class=\"h2\">",
"     Pelvic pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pelvic pain is the most common presenting symptom of ovarian torsion. The pain is typically of sudden onset (59 percent) and most patients present for evaluation within one to three days of the onset of the pain [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. There are rare reports of torsion associated with pelvic pain that was present for up to 210 days, and these are thought to possibly represent intermittent torsion [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/56\">",
"     56",
"    </a>",
"    ]. The pain is usually moderate to severe (82 percent). The character of the pain may be sharp, stabbing, colicky, or crampy, and may radiate to the flank, back, or groin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3552339\">",
"    <span class=\"h2\">",
"     Adnexal mass",
"    </span>",
"    &nbsp;&mdash;&nbsp;An adnexal mass is present in most patients with ovarian torsion. The mass is typically an ovarian cyst or neoplasm, but the ovary may be diffusely enlarged (eg, ovarian hyperstimulation syndrome, polycystic ovarian syndrome). The likelihood of torsion is higher if the mass is 5 cm in diameter or larger. A paraovarian cyst may be associated with ovarian or tubal torsion or a paratubal cyst may torse around its own pedicle. The size and other characteristics of ovarian masses associated with torsion are described above. (See",
"    <a class=\"local\" href=\"#H14908185\">",
"     'Ovarian mass'",
"    </a>",
"    above.) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H295757\">",
"    <span class=\"h2\">",
"     Nausea and vomiting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with adnexal torsion often experience waves of nausea with or without vomiting [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/27,28,33,50\">",
"     27,28,33,50",
"    </a>",
"    ]. In our experience, the onset of nausea typically coincides with the onset of pelvic pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H295765\">",
"    <span class=\"h2\">",
"     Fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fever is present in some patients with ovarian torsion, and is typically low grade [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/27,28,33,50\">",
"     27,28,33,50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H849965\">",
"    <span class=\"h1\">",
"     EVALUATION OF PATIENTS WITH SUSPECTED TORSION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H850111\">",
"    <span class=\"h2\">",
"     Medical history",
"    </span>",
"    &nbsp;&mdash;&nbsp;The medical history should include questions regarding symptoms associated with ovarian torsion, including pelvic pain and nausea. The patient should be asked regarding a history, or recent diagnosis, of an adnexal mass. (See",
"    <a class=\"local\" href=\"#H327710\">",
"     'Clinical presentation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A history of recent vigorous activity may be an inciting event and should prompt the clinician to consider the diagnosis of torsion in patients with other suggestive symptoms or findings. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Mechanism of torsion'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H850119\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A low grade fever is present in some patients with torsion. Some patients with torsion present with a slightly elevated heart rate or blood pressure, typically in association with severe pelvic pain. (See",
"    <a class=\"local\" href=\"#H295765\">",
"     'Fever'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    An abdominal and pelvic examination should be performed. Findings on physical examination are variable. Most patients exhibit pelvic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    abdominal tenderness, although tenderness on examination is absent in as many as one-third of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/27,28,33\">",
"     27,28,33",
"    </a>",
"    ]. Tenderness may be localized to the side of an adnexal mass, if present, or may be diffuse. Similarly, a palpable pelvic mass may or may not be present. Peritoneal signs are present in a small number of patients, and should raise concern for adnexal necrosis. (See",
"    <a class=\"local\" href=\"#H327826\">",
"     'Natural history'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H850127\">",
"    <span class=\"h2\">",
"     Laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A serum human chorionic gonadotropin, hematocrit, white blood cell count, and electrolyte panel should be drawn.",
"   </p>",
"   <p>",
"    Pregnancy testing with human chorionic gonadotropin is essential, since the risk of torsion is increased in pregnant women. In addition, ectopic pregnancy must be excluded in pregnant women with acute pelvic pain. Also, knowledge of pregnancy status helps to guide management to ensure maternal and fetal safety.",
"   </p>",
"   <p>",
"    In the setting of ovarian torsion, in rare cases, hemorrhage may result in anemia and adnexal necrosis may cause infection with associated leukocytosis. Laboratory abnormalities are absent in many patients and, when present, anemia or leukocytosis are nonspecific and do not contribute to establishing the diagnosis of torsion. However, if these laboratory findings are present in a patient with suspected torsion, they raise concern for severe adnexal damage.",
"   </p>",
"   <p>",
"    There is no serum marker for the diagnosis of adnexal torsion. Small observational studies have found an association between an increased level of serum interleukin-6 (IL-6) and ovarian torsion [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]; further investigation is needed to evaluate use of serum IL-6 for diagnosis of torsion.",
"   </p>",
"   <p>",
"    If an adnexal mass is present and malignancy is suspected, serum tumor markers should be drawn. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24601?source=see_link&amp;anchor=H543206#H543206\">",
"     \"Approach to the patient with an adnexal mass\", section on 'Laboratory studies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest pelvic ultrasound as the first line imaging study for patients with suspected ovarian torsion. Pelvic magnetic resonance imaging (MRI) or computed tomography (CT) scan are not usually used for the diagnosis of adnexal torsion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasound is the initial imaging study of choice for patients with suspected ovarian torsion. Ultrasound is relatively less expensive than other imaging modalities and its diagnostic performance is similar. Both a transvaginal and transabdominal ultrasound should be obtained in most patients to visualize both abdominal processes and provide the best images of pelvic structures.",
"   </p>",
"   <p>",
"    The sonographic findings that are associated with ovarian torsion are listed here and examples are shown in the images (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef86199 \" href=\"UTD.htm?42/46/43746\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef86200 \" href=\"UTD.htm?33/16/34053\">",
"     image 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. The presence of these findings varies across patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An ovary that is rounded and enlarged compared with the contralateral ovary &ndash; This is due to edema and vascular and lymph engorgement.",
"     </li>",
"     <li>",
"      An ovarian mass &ndash; While the ultrasound is being performed, it is often helpful to note whether the patient has tenderness associated with the mass. In torsion, the patient will have pain ipsilateral to the mass, and scanning with the vaginal probe in the region of the mass will elicit pain.",
"     </li>",
"     <li>",
"      Heterogenous appearance of the ovarian stroma &ndash; This is due to edema and hemorrhage.",
"     </li>",
"     <li>",
"      Multiple small peripheral follicles (&ldquo;string of pearls&rdquo;) &ndash; This is thought to be due to displacement by edema. This feature is also seen in polycystic ovarian syndrome, although in polycystic ovaries, the stroma is echogenic centrally and the patient does not have acute pain.",
"     </li>",
"     <li>",
"      Abnormal ovarian location &ndash; The normal location of the ovaries is lateral to the uterus, but in torsion, they may be located anterior to the uterus.",
"     </li>",
"     <li>",
"      Decreased or absent Doppler flow within the ovary &ndash; Diminished or absent ovarian vessel flow on two-dimensional, color, and three-dimensional Doppler ultrasound has been proposed as a test for ovarian torsion [",
"      <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/14,61-64\">",
"       14,61-64",
"      </a>",
"      ]. Since the ovary has a dual blood supply, flow can be present even in the presence of torsion. Arterial flow in systole without flow in diastole is evidence for outflow obstruction. Venous flow in the setting of torsion is associated with ovarian viability. In our practice, we have not found either the presence or absence of Doppler flow to be diagnostically useful in children [",
"      <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/15\">",
"       15",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In a prospective study of 199 patients with an adnexal mass in the setting of pelvic pain, absence or impaired ovarian venous flow on Doppler ultrasound was found to have 100 percent sensitivity and 97 percent specificity for a diagnosis of ovarian torsion [",
"      <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/65\">",
"       65",
"      </a>",
"      ]. In contrast, a retrospective study of 78 patients who underwent laparoscopy for presumed torsion reported that abnormal Doppler flow had a sensitivity and specificity of 43 and 92 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/66\">",
"       66",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Doppler grayscale &ldquo;whirlpool sign&rdquo; in the ovarian vessels &ndash; This is visualized as a round hyperechoic structure with concentric hypoechoic stripes or a tubular structure with internal heterogeneous echoes. This sign is thought to represent the twisting of the vascular pedicle. Two small series of 20 patients with suspected torsion found this sign to have a sensitivity of 90 percent or higher for the diagnosis of torsion [",
"      <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/67,68\">",
"       67,68",
"      </a>",
"      ]. Further study is needed to determine the usefulness of this sign in patients who present with pelvic pain.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The reported sensitivity of ultrasound for the diagnosis of ovarian torsion ranges from 46 to 75 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/60,69\">",
"     60,69",
"    </a>",
"    ]. As an example, in one series of 63 patients with suspected torsion, the most sensitive sonographic findings were: abnormal ovarian location (sensitivity: 90 percent and specificity: 68 percent); free fluid around ovary or in posterior cul-de-sac (89 and 54 percent); ovarian",
"    <span class=\"nowrap\">",
"     cyst/mass",
"    </span>",
"    (83 and 70 percent); and abnormal ovarian blood flow (80 and 54 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/69\">",
"     69",
"    </a>",
"    ]. A sensitivity of 100 percent was achieved by combining two or more findings, although the highest specificity was approximately 70 percent even when findings were combined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Other imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRI may be helpful if findings on ultrasound are equivocal, but the cost and time required for MRI does not justify its routine use for the evaluation of suspected adnexal torsion [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/70-75\">",
"     70-75",
"    </a>",
"    ]. MRI findings consistent with ovarian torsion include an enlarged, edematous ovary in an abnormal location and, with contrast enhancement, the coiled ovarian vessels may be visualized with the &ldquo;whirlpool&rdquo; sign.",
"   </p>",
"   <p>",
"    CT is not typically used for the evaluation of ovarian torsion, but a woman with acute abdominal or pelvic pain may undergo CT as an initial study (eg, to exclude appendicitis). Similar to MRI, findings on CT that are consistent with torsion include an enlarged, edematous ovary in an abnormal location, lack of enhancement of the ovary after administration of intravenous contrast, and coiled ovarian vessels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H850001\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A definitive diagnosis of ovarian torsion is made by direct visualization of a rotated ovary at the time of surgical evaluation.",
"   </p>",
"   <p>",
"    The decision to proceed with surgery is based upon a clinical diagnosis made with a combination of symptoms, signs, and ultrasound findings. A presumptive diagnosis of torsion can be made with a fair degree of confidence in the presence of acute pelvic pain and an adnexal mass with a sonographic appearance consistent with torsion and after exclusion of ectopic pregnancy, tuboovarian abscess, and appendicitis. Additional findings, such as nausea, fever, and pelvic tenderness on examination further support the diagnosis. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Ultrasound'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H850103\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The decision to proceed with surgery, however, must often be made in the absence of some of these clinical features. It is important to note that the absence of an adnexal mass does not exclude a diagnosis of torsion. Torsion may occur in patients with ovaries with no underlying lesion, particularly in premenarchal patients, as noted above. (See",
"    <a class=\"local\" href=\"#H1942422\">",
"     'Normal ovaries'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The difficulty in diagnosis was illustrated in a series of 115 cases of adnexal torsion that revealed that the correct preoperative diagnosis was made in only 38 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H850103\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of ovarian torsion includes other conditions that present in a similar manner.",
"   </p>",
"   <p>",
"    In a woman with acute pelvic pain and an adnexal mass, ectopic pregnancy, a ruptured ovarian cyst, and tuboovarian abscess should be excluded. A negative serum human chorionic gonadotropin excludes ectopic pregnancy.",
"   </p>",
"   <p>",
"    In pregnant women, sonographic evidence of an intrauterine pregnancy decreases the likelihood of ectopic pregnancy (but does not exclude heterotopic pregnancy). If it is too early in pregnancy to visualize an intrauterine gestation, the two conditions are typically differentiated by risk factors, symptoms and ultrasound findings. Patients with either ectopic pregnancy or ovarian torsion may have pelvic pain, an adnexal mass, and nausea. However, the onset of the pain is typically followed shortly by nausea in torsion. In addition, ectopic pregnancy is usually associated with vaginal bleeding, while torsion is usually not. Either condition requires urgent intervention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1178?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and management of ectopic pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rupture of an ovarian cyst is often accompanied by sonographic evidence of hematoperitoneum or free fluid in the pelvis; free fluid may also be seen with torsion [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/60\">",
"     60",
"    </a>",
"    ]. In addition, the classic history of cyst rupture is the sudden onset of pelvic pain at midcycle, often following sexual intercourse. Symptom patterns and ultrasound findings vary for both conditions, and may appear similar. If torsion is suspected, surgical evaluation should be performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9863?source=see_link\">",
"     \"Evaluation and management of ruptured ovarian cyst\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Tuboovarian abscess is more likely to have an indolent course and be associated with fever than torsion, and the characteristic sonographic appearance of an abscess is a complex, multilocular mass, which is not usually found in torsion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36823?source=see_link&amp;anchor=H2457328#H2457328\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of tuboovarian abscess\", section on 'Evaluation of women with suspected toa'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Appendicitis is another etiology of pelvic pain, nausea, and fever that must be excluded. Appendicitis is not associated with an adnexal mass, unless there is a periappendiceal abscess; however, the absence of a mass does not exclude torsion. The two conditions are usually differentiated by physical examination to localize the pain and by the presence of characteristic imaging findings. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/40/31370?source=see_link\">",
"     \"Acute appendicitis in adults: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pattern of pain associated with ovarian torsion is variable, and thus, the differential diagnosis also includes other conditions that are associated with acute or chronic pelvic pain, including an ovarian cyst or neoplasm that is not torsed, endometriosis, or a degenerating leiomyoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/44/17095?source=see_link\">",
"     \"Evaluation of acute pelvic pain in women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/26/41384?source=see_link\">",
"     \"Causes of chronic pelvic pain in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H329352\">",
"    <span class=\"h1\">",
"     SURGICAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to proceed with a surgical evaluation is based upon a clinical diagnosis of ovarian torsion. (See",
"    <a class=\"local\" href=\"#H850001\">",
"     'Diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The goals of the intraoperative evaluation are to confirm the presence of torsion and evaluate the viability of the ovary and tube. Most torsed ovaries are considered potentially viable, unless there is a clearly necrotic appearance. &nbsp;",
"   </p>",
"   <p>",
"    A laparoscopic approach is typically used, unless there is a suspicion of ovarian or fallopian tubal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/33,77\">",
"     33,77",
"    </a>",
"    ]. Surgical treatment should be performed by a gynecologist, whenever possible, for optimal evaluation of the ovary. In children, if a gynecologic pediatric surgeon is not available, an intraoperative consultation from a gynecologist should be obtained [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/78\">",
"     78",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24601?source=see_link&amp;anchor=H3884375#H3884375\">",
"     \"Approach to the patient with an adnexal mass\", section on 'Evaluation for malignancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1942775\">",
"    <span class=\"h2\">",
"     Confirm torsion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of torsion is confirmed by direct visualization of the rotated ovary, tube, or paratubal or paraovarian cyst. Most surgeons document the findings with laparoscopic photographs of the adnexa.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1942783\">",
"    <span class=\"h2\">",
"     Assess ovarian viability",
"    </span>",
"    &nbsp;&mdash;&nbsp;The standard approach to determining the viability of a torsed ovary is gross visual inspection. An ovary that is dark and enlarged likely has vascular and lymphatic congestion and may have hemorrhagic lesions (",
"    <a class=\"graphic graphic_picture graphicRef61891 graphicRef72645 \" href=\"UTD.htm?9/18/9511\">",
"     picture 1A-B",
"    </a>",
"    ). Traditionally, ovaries with this appearance have been thought to be nonviable, but multiple studies have found that many women (even those with an ovary that is blue or black) retain ovarian function following detorsion [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/77,79-86\">",
"     77,79-86",
"    </a>",
"    ]. In studies with ultrasound follow-up, the rate of follicular development after detorsion was 80 percent or higher [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/74,82,85,86\">",
"     74,82,85,86",
"    </a>",
"    ]. As an example, in a study of 40 women with ovarian torsion who had a &ldquo;bluish-black&rdquo; appearance of the ovary at surgery and underwent detorsion, normal follicular development was demonstrated on ultrasound in 35 of 37 patients who were followed after surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/82\">",
"     82",
"    </a>",
"    ]. A possible explanation of the viability of ovarian tissue, based upon rat data, is that total arterial occlusion may not be present in the torsed ovary despite venous and lymphatic congestion [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rarely, ovarian or tubal necrosis are present at time of surgery. The appearance on gross inspection of a necrotic ovary or tube includes a loss of normal anatomic structure and a gelatinous or friable consistency.",
"   </p>",
"   <p>",
"    Other approaches have been proposed to assess whether ovarian perfusion is present, but these are investigational. One technique is ovarian bivalving, in which the ovary is untwisted and the ovarian cortex incised. In our practice, we make the incision with a laparoscopic instrument with an electrosurgical &ldquo;L-hook&rdquo; needle tip attachment. This method allows visualization of whether blood flow is present at the incision. In addition, there is a potential therapeutic effect by relieving the increased pressure exerted by the lymphatic and venous congestion (",
"    <a class=\"graphic graphic_picture graphicRef52835 graphicRef65607 graphicRef78492 \" href=\"UTD.htm?33/46/34535\">",
"     picture 2A-C",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. This approach was reported in one series of five patients who underwent bivalving, four of whom had normal postoperative follicular development documented by ultrasound [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/88\">",
"     88",
"    </a>",
"    ]. Another approach that has been reported is intraoperative intravenous fluorescein injection followed by direct visualization of the affected ovary under ultraviolet light [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/90\">",
"     90",
"    </a>",
"    ]. However, this approach requires specialized equipment and its efficacy has not been validated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mainstay of treatment of ovarian torsion is swift operative evaluation to preserve ovarian function and prevent other adverse effects (eg, hemorrhage, peritonitis, adhesion formation). For most premenopausal patients with ovarian torsion and an ovary that appears potentially viable on direct visualization, we recommend detorsion and ovarian conservation rather than salpingo-oophorectomy. Ovarian cystectomy is often performed if a benign mass is present. Patients with an apparently necrotic ovary or an ovarian mass that is suspicious for malignancy require salpingo-oophorectomy. Salpingo-oophorectomy is also reasonable for postmenopausal women. &nbsp;",
"   </p>",
"   <p>",
"    Historically, salpingo-oophorectomy on the affected side had been the standard treatment of a torsed ovary because it was believed that conserving the ovary would leave behind necrotic tissue and restoring normal anatomy via detorsion could dislodge a clot in the ovarian vein and result in an embolus [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/91\">",
"     91",
"    </a>",
"    ]. However, it appears that detorsion is associated with continued ovarian function in many women, based upon multiple observational studies, as discussed above [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/79-83\">",
"     79-83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The key factor is to perform detorsion as quickly as possible. A study in rats found that necrosis occurred after occlusion of the ovarian vessels for 36 hours or longer [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/87\">",
"     87",
"    </a>",
"    ]. Consistent with the increasing risk of ovarian ischemic damage over time, the rate of ovarian conservation reported in studies decreases with an increasing interval between symptoms to surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/37,84\">",
"     37,84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is also no evidence of an increase of adverse events with detorsion. In the only comparative data, a retrospective study of 94 women under age 40 years with ovarian torsion, there was no increase in postoperative complications in those who underwent detorsion with cystectomy compared with salpingo-oophorectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/92\">",
"     92",
"    </a>",
"    ]. No pulmonary embolic events were identified in either group. In addition, a case report and review of the literature described 981 cases of torsion in which 309 were managed with detorsion and 672 with adnexal resection [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/16\">",
"     16",
"    </a>",
"    ]. Two pulmonary embolisms were observed in the adnexal resection group, and none in the detorsion group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H329640\">",
"    <span class=\"h2\">",
"     Premenopausal patients with a viable ovary",
"    </span>",
"    &nbsp;&mdash;&nbsp;In premenopausal patients, the surgical evaluation is performed. Following detorsion, the adnexa is assessed for the presence of an ovarian cyst or neoplasm. If a mass is present and there is no suspicion of malignancy, a cystectomy is performed. If malignancy is suspected, a salpingo-oophorectomy should be performed. (See",
"    <a class=\"local\" href=\"#H329352\">",
"     'Surgical evaluation'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H29\">",
"     'Patients with a nonviable ovary, suspected malignancy, or postmenopausal patients'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The evaluation and management of an ovarian cyst or neoplasm is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24601?source=see_link\">",
"     \"Approach to the patient with an adnexal mass\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30905?source=see_link\">",
"     \"Management of an adnexal mass\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Detorsion and ovarian conservation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Detorsion consists of untwisting the torsed ovary and any other torsed structure. During laparoscopy, this can be accomplished with a blunt probe or an atraumatic grasper. If laparotomy is performed, the ovary can be untwisted manually.",
"   </p>",
"   <p>",
"    While the benefits of conservative surgery appear to outweigh the theoretical surgical risks of detorsion, irreversible ischemic damage to the adnexa can occur and may lead to infection if a necrotic ovary is retained. Postoperative care and instructions following detorsion should include observation for signs of peritonitis or sepsis (fever, abdominal pain, peritoneal signs, hemodynamic instability). This rare complication was reported in a pregnant patient who underwent laparotomy and detorsion of a hyperstimulated ovary with reperfusion of the torsed adnexa observed intraoperatively [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/21\">",
"     21",
"    </a>",
"    ]. Reexploration because of peritonitis two days postoperatively revealed clear evidence of a necrotic ovary. (See",
"    <a class=\"local\" href=\"#H327826\">",
"     'Natural history'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Patients with a nonviable ovary, suspected malignancy, or postmenopausal patients",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H329708\">",
"    <span class=\"h3\">",
"     Salpingo-oophorectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with an ovary that is apparently necrotic (black color combined with loss of normal anatomic structure and a diminished size) during intraoperative evaluation should undergo salpingo-oophorectomy.",
"   </p>",
"   <p>",
"    Salpingo-oophorectomy is required if ovarian or fallopian tubal cancer is suspected. Ovarian torsion is rare in postmenopausal women, but when it occurs, salpingo-oophorectomy is reasonable to prevent recurrence. In addition, if an ovarian mass is present, removal of the adnexa is the standard in this patient population due to the risk of malignancy.",
"   </p>",
"   <p>",
"    Evaluation for malignancy typically depends in part on measurement of serum tumor markers and often on serial pelvic sonography. These results are often not available for patients who require urgent surgery, so decisions regarding salpingo-oophorectomy should be made based upon the available information. In a premenopausal patient, the ovary should be preserved unless there is a high clinical suspicion of malignancy. In contrast, in the rare postmenopausal woman with an ovarian mass, salpingo-oophorectomy is the preferred approach.",
"   </p>",
"   <p>",
"    Intraoperatively, the adnexa should be detorsed to better visualize the mass. In addition, this allows better delineation of the infundibulopelvic ligament and location of the ureter to avoid surgical complications. The adnexa is then removed in the usual fashion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12393?source=see_link\">",
"     \"Oophorectomy and ovarian cystectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The evaluation and management of an adnexal mass if malignancy is suspected is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24601?source=see_link&amp;anchor=H3884375#H3884375\">",
"     \"Approach to the patient with an adnexal mass\", section on 'Evaluation for malignancy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30905?source=see_link\">",
"     \"Management of an adnexal mass\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H329765\">",
"    <span class=\"h2\">",
"     Pregnant women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of torsion in pregnancy is similar to that in nonpregnant patients, but may be technically more difficult given the size of the gravid uterus. One review examined 47 patients (17 in the first trimester, 27 in the second trimester, 4 in the third trimester) who underwent laparoscopic management of ovarian cysts (n = 36), torsion (n = 8), and pelvic mass (n = 3 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/93\">",
"     93",
"    </a>",
"    ]). One pregnancy loss occurred four days after the procedure, suggesting that the laparoscopic approach remains a safe option even in pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/93\">",
"     93",
"    </a>",
"    ]. Other reviews have confirmed the safety and effectiveness of laparoscopic management of torsion in pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/94-96\">",
"     94-96",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8727?source=see_link\">",
"     \"Laparoscopic surgery in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1943053\">",
"    <span class=\"h2\">",
"     Fetuses and neonates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ovarian masses in a fetus are occasionally detected on prenatal ultrasound and are followed with serial sonography. In-utero ovarian torsion may occur, in which case, the ovary may undergo necrosis and develop into a calcified persistent mass or resorb. Prenatal puncture of ovarian cysts thought to be at risk for torsion has been described, but is investigational [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/97\">",
"     97",
"    </a>",
"    ]. Consultation with a maternal-fetal medicine specialist is advised.",
"   </p>",
"   <p>",
"    Ovarian masses may also be found in neonates; these are typically first noted prenatally. In a neonate with an ovarian mass, if there is suspicion of torsion based upon irritability,",
"    <span class=\"nowrap\">",
"     pelvic/abdominal",
"    </span>",
"    tenderness, and suggestive ultrasound findings, the patient should be evaluated surgically and managed in the same fashion as other patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/54,98,99\">",
"     54,98,99",
"    </a>",
"    ]. A laparoscopic approach is appropriate, if a surgeon with expertise in pediatric laparoscopy is available [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/100\">",
"     100",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/63/21495?source=see_link\">",
"     \"Overview of laparoscopy in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Management of ovarian masses in the pediatric population is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/34/21033?source=see_link\">",
"     \"Ovarian cysts and neoplasms in infants, children, and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     PREVENTION OF RECURRENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ovarian torsion may recur, although the incidence of and risk factors for recurrence are unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/6,26,101-103\">",
"     6,26,101-103",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H20600912\">",
"     'Prior ovarian torsion'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    There are several options to decrease the risk of recurrence:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Suppression of ovarian cysts &ndash; Use of high dose oral contraceptives (&ge;50 mcg estrogen) results in fewer ovulations and cysts [",
"      <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/104-107\">",
"       104-107",
"      </a>",
"      ]; however, prolonged use of these is associated with thrombotic risks and it has not been shown that this therapy decreases the risk of recurrent ovarian torsion. Low dose estrogen-progestin contraceptives may not prevent development of ovarian cysts [",
"      <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/108\">",
"       108",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30905?source=see_link&amp;anchor=H15996796#H15996796\">",
"       \"Management of an adnexal mass\", section on 'Clinical scenarios for ovarian masses'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39034?source=see_link\">",
"       \"Risks and side effects associated with estrogen-progestin contraceptives\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Oophoropexy &ndash; Unilateral or bilateral oophoropexy following ovarian detorsion has also been used to prevent recurrence, although there are no high quality data regarding the efficacy of this approach [",
"      <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/94,109,110\">",
"       94,109,110",
"      </a>",
"      ]. Some experts advise this procedure be performed in every case of childhood torsion, especially if one ovary is removed [",
"      <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/8,111\">",
"       8,111",
"      </a>",
"      ], but others are concerned about the routine use of oophoropexy, since long-term follow-up fertility studies have not been performed [",
"      <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/13\">",
"       13",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In our practice, we perform oophoropexy on children with ovarian torsion who do not have an ovarian mass, but not in those with an ovarian mass present at the time of torsion. We also offer oophoropexy for girls and young women who have previously undergone an oophorectomy for prior ovarian torsion. The procedure can be performed laparoscopically and we typically shorten the utero-ovarian ligament or, if the ovary is greatly enlarged without a discrete mass, then it can be sutured to the uterosacral ligament (",
"      <a class=\"graphic graphic_picture graphicRef54364 \" href=\"UTD.htm?26/43/27319\">",
"       picture 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/112\">",
"       112",
"      </a>",
"      ], and has been done in pregnant women [",
"      <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/94\">",
"       94",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/47/6902?source=see_link\">",
"       \"Ovarian transposition before pelvic radiation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H426482\">",
"    <span class=\"h1\">",
"     TORSION OF OTHER ADNEXAL STRUCTURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Isolated fallopian tube torsion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Torsion of the fallopian tube without ovarian torsion is a rare, but noteworthy, cause of lower abdominal pain in reproductive age women (",
"    <a class=\"graphic graphic_picture graphicRef82480 \" href=\"UTD.htm?15/44/16066\">",
"     picture 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/113\">",
"     113",
"    </a>",
"    ]. Torsion of the midportion of the fallopian tube causes compression of the tissue and may result in ischemic or traumatic tubal injury. Tubal injury caused by torsion, similar to injury resulting from infection or adhesive disease, may result in an adverse effect on fertility. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/18/3367?source=see_link&amp;anchor=H5#H5\">",
"     \"Causes of female infertility\", section on 'Fallopian tube abnormalities/pelvic adhesions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Possible risk factors for tubal torsion include tubal pathology (eg, hydrosalpinx, paratubal cyst, neoplasm, tubal ligation device, ectopic pregnancy, congenital anomaly), ovarian mass, infection, ectopic pregnancy, altered tubal function (eg, abnormal peristalsis, spasm), or extrinsic lesions (eg, adhesions, endometriosis) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/114\">",
"     114",
"    </a>",
"    ]. In the largest retrospective review of patients with tubal torsion, 24 percent had normal-appearing tubes, 18 percent had hydrosalpinx, and 13 percent had infection; 12 percent of torsions were diagnosed during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/113\">",
"     113",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presenting symptoms and physical examination findings for tubal torsion are similar to those for ovarian torsion, including pain, nausea and, occasionally, fever [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/115,116\">",
"     115,116",
"    </a>",
"    ]. Radiologic diagnosis is limited. In one case series, the most consistent finding on either pelvic ultrasound or computed tomography was a midline cystic mass (either in the posterior cul-de-sac or superior to the uterus) associated with a normal ipsilateral ovary [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/115\">",
"     115",
"    </a>",
"    ]. Ultimately, the diagnosis is generally made at time of surgical exploration. As with ovarian torsion, prompt consideration of this diagnosis and surgical detorsion may prevent irreversible ischemic damage. (See",
"    <a class=\"local\" href=\"#H327710\">",
"     'Clinical presentation'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H23\">",
"     'Management'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H426499\">",
"    <span class=\"h2\">",
"     Paratubal or paraovarian cyst torsion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paratubal cysts are often connected with the mesosalpinx with a stalk, around which torsion may occur [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/3,117\">",
"     3,117",
"    </a>",
"    ]. The incidence of torsion of paratubal cysts is uncertain, but should be suspected in a patient with acute or intermittent pelvic pain who has a paratubal cyst identified on pelvic ultrasound. The diagnosis of torsion can be made only with surgical evaluation. These cysts can easily be removed at time of surgery without compromise of the ovary or fallopian tube. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19352?source=see_link&amp;anchor=H14#H14\">",
"     \"Differential diagnosis of the adnexal mass\", section on 'Paraovarian/paratubal cysts and other tubal and broad ligament neoplasms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Paraovarian cysts are often incorporated in the broad ligament close to the fallopian tube and may increase the risk of tubal torsion [",
"    <a class=\"abstract\" href=\"UTD.htm?23/8/23690/abstract/4,118,119\">",
"     4,118,119",
"    </a>",
"    ]. In such cases, the fallopian tube is often distended, and if torsion occurs, the cyst must be removed with great care to avoid compromise of tubal function. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ovarian torsion refers to the complete or partial rotation of the ovary on its ligamentous supports, often resulting in ischemia. It is one of the most common gynecologic emergencies. The fallopian tube often twists along with the ovary; when this occurs, it is referred to as adnexal torsion. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ovarian torsion occurs in all age groups, but the majority of cases occur in women of reproductive age. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Epidemiology and risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The primary risk factor for ovarian torsion is an ovarian mass and is most common if the ovary is 5 cm or larger. However, torsion may also occur without an underlying lesion, particularly in the pediatric population. (See",
"      <a class=\"local\" href=\"#H14908185\">",
"       'Ovarian mass'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The classic presentation of ovarian torsion is the acute onset of pelvic pain, often with nausea and possibly vomiting, in a woman with an adnexal mass. The presentation is variable (eg, the pain may be chronic, some patients present without an adnexal mass, a low grade fever may be occasionally present). (See",
"      <a class=\"local\" href=\"#H327710\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pelvic ultrasound is the first line imaging study for patients with suspected ovarian torsion. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Imaging studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A definitive diagnosis of ovarian torsion is made by direct visualization of a rotated ovary at the time of surgical evaluation. The decision to proceed with surgery is based upon a clinical diagnosis, which is often based upon the presence of acute pelvic pain and an adnexal mass with a sonographic appearance consistent with torsion, and after exclusion of other conditions. (See",
"      <a class=\"local\" href=\"#H850001\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of ovarian torsion includes ectopic pregnancy, tuboovarian abscess, and appendicitis, as well as other conditions associated with acute or chronic pelvic pain. (See",
"      <a class=\"local\" href=\"#H850103\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most premenopausal patients with ovarian torsion, we recommend detorsion and ovarian conservation rather than salpingo-oophorectomy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Ovarian cystectomy is often performed if a benign mass is present. Patients with an obviously necrotic ovary or an ovarian mass that is suspicious for malignancy require salpingo-oophorectomy. Salpingo-oophorectomy is also reasonable for postmenopausal women. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Management'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1942783\">",
"       'Assess ovarian viability'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Isolated torsion of the fallopian tube is uncommon, but may also occur and may result in an adverse impact on tubal function. Tubal torsion occurs most commonly in the mid-portion of the tube itself, but may also occur around the ligamentous supports of the tube. In addition, torsion of paratubal or paraovarian cysts may occur. (See",
"      <a class=\"local\" href=\"#H426482\">",
"       'Torsion of other adnexal structures'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/1\">",
"      McWilliams GD, Hill MJ, Dietrich CS 3rd. Gynecologic emergencies. Surg Clin North Am 2008; 88:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/2\">",
"      Schrager J, Robles G, Platz T. Isolated fallopian tube torsion: a rare entity in a premenarcheal female. Am Surg 2012; 78:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/3\">",
"      Muolokwu E, Sanchez J, Bercaw JL, et al. The incidence and surgical management of paratubal cysts in a pediatric and adolescent population. J Pediatr Surg 2011; 46:2161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/4\">",
"      Said MR, Bamigboye V. Twisted paraovarian cyst in a young girl. J Obstet Gynaecol 2008; 28:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/5\">",
"      Celik A, Erg&uuml;n O, Aldemir H, et al. Long-term results of conservative management of adnexal torsion in children. J Pediatr Surg 2005; 40:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/6\">",
"      Germain M, Rarick T, Robins E. Management of intermittent ovarian torsion by laparoscopic oophoropexy. Obstet Gynecol 1996; 88:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/7\">",
"      Buss JG, Lee RA. Sequential torsion of the uterine adnexa. Mayo Clin Proc 1987; 62:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/8\">",
"      Beaunoyer M, Chapdelaine J, Bouchard S, Ouimet A. Asynchronous bilateral ovarian torsion. J Pediatr Surg 2004; 39:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/9\">",
"      Huchon C, Fauconnier A. Adnexal torsion: a literature review. Eur J Obstet Gynecol Reprod Biol 2010; 150:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/10\">",
"      Littman ED, Rydfors J, Milki AA. Exercise-induced ovarian torsion in the cycle following gonadotrophin therapy: case report. Hum Reprod 2003; 18:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/11\">",
"      Liu YP, Shih SL, Yang FS. Sudden onset of right lower quadrant pain after heavy exercise. Am Fam Physician 2008; 78:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/12\">",
"      Yancey LM. Intermittent torsion of a normal ovary in a child associated with use of a trampoline. J Emerg Med 2012; 42:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/13\">",
"      Kokoska ER, Keller MS, Weber TR. Acute ovarian torsion in children. Am J Surg 2000; 180:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/14\">",
"      Albayram F, Hamper UM. Ovarian and adnexal torsion: spectrum of sonographic findings with pathologic correlation. J Ultrasound Med 2001; 20:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/15\">",
"      Servaes S, Zurakowski D, Laufer MR, et al. Sonographic findings of ovarian torsion in children. Pediatr Radiol 2007; 37:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/16\">",
"      McGovern PG, Noah R, Koenigsberg R, Little AB. Adnexal torsion and pulmonary embolism: case report and review of the literature. Obstet Gynecol Surv 1999; 54:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/17\">",
"      Shukunami K, Nishijima K, Orisaka M, et al. Acute abdomen in a Jehovah's witness with chronic anemia. Am J Emerg Med 2004; 22:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/18\">",
"      Abolmakarem H, Tharmaratnum S, Thilaganathan B. Fetal anemia as a consequence of hemorrhage into an ovarian cyst. Ultrasound Obstet Gynecol 2001; 17:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/19\">",
"      Chapron C, Capella-Allouc S, Dubuisson JB. Treatment of adnexal torsion using operative laparoscopy. Hum Reprod 1996; 11:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/20\">",
"      Cunnion KM, Dolan MA, Sonnino RE. Case records of the Medical College of Virginia: a 10-year-old girl presenting with an acute onset of abdominal pain. Pediatr Emerg Care 1996; 12:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/21\">",
"      Pryor RA, Wiczyk HP, O'Shea DL. Adnexal infarction after conservative surgical management of torsion of a hyperstimulated ovary. Fertil Steril 1995; 63:1344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/22\">",
"      Hibbard LT. Adnexal torsion. Am J Obstet Gynecol 1985; 152:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/23\">",
"      Bouguizane S, Bibi H, Farhat Y, et al. [Adnexal torsion: a report of 135 cases]. J Gynecol Obstet Biol Reprod (Paris) 2003; 32:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/24\">",
"      Varras M, Tsikini A, Polyzos D, et al. Uterine adnexal torsion: pathologic and gray-scale ultrasonographic findings. Clin Exp Obstet Gynecol 2004; 31:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/25\">",
"      Oltmann SC, Fischer A, Barber R, et al. Cannot exclude torsion--a 15-year review. J Pediatr Surg 2009; 44:1212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/26\">",
"      Pansky M, Smorgick N, Herman A, et al. Torsion of normal adnexa in postmenarchal women and risk of recurrence. Obstet Gynecol 2007; 109:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/27\">",
"      Houry D, Abbott JT. Ovarian torsion: a fifteen-year review. Ann Emerg Med 2001; 38:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/28\">",
"      White M, Stella J. Ovarian torsion: 10-year perspective. Emerg Med Australas 2005; 17:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/29\">",
"      Kirkham YA, Lacy JA, Kives S, Allen L. Characteristics and management of adnexal masses in a canadian pediatric and adolescent population. J Obstet Gynaecol Can 2011; 33:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/30\">",
"      Chinchure D, Ong CL, Loh AH, Rajadurai VS. Neonatal ovarian cysts: role of sonography in diagnosing torsion. Ann Acad Med Singapore 2011; 40:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/31\">",
"      Sakala EP, Leon ZA, Rouse GA. Management of antenatally diagnosed fetal ovarian cysts. Obstet Gynecol Surv 1991; 46:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/32\">",
"      Heling KS, Chaoui R, Kirchmair F, et al. Fetal ovarian cysts: prenatal diagnosis, management and postnatal outcome. Ultrasound Obstet Gynecol 2002; 20:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/33\">",
"      Tsafrir Z, Hasson J, Levin I, et al. Adnexal torsion: cystectomy and ovarian fixation are equally important in preventing recurrence. Eur J Obstet Gynecol Reprod Biol 2012; 162:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/34\">",
"      Eitan R, Galoyan N, Zuckerman B, et al. The risk of malignancy in post-menopausal women presenting with adnexal torsion. Gynecol Oncol 2007; 106:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/35\">",
"      Lee RA, Welch JS. Torsion of the uterine adnexa. Am J Obstet Gynecol 1967; 97:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/36\">",
"      SCHULTZ LR, NEWTON WA Jr, CLATWORTHY HW Jr. Torsion of previously normal tube and ovary in children. N Engl J Med 1963; 268:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/37\">",
"      Anders JF, Powell EC. Urgency of evaluation and outcome of acute ovarian torsion in pediatric patients. Arch Pediatr Adolesc Med 2005; 159:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/38\">",
"      Tsafrir Z, Azem F, Hasson J, et al. Risk factors, symptoms, and treatment of ovarian torsion in children: the twelve-year experience of one center. J Minim Invasive Gynecol 2012; 19:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/39\">",
"      Worthington-Kirsch RL, Raptopoulos V, Cohen IT. Sequential bilateral torsion of normal ovaries in a child. J Ultrasound Med 1986; 5:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/40\">",
"      Davis AJ, Feins NR. Subsequent asynchronous torsion of normal adnexa in children. J Pediatr Surg 1990; 25:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/41\">",
"      Koonings PP, Grimes DA. Adnexal torsion in postmenopausal women. Obstet Gynecol 1989; 73:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/42\">",
"      Johnson TR Jr, Woodruff JD. Surgical emergencies of the uterine adnexae during pregnancy. Int J Gynaecol Obstet 1986; 24:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/43\">",
"      Yen CF, Lin SL, Murk W, et al. Risk analysis of torsion and malignancy for adnexal masses during pregnancy. Fertil Steril 2009; 91:1895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/44\">",
"      Bromley B, Benacerraf B. Adnexal masses during pregnancy: accuracy of sonographic diagnosis and outcome. J Ultrasound Med 1997; 16:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/45\">",
"      Schmeler KM, Mayo-Smith WW, Peipert JF, et al. Adnexal masses in pregnancy: surgery compared with observation. Obstet Gynecol 2005; 105:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/46\">",
"      Gorkemli H, Camus M, Clasen K. Adnexal torsion after gonadotrophin ovulation induction for IVF or ICSI and its conservative treatment. Arch Gynecol Obstet 2002; 267:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/47\">",
"      Shah AA, Likes CE, Price TM. Early polycystic ovary syndrome as a possible etiology of unexplained premenarcheal ovarian torsion. J Pediatr Adolesc Gynecol 2009; 22:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/48\">",
"      Tay J, Parker H, Dhange P, et al. Isolated torsion of the fallopian tube in a patient with polycystic ovarian syndrome (PCOS). Eur J Obstet Gynecol Reprod Biol 2010; 150:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/49\">",
"      Rousseau V, Massicot R, Darwish AA, et al. Emergency management and conservative surgery of ovarian torsion in children: a report of 40 cases. J Pediatr Adolesc Gynecol 2008; 21:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/50\">",
"      Huchon C, Panel P, Kayem G, et al. Does this woman have adnexal torsion? Hum Reprod 2012; 27:2359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/51\">",
"      Pinto AB, Ratts VS, Williams DB, et al. Reduction of ovarian torsion 1 week after embryo transfer in a patient with bilateral hyperstimulated ovaries. Fertil Steril 2001; 76:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/52\">",
"      Hamrick HJ, Fordham LA. Ovarian cyst and torsion in a young infant. Arch Pediatr Adolesc Med 1998; 152:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/53\">",
"      Suita S, Handa N, Nakano H. Antenatally detected ovarian cysts--a therapeutic dilemma. Early Hum Dev 1992; 29:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/54\">",
"      Lee JH, Tang JR, Wu MZ, et al. Ovarian cyst with torsion presenting as a wandering mass in a newborn. Acta Paediatr Taiwan 2003; 44:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/55\">",
"      Schmahmann S, Haller JO. Neonatal ovarian cysts: pathogenesis, diagnosis and management. Pediatr Radiol 1997; 27:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/56\">",
"      Sasso RA. Intermittent partial adnexal torsion after electrosurgical tubal ligation. J Am Assoc Gynecol Laparosc 1996; 3:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/57\">",
"      Cohen SB, Wattiez A, Stockheim D, et al. The accuracy of serum interleukin-6 and tumour necrosis factor as markers for ovarian torsion. Hum Reprod 2001; 16:2195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/58\">",
"      Daponte A, Pournaras S, Hadjichristodoulou C, et al. Novel serum inflammatory markers in patients with adnexal mass who had surgery for ovarian torsion. Fertil Steril 2006; 85:1469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/59\">",
"      Anthony EY, Caserta MP, Singh J, Chen MY. Adnexal masses in female pediatric patients. AJR Am J Roentgenol 2012; 198:W426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/60\">",
"      Wilkinson C, Sanderson A. Adnexal torsion -- a multimodality imaging review. Clin Radiol 2012; 67:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/61\">",
"      Ben-Ami M, Perlitz Y, Haddad S. The effectiveness of spectral and color Doppler in predicting ovarian torsion. A prospective study. Eur J Obstet Gynecol Reprod Biol 2002; 104:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/62\">",
"      Vijayaraghavan SB. Sonographic whirlpool sign in ovarian torsion. J Ultrasound Med 2004; 23:1643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/63\">",
"      Yaman C, Ebner T, Jesacher K. Three-dimensional power Doppler in the diagnosis of ovarian torsion. Ultrasound Obstet Gynecol 2002; 20:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/64\">",
"      Lee EJ, Kwon HC, Joo HJ, et al. Diagnosis of ovarian torsion with color Doppler sonography: depiction of twisted vascular pedicle. J Ultrasound Med 1998; 17:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/65\">",
"      Nizar K, Deutsch M, Filmer S, et al. Doppler studies of the ovarian venous blood flow in the diagnosis of adnexal torsion. J Clin Ultrasound 2009; 37:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/66\">",
"      Bar-On S, Mashiach R, Stockheim D, et al. Emergency laparoscopy for suspected ovarian torsion: are we too hasty to operate? Fertil Steril 2010; 93:2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/67\">",
"      Valsky DV, Esh-Broder E, Cohen SM, et al. Added value of the gray-scale whirlpool sign in the diagnosis of adnexal torsion. Ultrasound Obstet Gynecol 2010; 36:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/68\">",
"      Vijayaraghavan SB, Senthil S. Isolated torsion of the fallopian tube: the sonographic whirlpool sign. J Ultrasound Med 2009; 28:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/69\">",
"      Mashiach R, Melamed N, Gilad N, et al. Sonographic diagnosis of ovarian torsion: accuracy and predictive factors. J Ultrasound Med 2011; 30:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/70\">",
"      Born C, Wirth S, St&auml;bler A, Reiser M. Diagnosis of adnexal torsion in the third trimester of pregnancy: a case report. Abdom Imaging 2004; 29:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/71\">",
"      Haque TL, Togashi K, Kobayashi H, et al. Adnexal torsion: MR imaging findings of viable ovary. Eur Radiol 2000; 10:1954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/72\">",
"      Kawakami K, Murata K, Kawaguchi N, et al. Hemorrhagic infarction of the diseased ovary: a common MR finding in two cases. Magn Reson Imaging 1993; 11:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/73\">",
"      Schlaff WD, Lund KJ, McAleese KA, Hurst BS. Diagnosing ovarian torsion with computed tomography. A case report. J Reprod Med 1998; 43:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/74\">",
"      Kimura I, Togashi K, Kawakami S, et al. Ovarian torsion: CT and MR imaging appearances. Radiology 1994; 190:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/75\">",
"      Hiller N, Appelbaum L, Simanovsky N, et al. CT features of adnexal torsion. AJR Am J Roentgenol 2007; 189:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/76\">",
"      Argenta PA, Yeagley TJ, Ott G, Sondheimer SJ. Torsion of the uterine adnexa. Pathologic correlations and current management trends. J Reprod Med 2000; 45:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/77\">",
"      Oelsner G, Cohen SB, Soriano D, et al. Minimal surgery for the twisted ischaemic adnexa can preserve ovarian function. Hum Reprod 2003; 18:2599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/78\">",
"      Bristow RE, Nugent AC, Zahurak ML, et al. Impact of surgeon specialty on ovarian-conserving surgery in young females with an adnexal mass. J Adolesc Health 2006; 39:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/79\">",
"      Harkins G. Ovarian torsion treated with untwisting: second look 36 hours after untwisting. J Minim Invasive Gynecol 2007; 14:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/80\">",
"      Mashiach S, Bider D, Moran O, et al. Adnexal torsion of hyperstimulated ovaries in pregnancies after gonadotropin therapy. Fertil Steril 1990; 53:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/81\">",
"      Bider D, Mashiach S, Dulitzky M, et al. Clinical, surgical and pathologic findings of adnexal torsion in pregnant and nonpregnant women. Surg Gynecol Obstet 1991; 173:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/82\">",
"      Oelsner G, Bider D, Goldenberg M, et al. Long-term follow-up of the twisted ischemic adnexa managed by detorsion. Fertil Steril 1993; 60:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/83\">",
"      Dolgin SE, Lublin M, Shlasko E. Maximizing ovarian salvage when treating idiopathic adnexal torsion. J Pediatr Surg 2000; 35:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/84\">",
"      Aziz D, Davis V, Allen L, Langer JC. Ovarian torsion in children: is oophorectomy necessary? J Pediatr Surg 2004; 39:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/85\">",
"      Shalev J, Goldenberg M, Oelsner G, et al. Treatment of twisted ischemic adnexa by simple detorsion. N Engl J Med 1989; 321:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/86\">",
"      Wang JH, Wu DH, Jin H, Wu YZ. Predominant etiology of adnexal torsion and ovarian outcome after detorsion in premenarchal girls. Eur J Pediatr Surg 2010; 20:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/87\">",
"      Taskin O, Birincioglu M, Aydin A, et al. The effects of twisted ischaemic adnexa managed by detorsion on ovarian viability and histology: an ischaemia-reperfusion rodent model. Hum Reprod 1998; 13:2823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/88\">",
"      Styer AK, Laufer MR. Ovarian bivalving after detorsion. Fertil Steril 2002; 77:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/89\">",
"      Eckler K, Laufer MR, Perlman SE. Conservative management of bilateral asynchronous adnexal torsion with necrosis in a prepubescent girl. J Pediatr Surg 2000; 35:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/90\">",
"      McHutchinson LL, Koonings PP, Ballard CA, d'Ablaing G 3rd. Preservation of ovarian tissue in adnexal torsion with fluorescein. Am J Obstet Gynecol 1993; 168:1386.",
"     </a>",
"    </li>",
"    <li>",
"     Jones HW, Jones GS. Novak Textbook of Gynecology, 10th ed, Wolters Kluwer Lippincott Williams &amp; Wilkins, Baltimore 1981. p.471.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/92\">",
"      Zweizig S, Perron J, Grubb D, Mishell DR Jr. Conservative management of adnexal torsion. Am J Obstet Gynecol 1993; 168:1791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/93\">",
"      Mathevet P, Nessah K, Dargent D, Mellier G. Laparoscopic management of adnexal masses in pregnancy: a case series. Eur J Obstet Gynecol Reprod Biol 2003; 108:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/94\">",
"      Djavadian D, Braendle W, Jaenicke F. Laparoscopic oophoropexy for the treatment of recurrent torsion of the adnexa in pregnancy: case report and review. Fertil Steril 2004; 82:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/95\">",
"      Bisharah M, Tulandi T. Laparoscopic surgery in pregnancy. Clin Obstet Gynecol 2003; 46:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/96\">",
"      Upadhyay A, Stanten S, Kazantsev G, et al. Laparoscopic management of a nonobstetric emergency in the third trimester of pregnancy. Surg Endosc 2007; 21:1344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/97\">",
"      Crombleholme TM, Craigo SD, Garmel S, D'Alton ME. Fetal ovarian cyst decompression to prevent torsion. J Pediatr Surg 1997; 32:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/98\">",
"      Alrabeeah A, Galliani CA, Giacomantonio M, et al. Neonatal ovarian torsion: report of three cases and review of the literature. Pediatr Pathol 1988; 8:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/99\">",
"      Bryant AE, Laufer MR. Fetal ovarian cysts: incidence, diagnosis and management. J Reprod Med 2004; 49:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/100\">",
"      Steyaert H, Meynol F, Valla JS. Torsion of the adnexa in children: the value of laparoscopy. Pediatr Surg Int 1998; 13:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/101\">",
"      Crouch NS, Gyampoh B, Cutner AS, Creighton SM. Ovarian torsion: to pex or not to pex? Case report and review of the literature. J Pediatr Adolesc Gynecol 2003; 16:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/102\">",
"      Ozcan C, Celik A, Ozok G, et al. Adnexal torsion in children may have a catastrophic sequel: asynchronous bilateral torsion. J Pediatr Surg 2002; 37:1617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/103\">",
"      Grunewald B, Keating J, Brown S. Asynchronous ovarian torsion--the case for prophylactic oophoropexy. Postgrad Med J 1993; 69:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/104\">",
"      Functional ovarian cysts and oral contraceptives. Negative association confirmed surgically. A cooperative study. JAMA 1974; 228:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/105\">",
"      Caillouette JC, Koehler AL. Phasic contraceptive pills and functional ovarian cysts. Am J Obstet Gynecol 1987; 156:1538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/106\">",
"      Mishell DR Jr. Noncontraceptive benefits of oral contraceptives. J Reprod Med 1993; 38:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/107\">",
"      Grimes DA, Godwin AJ, Rubin A, et al. Ovulation and follicular development associated with three low-dose oral contraceptives: a randomized controlled trial. Obstet Gynecol 1994; 83:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/108\">",
"      Holt VL, Cushing-Haugen KL, Daling JR. Oral contraceptives, tubal sterilization, and functional ovarian cyst risk. Obstet Gynecol 2003; 102:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/109\">",
"      Kaleli B, Aktan E, Gezer S, Kirkali G. Reperfusion injury after detorsion of unilateral ovarian torsion in rabbits. Eur J Obstet Gynecol Reprod Biol 2003; 110:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/110\">",
"      Dolgin SE. Acute ovarian torsion in children. Am J Surg 2002; 183:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/111\">",
"      Abe�� M, Sarihan H. Oophoropexy in children with ovarian torsion. Eur J Pediatr Surg 2004; 14:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/112\">",
"      Laufer, MR, Billett, A, Diller, L, et al. A new technique for laparoscopic prophylactic oophoropexy prior to craniospinal irradiation in children with medulloblastoma. Adolesc Pediatr Gynecol 1995; 8:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/113\">",
"      Regad, J. Etude anatomo-pathologique de la torsion des trompets uterines. Gynecol Obstet 1933; 27:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/114\">",
"      Comerci G, Colombo FM, Stefanetti M, Grazia G. Isolated fallopian tube torsion: a rare but important event for women of reproductive age. Fertil Steril 2008; 90:1198.e23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/115\">",
"      Harmon JC, Binkovitz LA, Binkovitz LE. Isolated fallopian tube torsion: sonographic and CT features. Pediatr Radiol 2008; 38:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/116\">",
"      Krissi H, Shalev J, Bar-Hava I, et al. Fallopian tube torsion: laparoscopic evaluation and treatment of a rare gynecological entity. J Am Board Fam Pract 2001; 14:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/117\">",
"      Kiseli M, Caglar GS, Cengiz SD, et al. Clinical diagnosis and complications of paratubal cysts: review of the literature and report of uncommon presentations. Arch Gynecol Obstet 2012; 285:1563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/118\">",
"      Kostov M, Mijovi�� Z, Mihailovi�� D. Giant paraovarian cyst in a child complicated with torsion. Vojnosanit Pregl 2008; 65:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/8/23690/abstract/119\">",
"      Varras M, Akrivis Ch, Polyzos D, et al. A voluminous twisted paraovarian cyst in a 74-year-old patient: case report and review of the literature. Clin Exp Obstet Gynecol 2003; 30:253.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3305 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-118.97.94.19-55A78CA94E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_8_23690=[""].join("\n");
var outline_f23_8_23690=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H327777\">",
"      RELEVANT ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H849034\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Mechanism of torsion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Mechanism of ovarian or tubal injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H327826\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EPIDEMIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14908185\">",
"      Ovarian mass",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14908713\">",
"      - Size",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14908739\">",
"      - Benign versus malignant masses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1942422\">",
"      - Normal ovaries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28078997\">",
"      Reproductive age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20600973\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14908210\">",
"      Ovulation induction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20600912\">",
"      Prior ovarian torsion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20603472\">",
"      Other risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H327710\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H295749\">",
"      Pelvic pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3552339\">",
"      Adnexal mass",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H295757\">",
"      Nausea and vomiting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H295765\">",
"      Fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H849965\">",
"      EVALUATION OF PATIENTS WITH SUSPECTED TORSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H850111\">",
"      Medical history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H850119\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H850127\">",
"      Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Ultrasound",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Other imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H850001\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H850103\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H329352\">",
"      SURGICAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1942775\">",
"      Confirm torsion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1942783\">",
"      Assess ovarian viability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H329640\">",
"      Premenopausal patients with a viable ovary",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Detorsion and ovarian conservation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Patients with a nonviable ovary, suspected malignancy, or postmenopausal patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H329708\">",
"      - Salpingo-oophorectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H329765\">",
"      Pregnant women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1943053\">",
"      Fetuses and neonates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      PREVENTION OF RECURRENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H426482\">",
"      TORSION OF OTHER ADNEXAL STRUCTURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Isolated fallopian tube torsion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H426499\">",
"      Paratubal or paraovarian cyst torsion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/3305\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3305|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?33/59/34736\" title=\"diagnostic image 1\">",
"      Ovarian torsion sonogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?42/46/43746\" title=\"diagnostic image 2\">",
"      Ovarian torsion sonogram 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?33/16/34053\" title=\"diagnostic image 3\">",
"      Ovarian torsion sonogram 3",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3305|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/52/25412\" title=\"figure 1\">",
"      Uterine broad ligament",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3305|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/8/18561\" title=\"picture 1A\">",
"      Torsion with nonviable ovary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/20/17730\" title=\"picture 1B\">",
"      Torsion with salvageable ovary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/61/3024\" title=\"picture 2A\">",
"      Bivalving of torsed ovary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/43/8880\" title=\"picture 2B\">",
"      Bivalving of torsed ovary 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/48/18176\" title=\"picture 2C\">",
"      Bivalving of torsed ovary 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/43/27319\" title=\"picture 3\">",
"      Oophoropexy for ovarian torsion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/44/16066\" title=\"picture 4\">",
"      Torsion of fallopian tube",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3305|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/29/7643\" title=\"table 1\">",
"      Causes of ovarian torsion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/40/31370?source=related_link\">",
"      Acute appendicitis in adults: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24601?source=related_link\">",
"      Approach to the patient with an adnexal mass",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/26/41384?source=related_link\">",
"      Causes of chronic pelvic pain in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/18/3367?source=related_link\">",
"      Causes of female infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1178?source=related_link\">",
"      Clinical manifestations, diagnosis, and management of ectopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19352?source=related_link\">",
"      Differential diagnosis of the adnexal mass",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36823?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of tuboovarian abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9863?source=related_link\">",
"      Evaluation and management of ruptured ovarian cyst",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/44/17095?source=related_link\">",
"      Evaluation of acute pelvic pain in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8727?source=related_link\">",
"      Laparoscopic surgery in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30905?source=related_link\">",
"      Management of an adnexal mass",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12393?source=related_link\">",
"      Oophorectomy and ovarian cystectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/34/21033?source=related_link\">",
"      Ovarian cysts and neoplasms in infants, children, and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/47/6902?source=related_link\">",
"      Ovarian transposition before pelvic radiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/63/21495?source=related_link\">",
"      Overview of laparoscopy in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/10/13482?source=related_link\">",
"      Overview of ovulation induction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39034?source=related_link\">",
"      Risks and side effects associated with estrogen-progestin contraceptives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/27/41400?source=related_link\">",
"      Surgical female pelvic anatomy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_8_23691="Neuropathic causes of tonic pupil";
var content_f23_8_23691=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F67360&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F67360&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Neuropathies causing a tonic pupil",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Autonomic or peripheral neuropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute sensorimotor polyneuropathy, tonic pupils and abduction deficit with polyarteritis nodosa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alcohol-related",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amyloidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Charcot-Marie-Tooth disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic inflammatory demyelinating polyradiculoneuropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diabetes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Familial dysautonomia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fisher syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Guillain-Barr&eacute; syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hereditary neuropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pandysautonomia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Progressive autonomic failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ross syndrome (tonic pupil, hyporeflexia, segmental anhidrosis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Shy-Drager syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sjogren syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Syphilis (congenital or acquired)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Systemic infectious",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_8_23691=[""].join("\n");
var outline_f23_8_23691=null;
var title_f23_8_23692="Concentrations of food additives for skin testing";
var content_f23_8_23692=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F86541&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F86541&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Concentrations of food additives used for skin testing",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Food additive",
"       </td>",
"       <td class=\"subtitle1\">",
"        Preparation of epicutaneous skin&nbsp;test solution",
"       </td>",
"       <td class=\"subtitle1\">",
"        Reference",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gelatin",
"       </td>",
"       <td>",
"        Dissolve 1 teaspoon (5 grams) of gelatin powder (plain or flavored) in 5 mL normal saline",
"       </td>",
"       <td>",
"        Vaccine allergy practice parameterKelso JM, Li JT. Practice Parameters: Adverse reactions to vaccines. Ann Allergy Asthma Immunol 2009; 103(4 Suppl 2):1.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carmine",
"       </td>",
"       <td>",
"        Make 10 percent solution of carmine powder in phosphate buffered saline, agitate at 4C for 2 hours. Dialyze against purified water and filter through 0.22 micron filter.",
"       </td>",
"       <td>",
"        Anibarro B, Seoane J, Vila C, et al. Occupational asthma induced by inhaled carmine among butchers. International Journal of Occupational Medicine and Environmental Health 2003; 16(2):133.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Annato",
"       </td>",
"       <td>",
"        Additive containing food (Gouda cheese) and a commercial preparation of annato dye, diluted 1000-fold was used",
"       </td>",
"       <td>",
"        Ebo DG, Ingelbrecht S, Bridts CH, et al. Allergy for cheese; evidence for an IgE-mediated reaction from the natural dye annatto. Allergy 2009; 64(10): 1558.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Guar gum",
"       </td>",
"       <td>",
"        Additive containing food (a meal substitute) and guar gum preparation (no details provided)",
"       </td>",
"       <td>",
"        Papanikolaou I, Stenger R, Bessot JC, et al. Anaphylactic shock to guar gum (food additive E412) contained in a meal substitute. Allergy 2007; 62(7):822.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Psyllium",
"       </td>",
"       <td>",
"        Extract commercially available",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carrageenen",
"       </td>",
"       <td>",
"        0.4 percent wt/vol sodium carrageenan",
"       </td>",
"       <td>",
"        Tarlo SM, Dolovich J, Listgarten C. Anaphylaxis to carrageenan: a pseudo-latex allergy. J Allergy Clin Immunol 1995 (5 part 1):933.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Potassium metabisulfite",
"       </td>",
"       <td>",
"        Maximum concentration of 1 mg/mL",
"       </td>",
"       <td>",
"        Bush RK, Zoratti E, Taylor SL. Diagnosis of sulfite and aspirin sensitivity. Clinical Reviews in Allergy 1990; 8:159.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Yeast (saccharomyces cerevisiae)",
"       </td>",
"       <td>",
"        Extract commercially available",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Concentrations of food additives used for epicutaneous (prick-puncture) skin testing in published studies.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_8_23692=[""].join("\n");
var outline_f23_8_23692=null;
var title_f23_8_23693="Scrn CRC MSTF recs";
var content_f23_8_23693=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F62904&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F62904&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Multi-Society Task Force Guidelines for screening for the early detection of colorectal cancer and adenomas for average-risk women and men aged 50 years and older",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td colspan=\"3\">",
"        The following options are acceptable choices for colorectal cancer screening in average-risk adults beginning at age 50 years. Since each of the following tests has inherent characteristics related to prevention potential, accuracy, costs, and potential harms, individuals should have an opportunity to make an informed decision when choosing one of the following options.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        In the opinion of the guidelines development committee,",
"        <em>",
"         colon cancer prevention",
"        </em>",
"        should be the primary goal of colorectal cancer screening. Tests that are designed to detect both early cancer and adenomatous polyps should be encouraged if resources are available and patients are willing to undergo an invasive test.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Test",
"       </td>",
"       <td class=\"subtitle1\">",
"        Interval",
"       </td>",
"       <td class=\"subtitle1\">",
"        Key issues for informed decisions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Tests that detect adenomatous polyps and cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        FSIG with insertion to 40 cm or to splenic flexure",
"       </td>",
"       <td>",
"        Every 5 years",
"       </td>",
"       <td>",
"        <p>",
"         Complete or partial bowel prep is required.",
"        </p>",
"        <p>",
"         Sedation usually is not used, so there may be some discomfort during the procedure.",
"        </p>",
"        <p>",
"         The protective effect of sigmoidoscopy is primarily limited to the portion of the colon examined.",
"        </p>",
"        <p>",
"         Patients should understand that positive findings on sigmoidoscopy usually result in a referral for CSPY.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CSPY",
"       </td>",
"       <td>",
"        Every 10 years",
"       </td>",
"       <td>",
"        <p>",
"         Complete bowel prep is required.",
"        </p>",
"        <p>",
"         Conscious sedation is used in most centers; patients will miss a day of work and will need a chaperone for transportation from the facility.",
"        </p>",
"        <p>",
"         Risks include perforation and bleeding, which are rare but potentially serious; most of the risk is associated with polypectomy.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        DCBE",
"       </td>",
"       <td>",
"        Every 5 years",
"       </td>",
"       <td>",
"        <p>",
"         Complete bowel prep is required.",
"        </p>",
"        <p>",
"         If patients have one or more polyps &gt;6 mm, CSPY will be recommended; follow-up CSPY will require complete bowel prep.",
"        </p>",
"        <p>",
"         Risks of DCBE are very low; rare cases of perforation have been reported.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CTC*",
"       </td>",
"       <td>",
"        Every 5 years",
"       </td>",
"       <td>",
"        <p>",
"         Complete bowel prep is required.",
"        </p>",
"        <p>",
"         If patients have one or more polyps &gt;6 mm, CSPY will be recommended; if same day CSPY is not available, a second complete bowel prep will be required before CSPY.",
"        </p>",
"        <p>",
"         Risks of CTC are very low; rare cases of perforation have been reported.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Tests that primarily detect cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        gFOBT with high sensitivity for cancer",
"       </td>",
"       <td>",
"        Annual",
"       </td>",
"       <td>",
"        Depending on manufacturer's recommendations,&nbsp;two to&nbsp;three stool samples collected at home are needed to complete testing; a single sample of stool gathered during a digital exam in the clinical setting is not an acceptable stool test and should not be done.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        FIT with high sensitivity for cancer",
"       </td>",
"       <td>",
"        Annual",
"       </td>",
"       <td>",
"        <p>",
"         Positive tests are associated with an increased risk of colon cancer and advanced neoplasia; CSPY should be recommended if the test results are positive.",
"        </p>",
"        <p>",
"         If the test is negative, it should be repeated annually.",
"        </p>",
"        <p>",
"         Patients should understand that one-time testing is likely to be ineffective.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        sDNA with high sensitivity for cancer",
"       </td>",
"       <td>",
"        Interval uncertain",
"       </td>",
"       <td>",
"        <p>",
"         An adequate stool sample must be obtained and packaged with appropriate preservative agents for shipping to the laboratory.",
"        </p>",
"        <p>",
"         The unit cost of the currently available test is significantly higher than other forms of stool testing.",
"        </p>",
"        <p>",
"         If the test is positive, CSPY will be recommended.",
"        </p>",
"        <p>",
"         If the test is negative, the appropriate interval for a repeat test is uncertain.",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     FSIG: flexible sigmoidoscopy; CSPY: colonoscopy; DCBE: double-contrast barium enema; CTC: computed tomography colonography; gFOBT: guaiac-based fecal occult blood test; FIT: fecal immunochemical test; sDNA: stool DNA test.",
"     <br>",
"      * CTC, available commercially at the time of the development of these guidelines, is no longer commercially available in 2012.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Levin B, Lieberman DA, McFarland B, et al. Screening and Surveillance for the Early Detection of Colorectal Cancer and Adenomatous Polyps, 2008: A Joint Guideline From the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology, 134(5), 2008. Copyright &copy;2008 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_8_23693=[""].join("\n");
var outline_f23_8_23693=null;
var title_f23_8_23694="Modified FOLFOX7 plus bevacizumab chemotherapy";
var content_f23_8_23694=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F75802&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F75802&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Modified FOLFOX7 plus bevacizumab chemotherapy for advanced colorectal cancer",
"    <sup>",
"     [1]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr class=\"divider_bottom\">",
"       <td colspan=\"4\">",
"        Cycle length: 14 days.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose and route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Administration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Given on days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Bevacizumab",
"        </strong>",
"       </td>",
"       <td>",
"        5 mg/kg IV",
"       </td>",
"       <td>",
"        Dilute into a total volume of 100 mL normal saline (NS)*. The first dose should be administered over 90 minutes following chemotherapy. If well tolerated, the second infusion may be administered over 60 minutes after oxaliplatin and leucovorin. If well tolerated, all subsequent doses may be administered over 10 to 30 minutes after before chemotherapy",
"        <sup>",
"         &Delta;[2,3]",
"        </sup>",
"        .",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Oxaliplatin",
"        </strong>",
"       </td>",
"       <td>",
"        85 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        Dilute with 250 mL 5 percent dextrose in water (D5W)* and administer over two hours (on days 1 and 15, oxaliplatin and leucovorin can be administered concurrently in separate bags using a Y-connector).",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Leucovorin",
"        </strong>",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        200 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute with 250 mL D5W* and administer over two hours, concurrent with oxaliplatin.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Fluorouracil (FU)",
"        </strong>",
"       </td>",
"       <td>",
"        2400 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute with 500 to 1000 mL D5W and administer over 46 hours. To accommodate an ambulatory pump for outpatient treatment, can be administered undiluted (50 mg/mL) or the total dose can be diluted in 100 to 150 mL NS.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Pretreatment considerations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Emesis risk:",
"        </strong>",
"        MODERATE. Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Prophylaxis for infusion reactions:",
"        </strong>",
"        There is no standard premedication regimen. Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Vesicant/irritant properties:",
"        </strong>",
"        Oxaliplatin and FU are classified as irritants but oxaliplatin can cause significant tissue damage; avoid extravasation. Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-neoplastic vesicants\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Infection prophylaxis:",
"        </strong>",
"        Primary prophylaxis with granulocyte colony stimulating factors is not justified (estimated risk of febrile neutropenia &lt;5 percent",
"        <sup>",
"         [1]",
"        </sup>",
"        ). Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dose adjustment for baseline liver or renal dysfunction:",
"        </strong>",
"        A lower starting dose of oxaliplatin may be needed for severe renal impairment",
"        <sup>",
"         [4]",
"        </sup>",
"        . A lower starting dose of FU may be needed for patients with liver impairment. Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Maneuvers to prevent neurotoxicity:",
"        </strong>",
"        Pharmacologic methods to prevent/delay the onset of oxaliplatin-related neuropathy are controversial due to the absence of large clinical trials proving benefit. Counsel patients to avoid exposure to cold during and for approximately 48 hours after each infusion. Refer to UpToDate topic on \"Neurologic complications of platinum-based chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Monitoring parameters:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; CBC with differential and platelet count prior to each treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assess electrolytes and liver and renal function prior to treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assess changes in blood pressure, urine protein concentration, neurologic function, and risk for bleeding prior to each treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Suggested dose alterations for toxicity:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Myelotoxicity:",
"        </strong>",
"        Delay treatment cycle one week for total white blood cell count &lt;3000 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        , absolute neutrophil count &lt;1500 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        , or platelets &lt;100,000 /mm",
"        <sup>",
"         3",
"        </sup>",
"        on day of treatment. If treatment is delayed for two weeks or delayed for one week on two separate occasions, reduce the infusional FU by 20 percent and reduce oxaliplatin from 85 to 65 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Neurologic toxicity:",
"        </strong>",
"        For transient grade 3 paresthesias/dysesthesias or grade 2 symptoms lasting longer than seven days, decrease oxaliplatin dose by 25 percent. Discontinue oxaliplatin for grade 4 or persistent grade 3 paresthesia/dysesthesia",
"        <sup>",
"         [1]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Diarrhea:",
"        </strong>",
"        Withhold treatment for grade 2 or worse diarrhea, and restart at a lower dose after complete resolution",
"        <sup>",
"         [5]",
"        </sup>",
"        .",
"        <strong>",
"         NOTE:",
"        </strong>",
"        Severe diarrhea, mucositis, and myelosuppression after FU should prompt evaluation for dihydropyrimidine dehydrogenase deficiency. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Other toxicities:",
"        </strong>",
"        Discontinue bevacizumab for hypertensive crisis or hypertensive encephalopathy, serious hemorrhage, arterial thromboembolism, nephrotic syndrome, gastrointestinal perforation, fistula formation, or reversible posterior leukoencephalopathy syndrome (RPLS)",
"        <sup>",
"         [2]",
"        </sup>",
"        . Do not adminster bevacizumab within 28 days of surgery; suspend prior to elective surgery. Refer to UpToDate topics on \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\" and Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         If there is a change in body weight of at least 10 percent, doses should be recalculated.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"    </strong>",
"    <div class=\"footnotes\">",
"     IV: intravenous; CBC: complete blood count.",
"     <br/>",
"     * Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).",
"     <br/>",
"     &Delta; For the 5 mg/kg dose, many clinicians administer the first dose over 60 minutes and if well tolerated, subsequent doses are administered over 10 minutes",
"     <sup>",
"      [3]",
"     </sup>",
"     .",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     Many centers routinely infuse oxaliplatin through a central venous line because of local pain with infusion into a peripheral vein.",
"     <br/>",
"     &sect; Leucovorin dose is given for d,l-racemic mixture",
"     <sup>",
"      [6]",
"     </sup>",
"     . Use half the dose for LEVOleucovorin (l-leucovorin).",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Grothey A, et al. J Clin Oncol 2008; 26:180s.",
"      </li>",
"      <li>",
"       Avastin (bevacizumab) injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 13, 2011).",
"      </li>",
"      <li>",
"       Reidy DL, et al. J Clin Oncol 2007; 25:2691.",
"      </li>",
"      <li>",
"       Eloxatin (oxaliplatin) injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 13, 2011).",
"      </li>",
"      <li>",
"       Fluorouracil injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 13, 2011).",
"      </li>",
"      <li>",
"       Leucovorin calcium injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 13, 2011).",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_8_23694=[""].join("\n");
var outline_f23_8_23694=null;
var title_f23_8_23695="General hand function";
var content_f23_8_23695=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F69129&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F69129&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Physical examination for general function of the hand",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 347px; height: 291px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The patient is simply asked to open and close the hand, noting the ability to actively flex and extend the joints of the thumb and fingers.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_8_23695=[""].join("\n");
var outline_f23_8_23695=null;
